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CHAPTER 1 INTRODUCTION
The mitochondrion is one of the most important membrane-bound structures in
eukaryotic cells. Mitochondria play a pivotal role in cellular energy production as well as
metabolism. Mitochondria consist of outer and inner bilayer membranes, which
constitute a unique composition of phospholipids and proteins. The lipid composition of
the inner membrane determines its shape, which confers a functional role in anchoring
proteins, modulating protein activity and signal transduction. The signature lipid of
mitochondria is cardiolipin (CL), which is primarily localized in the inner membrane. In
the presence of reactive oxygen species (ROS), which are known to accumulate in the
mitochondria when the cells respire, CL acyl chains are peroxidized (Petrosillo et al.,
2001). The activity of peroxidized CL, and products generated downstream, are intrinsic
to mitochondrial signal transduction. The results of this dissertation research identify
novel functions of CL remodeling in peroxidized CL removal and myotube differentiation.
1. Structure and cellular functions of CL
CL (1,3 diphosphatidyl-sn-glycerol) was first isolated from bovine cardiac tissue,
in which it is most abundant (Pangborn, 1948; Shen et al., 2017). Unlike other
phospholipids that have two fatty acyl chains and one phosphatidyl group, CL contains
two phosphatidyl moieties, contributing two negative charges, and four acyl chains
(Lecocq and Ballou, 1964) (Figure 1-1).
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PE

CL

Figure 1-1 Cardiolipin (CL) has a unique structure
Unlike PE and other membrane phospholipids, CL has a dimeric structure in which
two phosphatidyl moieties are linked by a glycerol. Consequently, it is hydrophobic
and negatively charged due to the presence of four fatty acyl chains and two
phosphate groups respectively. CL interacts with diverse mitochondrial proteins by
hydrophobic and electrostatic interactions. The asymmetry of CL molecules,
resulting from the diversity of fatty acyl chains, leads to a variety of CL species,
which confer distinct functions of CL in different tissues. Symmetric CL molecules, in
which all four fatty acid chains are linoleic acid, are common in heart and muscle.
However, asymmetric CL molecules, with highly diversified acyl chains, are found in
mammalian brain (Cheng et al., 2008; Kagan et al., 2014; Schlame et al., 2005).
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Figure 1-2 Various cellular functions of CL have been identified in yeast.
CL-protein interactions stabilize respiratory chain supercomplexes (Pfeiffer et al.,
2003; Zhang et al., 2002), which is pivital to mitochondrial bioenergetics.
Interestingly, CL is essential in cellular functions not generally associated with
bioenergetics. Although the vacuolar concentration of CL is low, CL deficiency has
been linked to vacuolar morphology and acidification defects at elevated temperature
(Chen et al., 2008). The importance of CL to protein import is underscored by the
finding that the absence of CL leads to a reduced membrane potential and
decreased protein import (Jiang et al., 2000). Furthermore, CL is also required for
assembly of outer membrane protein translocases (Gebert et al., 2009). Increasing
evidence supports a role for CL in cellular signaling pathways, including PKC and
HOG, which affact cell wall biogenesis, aging, and mitophagy (Zhong and Greenberg,
2005; Zhou et al., 2009). Additionally, functions of CL in life span/stress response
(Gonzalvez and Gottlieb, 2007; Schug and Gottlieb, 2009), cell division (Chen et al.,
2010), iron homeostasis (Patil et al., 2013), and mitochondrial fusion (Joshi et al.,
2016) are now established.
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CL comprises approximately 15% of total mitochondrial phospholipids (Jakovcic
et al., 1971). CL interacts with a variety of mitochondrial proteins through both
hydrophobic and electrostatic interactions (Schlame et al., 2000a), including the
ADP/ATP carrier (Beyer and Klingenberg, 1985; Claypool et al., 2008b) and respiratory
complexes (Eble et al., 1990; Lange et al., 2001; Palsdottir et al., 2003). CL-protein
interactions stabilize and promote supramolecular associations such as respiratory
chain supercomplexes and ADP/ATP carrier (Claypool et al., 2008b; Pfeiffer et al., 2003;
Zhang et al., 2002). Additionally, CL deficiency leads to functional defects in diverse
biochemical pathways other than mitochondrial bioenergetics, including mitochondrial
dynamics (DeVay et al., 2009; Joshi et al., 2012); cell wall biogenesis (Zhong et al.,
2005; Zhong et al., 2007); mitochondrial protein import (Gebert et al., 2009; Jiang et al.,
2000); vacuolar function and morphology (Chen et al., 2008); aging (Zhou et al., 2009);
cell cycle (Chen et al., 2010); mitophagy (Shen et al., 2017); iron homeostasis (Patil et
al., 2013); and apoptosis (Gonzalvez and Gottlieb, 2007; Schug and Gottlieb, 2009). It
is likely that this list will grow in the future (Figure1-2). The regulation of CL synthesis
and remodeling is crucially important to the physiological state of an organism, as
different CL species are engaged in diverse, yet significant cellular pathways (Kagan et
al., 2014; Kagan et al., 2015).
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Figure 1-3 CL biosynthesis synthesis.
Prior to CL synthesis, CDP-DAG synthase (Tam41) catalyzes the transfer and
conversion of phosphatidic acid (PA) from the outer membrane to the matrix face of
inner mitochondrial membrane. To initiate CL synthesis, PGP synthase (Pgs1)
catalyzes
conversion
of
CDP-diacylglycerol
(CDP-DAG)
to
phosphatidylglycerolphosphate (PGP). In the second step, PGP phosphatase (Gep4)
dephosphorylate PGP to generate phosphatidylglycerol (PG). Lastly, CL synthase
(Crd1) converts PG to nascent CL that contains saturated and unsaturated fatty acyl
chains.
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2. CL biosynthesis
According to current literature, “the life of a CL molecule can be divided into
several

discreet

phases:

biosynthesis,

remodeling,

peroxidation

modification,

translocation, and degradation” (Schlame and Greenberg, 2017). TAM41-encoded
CDP-DAG synthase, located on the matrix side of the mitochondrial inner membrane,
initiates CL biosynthesis through the conversion of phosphatidic acid (PA) to CDPdiacylglycerol (CDP-DAG) (Kutik et al., 2008; Tamura et al., 2013). PA is synthesized
on the mitochondrial outer membrane and translocated to the inner membrane via the
UPS1-encoded PA transfer protein (Athenstaedt and Daum, 1999). Secondly, CDPDAG is converted to phosphatidylglycerol phosphate (PGP) by PGS1-encoded PGP
synthase (Chang et al., 1998a), which is then dephosphorylated to phosphatidylglycerol
(PG) by GEP4-encoded PGP phosphatase (Osman et al., 2010). CL synthase (Crd1)
catalyzes the last step of CL synthesis by condensing CDP-DAG and PG to form CL
(Figure 1-3) (Chang et al., 1998b; Jiang et al., 1997; Tamai and Greenberg, 1990; Tuller
et al., 1998). Following de novo synthesis, CL undergoes a remodeling process in which
saturated acyl chains are exchanged for unsaturated acyl chains.
3. CL remodeling
CL remodeling is a structural modification that follows de novo biosynthesis. This
process facilitates fatty acyl chain transfer. The remodeled CL acyl chain species are
organism and tissue specific. In the mammalian brain, the CL species are very diverse
(Kiebish et al., 2008). However, in tissues with high energy turnover, such as the heart,
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CL species are typically dominated by acyl groups with one or two double bonds
(Schlame et al., 2005).
In yeast, a CL-specific phospholipase (Cld1) initiates CL remodeling as it
deacylates CL to monolysocardiolipin (MLCL) on the matrix side of the inner
mitochondrial membrane (Baile et al., 2013; Beranek et al., 2009). The CL transacylase,
Taz1, utilizes donor phospholipids, particularly PC and PE, to reacylate MLCL and
produce remodeled CL in the mitochondrial periphery (Figure 1-4) (Brandner et al.,
2005; Gu et al., 2004; Testet et al., 2005). Remodeled CL contains more unsaturated
acyl chains than CL synthesized de novo (Beranek et al., 2009; Gu et al., 2004; Vaz et
al., 2003). Presently, the scientific community debates whether tafazzin transfers fatty
acyl-chains from PE and PC to MLCL specifically. Although Abe et al. purport that
purified yeast tafazzin catalyzes acyl-specific transacylation in bilayers, Schlame and
Greenberg contend that tafazzin is simply a vehicle to facilitate fatty acid exchange
between phospholipid molecules. Specifically, they argue that in order to generate
specific CL species, the free energy of remodeled CL must be lower than the free
energy of other molecular species (Abe et al., 2016; Schlame and Greenberg, 2017).
These theories attempt to elucidate the mechanistic functions of Taz1 to further our
understanding of the cellular role of CL remodeling. However, focus of my study was to
elucidate the link between the cellular functions of Cld1 and CL remodeling.
The experiments described in Chapter 3 demonstrate that yeast Cld1 exhibits
specificity for different CL molecular species. The observed molecular specificity
suggests that the functional role of Cld1, with respect to CL remodeling, is to maintain
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Figure 1-4 CL remodeling.
Unremodeled CL contains both saturated and unsaturated fatty acyl chains.
Remodeling occurs in the outer leaflet of the inner membrane. CLD1-encoded
phospholipase catalyzes the conversion of CL to monolyso-CL (MLCL). The
transacylase, Taz1, utilizes donor phospholipids, particularly PC and PE, to
reacylate MLCL to CL. Remodeled CL contains primarily unsaturated fatty acyl
chains.
the levels of various molecular species within the CL pool. The study described in
Chapter 2 identifies CL deacylation, catalyzed by Cld1, as the only step of CL
remodeling significantly upregulated at the mRNA level. Taken together, my findings
support this as a third possible explanation for the observed specificity of CL
composition generated by CL deacylation. However, maintaining a CL pool of specified
fatty acyl composition is not the only function of CL remodeling. My work also suggests
that CL deacylation serves to specifically remove peroxidized acyl chains in response to
oxidative stress.
4. CL peroxidation and translocation
In normally functioning mitochondria, the CL concentration is highest on the inner
leaflet of the mitochondrial inner membrane (Hovius et al., 1990; Krebs et al., 1979). A
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significant portion of CL is translocated to the mitochondrial outer membrane during
mitochondrial injury and depolarization, which distorts the highly asymmetric distribution
of CL between the outer and inner membranes (Baile et al., 2013; Garcia Fernandez et
al., 2002; Gonzalvez and Gottlieb, 2007). Externalized CL signals autophagy machinery
to remove damaged mitochondria (Chu et al., 2013). The translocation of CL from the
inner to outer mitochondrial membrane, along with oxidative modification of CL acyl
chains, leads to apoptotic death (Kagan et al., 2005b).
CL containing polyunsaturated fatty acyl chains are susceptible to oxidative
modifications. This process is, under certain conditions, enzymatically catalyzed by the
peroxidase function of an intermembrane space hemoprotein, cytochrome c (cyt c)
(Atkinson et al., 2011; Kagan et al., 2009). In the absence of CL, cyt c peroxidase
activity is negligible (Basova et al., 2007). Upon binding CL, cyt c undergoes a
conformational change facilitating CL-specific peroxidation. Cyt c tyrosyl radicals are
likely reactive intermediates of the peroxidase cycle, leading to CL peroxidation
(Kapralov et al., 2011). Recent studies reveal that acute reperfusion injury, such as the
massive apoptotic response observed during acute brain injury, is accompanied by the
generation of multiple peroxidized CL (CLox) species (Chan and Di Paolo, 2012; Ji et al.,
2012). The study also emphasizes that attenuating CL peroxidation confers a significant
countermeasure against the biochemical and physiological effects of oxidative stress.
Mammalian cells possess a similar mechanism to mitigate damage resulting from CL
peroxidation. Liu’s 2017 study reveals iPLA2γ, a gene product whose function is
analogous to Cld1, as the major enzyme responsible for deacylation of oxidized
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aliphatic chains from CL (Liu et al., 2017). Deletion of iPLA2γ results in the
accumulation of peroxidized CL in mouse mitochondria when subjected to oxidative
stress. There is mounting evidence to support CLs/CLox as necessitative signaling
molecules for immune responses, cell death, and coordination of metabolism (Kagan et
al., 2014; Maguire et al., 2017).
The physiological consequences and molecular mechanism of CL peroxidation
remain poorly understood, and represent a significant gap in the field. My work, in part,
focuses on the link between CL remodeling and peroxidation. Using the powerful yeast
model, in which well-characterized mutants for every step of CL synthesis and
remodeling are available, we are trying to elucidate the molecular mechanism of CL
peroxidation.
5. CL and Barth Syndrome
The importance of CL remodeling is underscored by the X-linked mitochondrial
disorder Barth syndrome (BTHS) (Figure 1-4). In 1983, Barth et al. identified a
mitochondrial disease that negatively impacts bioenergetics of the heart, muscle and
neutrophil leukocytes (Barth et al., 1983). Many abnormalities are well established in
BTHS patients, including cardiomyopathy (Kelley et al., 1991; Spencer et al., 2006a);
neutropenia (Kelley et al., 1991); underdeveloped skeletal musculature and weakness
(Barth et al., 1983); growth delay (Kelley et al., 1991); exercise intolerance; and
elevated urinary excretion of 3-methylglutaconic acid. Untreated BTHS patients die in
infancy, or during early childhood, due to defective development of heart and skeletal
muscle. Moreover, surviving BTHS patients are known to have a distinct cognitive
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Figure 1-5 The cause of BTHS is not clear.
Mutations in tafazzin lead to perturbed CL remodeling resulting in decreased total CL,
accumulation of MLCL, and aberrant CL acyl species that is associated with
cardiomyopathy, skeletal myopathy, growth retardation and exercise intolerance.
However, the link between CL deficiencies and the BTHS symptoms is not clear.

phenotype (Mazzocco et al., 2007a). After a decade, investigators mapped the mutant
locus (Bolhuis et al., 1991), and the functional loss of tafazzin (TAZ) was identified as
the genetic basis for clinical BTHS (Bione et al., 1996). Schlame and Ren showed that
tafazzin reacylates monolyso-CL (MLCL) to CL (Schlame and Ren, 2006). The yeast
and human tafazzin sequences are highly conserved, and encode a transacylase that
catalyzes CL reacylation. Approximately 28 different TAZ mutations, resulting in single
amino acid substitution, have been identified in BTHS patients (Schlame and Ren,
2006). These tafazzin mutations lead to either a complete loss of function, or expression
of a severely truncated protein resulting in decreased total CL, accumulation of MLCL
and

aberrant CL acyl species (Schlame et al., 2002).
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6. Yeast and mammalian BTHS models
The budding yeast, Saccharomyces cerevisiae, is an excellent eukaryotic model
system (Botstein et al., 1997) because it is nonpathogenic, grows rapidly, and can be
easily used for genetic analysis. More specifically, yeast is an excellent model for CLfocused research because deletion mutants for all CL biosynthetic genes are readily
available and viable. Although the yeast model has clarified the role of CL in cell
function and links the deficiency of CL to bioenergetic defects, a mammalian model
organism is essential to test and confirm hypotheses regarding CL function in humans.
BTHS lymphoblasts, generated by EBV transformation, exhibit decreased
mitochondrial membrane potential and abnormal mitochondrial proliferation (Xu et al.,
2005). These cells exhibit phospholipid deficiencies similar to those seen in BTHS
patients, namely impaired CL levels, increased MLCL, and aberrant acyl species.
Lymphoblasts are relatively inexpensive and simply grown, which make them an easy
model to work with. However, the disease phenotype may only manifest with a
substantial metabolic demand beyond cell growth and division. BTHS lymphoblasts do
not exhibit the same metabolic demand as cardiac and skeletal muscle cells. Most
importantly, a congenic control cell line is not available for BTHS lymphoblasts.
Induced pluripotent stem cells (iPSCs) generated from BTHS patients exhibit
mitochondrial defects similar to BTHS lymphoblasts (Dudek et al., 2013b). These cells
can readily differentiate into muscle cells that exhibit the same metabolic demand as
muscle cells. Unfortunately, they share the same disadvantage with BTHS lymphoblasts:
the lack of a congenic control cell line.
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Inducible short hairpin RNA (shRNA)-mediated tafazzin knockdown mice, and
tafazzin knockout mouse embryonic stem cells are very powerful models for BTHS
research (Acehan et al., 2009; Acehan et al., 2011; Soustek et al., 2011). Murine
tafazzin knockdown resulted in a dramatic decrease of tetralinoleoyl CL and
accumulation of MLCL. When tafazzin is knocked down, mitochondria, myofibrils, and
mitochondrial-associated membranes of murine skeletal and cardiac muscles exhibit
pathological changes similar to BTHS patients. Additionally, the congenic control is
available for both of these models. However, mice and stem cells are relatively
expensive and laborious to handle.
To circumvent the drawbacks of current mammalian models, I constructed a
stable mammalian cell line using C2C12 mouse myoblasts, which will be described in
Chapter 6. The C2C12 mouse skeletal muscle cell line is maintained as myoblasts
under high serum conditions, and is easily differentiated into myotubules under low
serum conditions. It is often employed in studies of mitochondrial bioenergetics (Leary
et al., 1998; Liu and Brooks, 2012; Nicholls et al., 2010). The TAZ-KO C2C12 cells
exhibit similar mitochondrial defects observed in other BTHS models such as decreased
membrane potential and respiration. Additionally, the TAZ-KO C2C12 cells exhibit the
same metabolic demand as skeletal muscle cells, have a congenic control cell line, and
are relatively inexpensive and easy to handle.
7. Project outline
The objectives of the studies described in this thesis were to elucidate functions
of CLD1 and CL remodeling in the yeast S. cerevisiae and murine myoblasts.
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In the studies summarized in Chapter 2, we assayed the regulation of yeast CL
phospholipase, Cld1. Our data indicated that an increased MLCL/CL ratio, but not
decreased CL unsaturation, is likely the primary cause of decreased respiratory growth
and chronological life span observed in taz1. This suggests that the physiological
defects of BTHS patients is possibly due to increased MLCL/CL rather than decreased
unsaturated CL, and that attenuation of CL phospholipases may potentially treat BTHS.
If unsaturated CL is not essential, as suggested by our finding, what is the
function of CL remodeling? Our finding that CLD1 expression was upregulated under
respiratory conditions suggests the possibility that CLD1 expression is upregulated in
response to oxidative stress. CL peroxidation, resulting from oxidative stress, has been
described in mammalian cells (Bayir et al., 2007; Kriska et al., 2005; Petrosillo et al.,
2001). Based on this, one of the physiological roles of CL remodeling may be to remove
peroxidized CL. To address this possibility, it was necessary to determine whether CL
species can be altered by nutritional supplementation of PUFA, because yeast does not
synthesize oxidizable CL (Chapter 3). Liquid chromatography−mass-spectrometrybased phospholipidomics was combined with genetic and nutritional manipulations to
assay CL incorporation of PUFA during the CL biosynthetic and post-synthetic
remodeling processes in yeast. Our results demonstrated that yeast readily
incorporated PUFA to synthesize oxidizable CL. To genetically manipulate CL species,
the H. brasiliensis Δ12-desaturase gene was expressed in yeast (Chapter 4). Lipidomic
analysis of this strain confirmed the presence of PUFA within molecular species of CL.
Although multiple CL-hydroperoxides and CL-dihydroperoxides were readily detected in
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these cells, cell growth and life span were not impacted. Using this novel yeast model,
in which cells expressed ∆12-desaturase, the specificity of Cld1 for peroxidized CL, and
its role in deacylating peroxidized CL, was determined (Chapter 5). cld1Δ cells
expressing ∆12-desaturase were utilized to determine the effect of peroxidation on CL
remodeling. In cells expressing desaturase, loss of CLD1 led to increased peroxidized
CL species, as well as decreased cell growth and life span. The findings from this study
may help to clarify the role of CL remodeling and its mechanistic roles in mitigating
oxidative stress.
To probe defects resulting from CL deficiency in mammalian cells (Chapter 6), I
constructed a tafazzin knockout C2C12 cell line, which exhibits an increased MLCL/CL
ratio, decreased respiration capacity, increased ROS generation and decreased
membrane potential. Although WT and TAZ-KO C2C12 cells can differentiate into
myotubes, differentiation was significantly decreased in TAZ-KO C2C12 cells under
certain conditions. Taken together, these findings indicate that CL remodeling plays a
role in myotube differentiation.
While the studies described here identify various functions of CL, many questions
remain unanswered. Future studies to elucidate functions of CL are suggested in
Chapter 7.
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CHAPTER 2 DELETION OF THE CARDIOLIPIN-SPECIFIC
PHOSPHOLIPASE CLD1 RESCUES GROWTH AND LIFESPAN
DEFECTS IN THE TAFAZZIN MUTANT: IMPLICATIONS FOR BARTH
SYNDROME
The work described in this chapter has been published in Ye*, C., W. Lou*, Y. Li,
I.A. Chatzispyrou, M. Huttemann, I. Lee, R.H. Houtkooper, F.M. Vaz, S. Chen, and M.L.
Greenberg. 2014. Deletion of the cardiolipin-specific phospholipase Cld1 rescues
growth and life span defects in the tafazzin mutant: implications for Barth syndrome.
The

Journal

of

biological

chemistry.

289:3114-3125.

*Equal

contributors

http://www.ncbi.nlm.nih.gov/pubmed/24318983
It has also been published in Ye, Cunqi, "Characterization And Identification Of
Novel Regulators Of The Synthesis Of Phospholipids" (2014). Wayne State University
Dissertations. Paper 1036.
INTRODUCTION
Cardiolipin (CL) is a unique phospholipid that is predominant in mitochondrial
membranes (Hostetler et al., 1972; Joshi et al., 2009a). Unlike other membrane
phospholipids, it contains two phosphatidyl moieties, four acyl chains and two negative
charges (Lecocq and Ballou, 1964; Pangborn, 1947). As the signature lipid of
mitochondria, it comprises about 15% of total mitochondrial phospholipids (Jakovcic et
al., 1971) and interacts with a wide range of mitochondrial proteins (Claypool, 2009;
Klingenberg, 2009; Schlame and Ren, 2009; Schlame et al., 2000a), including the
ADP/ATP carrier (Beyer and Klingenberg, 1985; Claypool et al., 2008b) and respiratory
complexes (Eble et al., 1990; Lange et al., 2001; Palsdottir et al., 2003; Shinzawa-Itoh
et al., 2007). CL-protein interactions stabilize respiratory chain supercomplexes (Pfeiffer
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et al., 2003; Zhang et al., 2002) and promote supramolecular associations between the
ADP/ATP carrier and respiratory supercomplexes (Claypool et al., 2008b). Therefore, it
is not surprising that mitochondrial respiration and energy production are highly
correlated with CL biosynthesis (Claypool et al., 2008b; Gohil et al., 2004; Jiang et al.,
2000). Interestingly, CL deficiency also leads to deficiencies in diverse cellular functions
other than mitochondrial bioenergetics, including mitochondrial dynamics (DeVay et al.,
2009; Joshi et al., 2012), mitochondrial protein import (Gebert et al., 2009; Jiang et al.,
2000), cell wall biogenesis (Zhong et al., 2005; Zhong et al., 2007), vacuolar function
and morphology (Chen et al., 2008), cell cycle (Chen et al., 2010), aging (Zhou et al.,
2009), and apoptosis (Gonzalvez and Gottlieb, 2007; Houtkooper and Vaz, 2008; Schug
and Gottlieb, 2009). As CL is engaged in a plethora of cellular activities, the regulation
of CL synthesis is crucially important.
The synthesis of CL is well-characterized in Saccharomyces cerevisiae. As seen
in Figure 2-1, Pgs1 catalyzes the committed step of CL synthesis by converting CDPDAG and glyerol-3-phosphate to phosphatidylglycerolphosphate (PGP) (Chang et al.,
1998a), which is dephosphorylated to phosphatidylglycerol (PG) by the PGP
phosphatase Gep4 (Kelly and Greenberg, 1990; Osman et al., 2010). CL synthase
(Crd1) catalyzes the final step of de novo CL synthesis by condensing PG and CDPDAG to form CL with primarily saturated acyl chains (Chang et al., 1998b; Jiang et al.,
1997; Tamai and Greenberg, 1990; Tuller et al., 1998). Following the de novo synthesis
of CL on the matrix side of the inner mitochondrial membrane, CL undergoes
remodeling in which acyl chains are exchanged. In this process, CL is deacylated to
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monolysocardiolipin (MLCL) by the CL-specific lipase Cld1 on the matrix side of the
inner mitochondrial membrane (Baile et al., 2013; Beranek et al., 2009). MLCL is
reacylated by the transacylase Taz1 in the mitochondrial periphery (Brandner et al.,
2005; Claypool et al., 2008a; Gu et al., 2004; Testet et al., 2005). Remodeled CL has
more unsaturated acyl chains than CL synthesized de novo (Beranek et al., 2009; Gu et
al., 2004; Vaz et al., 2003; Xu et al., 2003). Although the CL remodeling genes and
enzymes have been identified in yeast, the function of CL remodeling and mechanisms
underlying its regulation are not understood.
The importance of CL remodeling is underscored by the X-linked mitochondrial
disorder Barth syndrome (BTHS), a cardioskeletal myopathy that results from mutations
in the tafazzin gene (the homologue of yeast TAZ1) (Barth et al., 1983; Barth et al.,
2004; Barth et al., 1999a). Tafazzin deficiency leads to a decrease in the CL/MLCL ratio
and a decrease in CL species containing unsaturated fatty acids (Acehan et al., 2011;
Gu et al., 2004; Houtkooper et al., 2009; Schlame et al., 2003; Valianpour et al., 2002;
Vreken et al., 2000; Xu et al., 2006a). Which of these biochemical outcomes leads to
the pathology in BTHS is not understood. Genetic inactivation of the CL-specific
phospholipase iPLA2-GVIA rescued sterility defects associated with tafazzin deficiency
in Drosophila (Malhotra et al., 2009). The mechanism underlying this rescue is not
known. In mammals, CL-specific phospholipases have not been identified, and multiple
phospholipases supposedly catalyze the deacylation of CL (Hsu et al., 2013),
complicating experiments to elucidate the role of deacylation in mammalian cells. In

20

Table 2-1 Strains and plasmids used in this study
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0
MATα his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 crd1Δ::KanMX6
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 cld1Δ::KanMX6
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 taz1Δ::KanMX6
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 cld1Δ::KanMX6
taz1Δ::KanMX6
MATα his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 mig1Δ::KanMX6
MATα his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 hap2Δ::KanMX6
MATα his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 hap3Δ::KanMX6
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 hap4Δ::KanMX6
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 hap5Δ::KanMX6
ρ° mutant derived from BY4741
ρ° mutant derived from BY4741 crd1Δ
ρ° mutant derived from BY4741 cld1Δ
ρ° mutant derived from BY4741 taz1Δ

Invitrogen
Invitrogen
Invitrogen
Invitrogen
this study

ρ° mutant derived from BY4741 cld1Δtaz1Δ

this study

pYPGK18

2μm, LEU2

(Vaz et
al., 2003)

pYPGK18CL
D1

derived from pYPGK18, expression CLD1 from PGK1
promoter

this study

BY4741
BY4742
crd1Δ
cld1Δ
taz1Δ
cld1Δtaz1 Δ
mig1Δ
hap2Δ
hap3Δ
hap4Δ
hap5Δ
BY4741 ρ°
crd1Δ ρ°
cld1Δ ρ°
taz1Δ ρ°
cld1Δtaz1Δ
ρ°

this study
Invitrogen
Invitrogen
Invitrogen
Invitrogen
Invitrogen
this study
this study
this study
this study

contrast, CLD1 is the only CL-specific phospholipase in S. cerevisiae (Beranek et al.,
2009). The yeast cld1Δ mutant has decreased unsaturated CL compared to wild type
cells, but the CL/MLCL ratio is not altered. In this study, we demonstrated for the first
time that deletion of CLD1 rescued both respiratory and fermentative growth defects as
well as decreased chronological life span in yeast taz1Δ cells. This suggests that
deacylation of CL in the absence of tafazzin is deleterious because it leads to a
decrease in the CL/MLCL ratio. These findings argue against the current thought that
defects in tafazzin deficient cells result from decreased unsaturated CL. We further
show that expression of CLD1 is regulated in response to conditions affecting
mitochondrial respiration and controlled by the HAP transcriptional activator.
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Overexpression of CLD1 leads to decreased ATP production from mitochondrial
respiration that is compensated by increased glycolysis. Based on these findings, we
proposed that transcriptional regulation of CLD1 controls deacylation of CL, and the
regulation of this process modulates cellular energy production
METHODS AND MATERIALS
Yeast strains, plasmids and growth media—The yeast S. cerevisiae strains and
plasmids used in this study are listed in Table 2-1 and Table 2-2. Single deletion
mutants were obtained from the yeast knock-out deletion collection (Invitrogen). Double
mutants were obtained by tetrad dissection. Parental ρ+ cells were used to generate ρ°
derivatives by growing in yeast extract peptone dextrose (YPD) medium containing 20
μg/ml ethidium bromide to the early stationary phase. ρ° strains were confirmed by
inability to grow on yeast extract peptone glycerol ethanol (YPGE) medium, the absence
of mitochondrial DNA by DAPI staining, and the failure to complement ρ− tester strains
for growth on YPGE medium. To construct a CLD1-overexpression plasmid, a 1338-bp
sequence containing the entire open reading frame of CLD1 was amplified from yeast
genomic

DNA

using

an

EcoRI-tagged

forward

primer

CLD1_EcoRI_F

(5’-

TATAGAACATGAATTCAAAAGTGAGCTGCAATGAGCA) and an XbaI-tagged reverse
primer CLD1_XbaI_R (5′- ATTTTGAGATTCTAGAAAGAAGAAAAATAGCGGCGA -3′).
The PCR products were purified using the Wizard SV Gel and PCR Clean-up System
(Promega). The purified DNA fragments were ligated into pYPGK18 cut with EcoRI and
XbaI, downstream of the PGK1 promoter. All the plasmids were amplified and extracted
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using standard protocols. The plasmids were transformed into yeast strains using a
one-step transformation protocol.
Synthetic complete (SC) medium contained adenine (20.25 mg/L), arginine (20
mg/L), histidine (20 mg/L), leucine (60 mg/L), lysine (200 mg/L), methionine (20 mg/L),
threonine (300 mg/L), tryptophan (20 mg/L), uracil (20 mg/L), yeast nitrogen base
without amino acids (Difco), all the essential components of DIFCO vitamin (inositolfree), 0.2% ammonium sulfate, and glucose (2%). Inositol (75 μM) was supplemented in
all media used in this study. Synthetic dropout media contained all ingredients
mentioned above except for the amino acid used as a selectable marker, and were
used to culture strains containing a plasmid.
Chronological life span—Yeast chronological life span is determined by survival of
non-dividing cells in a prolonged stationary culture (Fabrizio and Longo, 2003). A
standard protocol previously described was followed (Hu et al., 2013) to assess
chronological life span. In brief, individual colonies were inoculated in 10 ml of SC
glucose medium and incubated overnight. The cultures were then diluted in 50 ml of SC
medium, and cells were allowed to grow until saturation. Viable cells were measured
every 2 or 3 days by counting colonies that were serially diluted and plated on YPD
plates and represented as percentage of cells at day 2. The viability is considered to be
100% at or before day 2.
Spotting assay—Cells were pre-cultured in SC medium to the early stationary growth
phase at 30°C and washed with sterile water. Three μL aliquots of a series of 10-fold

23

dilutions of 0.5 units of A550 cells were spotted onto indicated plates and incubated at
30°C.
Real-Time quantitative PCR (RT-qPCR) analysis—Cells were grown to the indicated
growth phase and harvested at 4°C. Total RNA was extracted using hot phenol (Kohrer
and Domdey, 1991) and purified using the RNeasy Mini Plus kit (QIAGEN, Valencia,
CA). Complementary DNA (cDNA) was synthesized using the First Strand cDNA
Synthesis Kit (Roche Applied Science, Indianapolis, IN) according to the manufacturer’s
manuals. RT-qPCR reactions were performed in a 20 μL volume using Brilliant III UltraFaster SYBR Green QPCR Master Mix (Agilent Technologies, Santa Clara, CA).
Triplicates were included for each reaction. The primers for RT-qPCR are listed in Table
2-2. RNA levels were normalized to ACT1. Relative values of mRNA transcripts are
shown as fold change relative to indicated controls. Primer sets were validated
according to Methods and Applications Guide from Agilent Technologies. Optimal
primer concentrations were determined, and primer specificity of a single product
monitored by a melt curve following the amplification reaction. All the primers were
validated by measurement of PCR reaction efficiency and have calculated reaction
efficiencies between 95-105%.
Measurement of respiration—Cell respiration was analyzed in a closed 500 L
chamber equipped with a micro Clark-type oxygen electrode (Oxygraph plus system,
Hansatech) at 30°C. Cells grown to the logarithmic phase were mixed in fresh growing
media using a
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Table 2-2. Real-time PCR primers used in this study.
Gene
ACT1
PGS1
GEP4
CRD1
CLD1
TAZ1
ADH1
ADH2
PGK1
GAPDH

Primers
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse

Sequence (5' to 3')
TCCGGTGATGGTGTTACTCA
GGCCAAATCGATTCTCAAAA
TTTGCTCCAACTCACTCGTCCTCA
ATTGCCAAATGGAGAAGGGTTCGC
AAAGGCCGTGGTCTTGGATAAGGA
ATTGGAACCGGCGGTATTGCTAA
TGCGGCGATAATTCTGGGTAGAGA
ATTCCATGCCACACGACCAGGATA
ACTGGCTTTGGCTTTATGGCGAT
TCCAGGTACAAGTGATGCCCTGA
CGAAGCCATCTTGGGTCCATGTT
CAATGGGCGGCTTTGTTGCTTCT
GGTCTAGGTTCTTTGGCTGTT
CACCACCGATGGATCTGAATAA
GTACTGTTGTCTTGGTTGGTTTG
GTAAGAGCCGACAATGGAGATAG
AGGCTTCTGCCCCAGGTTC
CAGCACGTTGTGGCAAGTC
AGTCTTTTGGGTGGCGGTCA
ACATTGACGCTGGTGCCAAG

this study
this study
this study
this study
this study
this study
this study
this study
(Szijgyarto et
al., 2011)
(Szijgyarto et
al., 2011)

protein concentration of 2 mg/mL following measurements of basal respiration. State 4
and 3 respiration was determined in the presence of 4 M oligomycin and 5 μM FCCP,
respectively. KCN (0.2 mM) was added at the end of the experiment to inhibit
cytochrome c oxidase to normalize for (subtract) cytochrome c oxidase independent
oxygen consumption. Oxygen consumption was recorded on a computer and analyzed
with the Oxygraph plus software. Respiration rates are defined as consumed O 2
(nmol)/min∙total protein (mg).
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Determination of ATP concentrations—Yeast cells were cultured to the logarithmic
phase and flash-frozen with liquid nitrogen. ATP levels were determined by the
bioluminescence method described previously (Lee et al., 2010).
Determination of ethanol concentrations—Yeast cells were cultured in 10-mL growth
medium for the indicated times to the logarithmic phase after inoculation at A550 of 0.05,
and cells were pelleted by a 5-min centrifugation at 3,000 rpm. Supernatants were used
to determine ethanol concentrations in the media. An ethanol colorimetric assay kit from
BioVision was used to assay ethanol concentrations according to the manufacturer’s
manual.
Mitochondrial aconitase activity—Cultures (2L) of yeast cells in the mid-logarithmic
phase were harvested for isolation of mitochondria. Mitochondria were isolated as
described previously (Diekert et al., 2001). Briefly, spheroplasts generated by
zymolyase treatment were ruptured by Dounce homogenization, and mitochondria were
obtained by differential centrifugation. Total mitochondrial protein concentration was
determined using the BCA protein assay (Pierce Protein). Mitochondrial aconitase
activity was determined in mitochondrial extracts (50-μg protein) using an aconitaseisocitrate dehydrogenase-coupled assay, in which NADPH formation was monitored at
A340 for 1 h (Gardner, 2002).
Determination of CL by mass spectrometry —Total lipid extracts from 10 mg of cells
(dry weight) were analyzed by HPLC-MS as described previously (Houtkooper et al.,
2006).
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RESULTS
Deletion of CLD1 rescues growth and life span defects of the taz1Δ mutant.
Deacylation of CL in the absence of tafazzin leads to a decreased ratio of
CL/MLCL and decreased unsaturated CL (Acehan et al., 2011; Gu et al., 2004;
Valianpour et al., 2002; Xu et al., 2006a), either of which may be responsible for cellular
defects in tafazzin-deficient cells. We wished to distinguish between decreased
CL/MLCL ratio vs. decreased unsaturated CL as the mechanism underlying the defects
in the taz1Δ mutant. Blocking CL deacylation by deletion of CLD1 prevents the
decrease in CL/MLCL ratio (Beranek et al., 2009). However, the CL that is synthesized
de novo but not remodeled is mostly saturated, in contrast to remodeled CL in wild type
(WT) cells, which is mostly unsaturated (Beranek et al., 2009). To determine if the
decreased CL/MLCL ratio is responsible for taz1Δ defects, we determined the effects of
CLD1 deletion in taz1Δ mutants. Interestingly, deletion of CLD1 rescued the respiratory
growth defect of the taz1Δ mutant (Figure 2-2A). Because mitochondrial respiration
varies in strains with different genetic backgrounds (Ocampo et al., 2012) and the
presence of polymorphic mitochondrial DNA can contribute to differences in
mitochondrial respiration (Dimitrov et al., 2009), we assayed the effects of CLD1
deletion independent of mitochondrial respiration. To do so, we constructed ρ 0 strains
(which lack mitochondrial DNA) of the WT and CL mutants. While CL deficient cells
grow

normally

on

glucose

(Figure

2-2A),

which

can

be

fermented,
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B
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Figure 2-1. Deletion of CLD1 rescues growth and chronological life span
defects in taz1Δ.
(A) Serial 10-fold dilutions of WT, crd1Δ, cld1Δ, taz1Δ, and crd1Δtaz1Δ cells were
spotted on synthetic complete medium with 2% glucose or 2% ethanol as carbon
sources. Plates were incubated at 30°C for 3 days. (B) Serial 10-fold dilutions of
0
respiration-incompetent (ρ ) cells of the above mutants were spotted on synthetic
complete medium with 2% glucose. (C) Chronological life span of WT, crd1Δ, cld1Δ,
taz1Δ, and crd1Δtaz1Δ cells was determined as described under “Experimental
Procedures.” The data depicted in the figure is a representative of three experiments.
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growth on glucose is compromised in the mutants if they lack mitochondrial DNA
(Figure 2-2B). Deletion of CLD1 rescued this growth defect (Figure 2-2B). We predicted
that CL deficient cells would exhibit a decreased chronological life span similar to the
decreased replicative life span observed in these cells (Zhou et al., 2009). As shown in
Figure 2-2C, both crd1Δ and taz1Δ mutants exhibited a dramatic decrease in
chronological life span. Deletion of CLD1 partially rescued the decrease in taz1Δ life
span, as the life span of taz1Δcld1Δ was almost similar to that of WT (Figure 2-2C). The
observation that deletion of CLD1 suppresses the defects in taz1Δ indicates that
deacylation of CL is deleterious in the absence of tafazzin, and that the decreased
CL/MLCL ratio but not decreased CL unsaturation is likely the primary cause of taz1Δ
defects.
CLD1 expression is highly regulated in response to growth phase, glucose
availability and respiratory activity.
The finding that cld1Δ rescued respiratory defects in taz1Δ suggested that CLD1
expression plays a role in respiration. We first compared expression of CL biosynthetic
genes, including PGS1, GEP4, CRD1, CLD1, and TAZ1, in logarithmically growing cells
(in which energy is generated primarily from glycolysis) and in cells in the stationary
phase (during which energy is generated from respiration). Expression of all the CL
biosynthetic genes was increased in the stationary phase (Figure 2-3A). However, while
PGS1, GEP4, CRD1, and TAZ1 were increased about 3-5 fold, CLD1 was increased by
about 10-fold in the early stationary phase and more than 30-fold in the later stationary
phase (Figure2-3A). The large increase in CLD1 expression suggests that levels of
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Figure 2-2. Increased CLD1 expression in the stationary phase is concomitant
with increased CL unsaturation.
(A) WT cells were grown in SC medium to the early-logarithmic (EL), mid-logarithmic
(ML), early-stationary (ES), and stationary (S) growth phases, and PGS1, GEP4,
CRD1, CLD1, and TAZ1 expression was quantified by RT-PCR as described under
“Experimental Procedures.” Values of each gene were normalized to the internal
control ACT1 and are represented as fold change relative to those in EL. Data shown
are mean ± S.E. (n = 3). (B) Cells grown in YPD in the logarithmic and stationary
phases were extracted for CL acyl composition analysis by HPLC-mass
spectrometry, described under “Experimental Procedures.” (C) WT and cld1Δ cells
grown in SC media in the logarithmic and stationary phases were extracted for CL
acyl composition analysis by HPLC-mass spectrometry, described under
“Experimental Procedures.”
unsaturated CL may be increased during stationary phase. This was in fact observed
(Figure 2-3B). Specifically, in the C68 cluster, the most unsaturated CL (C68:4, m/z
699.5) was abundant, while a more saturated species (C68:2, m/z 701.5) was less
abundant in stationary phase cells. Conversely, the C68:4 CL was much less abundant
than C68:2 in logarithmically growing cells. This is also evident in the C60 cluster as the
most saturated CL (C60:0, m/z 647.4) was absent from stationary cells but clearly
present in logarithmically growing cells. Deletion of CLD1 prevents CL remodeling and
leads to decreased unsaturated CL (Beranek et al., 2009). As expected, cld1Δ exhibited
a decreased degree of unsaturated CL compared to WT regardless of growth phase
(Figure 2-3C). Interestingly, unsaturated CL levels were greater in stationary phase than
in log phase cld1Δ cells. This finding suggests that an as yet unidentified mechanism
regulates CL saturation in the absence of Cld1.
Increased CLD1 expression in the stationary phase, during which glucose is
exhausted and cells shift from fermentation to oxidative phosphorylation, suggested that
CLD1 may be transcriptionally regulated in response to glucose availability and the
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need to respire. To test this prediction, we examined the expression of CLD1 in
response to acute removal of glucose and in respiration-deficient cells (ρ0 cells). As
expected, expression of CLD1 but not the other CL biosynthetic genes was greatly
increased in response to glucose starvation, by 6-fold and 10-fold, during 30-min and
60-min starvation, respectively (Figure 2-4A). Furthermore, CLD1 transcription was
increased in the stationary phase in ρ+ cells but not in respiration incompetent ρ0 cells
(Figure 2-4B). These findings indicate that CLD1 expression is upregulated during
respiratory conditions and in response to glucose deprivation.
Using the Promoter Database of Saccharomyces cerevisiae (SCPD) to search
for putative regulatory elements in the upstream region of the CLD1 gene, we identified
consensus sequences for Hap2 and Mig1 (Figure 2-4C), transcription factors that
mediate activation of respiratory gene expression and glucose repression, respectively
(Nehlin and Ronne, 1990; Pfeifer et al., 1989; Santangelo, 2006). Consistent with this
observation, the HAP complex regulates CLD1. As seen in Figure 2-4D, CLD1
expression in the stationary phase was greatly reduced in hap2Δ, hap3Δ, hap4Δ, and
hap5Δ mutants, indicating that the HAP complex up-regulates CLD1 transcription. Mig1
has been shown to repress gene expression in the presence of glucose (Santangelo,
2006; Schuller, 2003). If Mig1 repressed CLD1 transcription in the presence of glucose,
CLD1 transcription would be increased in mig1Δ cells. However, CLD1 transcription in
mig1Δ cells was decreased in these conditions (Figure 2-4E). Thus, Mig1 appears to be
a positive regulator of CLD1 expression. This is consistent with reported activator
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Figure 2-3. CLD1 expression is increased in response to respiration and
activated by HAP.
(A) Glucose limitation. WT cells harvested in the mid-logarithmic phase were washed
with pre-warmed media with or without glucose and resuspended in fresh media with
or without glucose for 30-min and 60-min. Analyses of PGS1, GEP4, CRD1, CLD1,
and TAZ1 expression was determined using RT-qPCR and normalized to ACT1, as
described under “Experimental Procedures.” The data represent as fold change
relative to expression in media containing glucose and include the mean ± S.E. (n =
+
0
6). (B) Respiratory competency. ρ and ρ cells were grown to the mid-logarithmic
(ML) and early stationary (ES) phases. The values shown represent the fold change
+
relative to expression of WT ρ cells in ML, and include mean ± S.E. (n = 6). (C)
Sequence alignment depicting consensus sequences for Mig1 and Hap2 in the
upstream region of the CLD1 gene using the Promoter Database of Saccharomyces
cerevisiae (SCPD). 1 indicates a 100% match with putative consensus sequences,
and 0.88 and 0.82 indicates one mismatch. (D) Effect of the HAP complex.
Expression was determined in hap2Δ, hap3Δ, hap4Δ, and hap5Δ cells grown to the
mid-logarithmic phase. Data shown are mean ± S.E. (n = 6). (E) Effect of MIG1.
Expression was determined in WT and mig1Δ cells grown to the mid-logarithmic
phase. Data shown are mean ± S.E. (n = 3).

activity of Mig1 (Bu and Schmidt, 1998; Wu and Trumbly, 1998). Taken together, these
findings indicate that expression of CLD1 is increased in response to respiration
conditions, and this increase is mediated by the HAP and Mig1 transcriptional factors.
Constitutive overexpression of CLD1 leads to decreases in respiration and
mitochondrial aconitase activity, and instability of mitochondrial DNA.
As expression of CLD1 is deleterious to tafazzin-deficient cells, we predicted that
increased CLD1 expression alters metabolism and perturbs cell growth. Consistent with
this, cell growth was decreased when CLD1 was overexpressed (Figure 2-5A). One
possible explanation for this is that increased CLD1 expression perturbs respiration. In
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Figure 2-4. Overexpression of CLD1 decreases cell growth, respiration, and
mitochondrial aconitase activity.
(A) Growth of WT cells in SC media overexpressing CLD1 or empty vector (EV).
Cells were inoculated at an initial A550 of 0.05, and A550 was measured at the
indicated times. The growth curves shown in the figure are representative of three
experiments. (B) Oxygen consumption was measured in logarithmically growing
cells using a Clark-type electrode as described under “Experimental Procedures.”
Data shown are mean ± S.E. (n = 3-6). (C) The kinetics of aconitase enzymatic
activity in mitochondria from control and CLD1 overexpressing cells grown to the
logarithmic phase were determined as described under “Experimental Procedures”.
Data shown are mean ± S.E. (n = 3).

support of this, basal respiration in mitochondria from cells that overexpressed CLD1
was about half that of control cells (Figure 2-5B). This difference was even more
pronounced comparing the maximum respiratory capacity that was achieved by
uncoupling the respiratory chain with trifluorocarbonylcyanide phenylhydrazone (FCCP).
Therefore, constitutive overexpression of CLD1 decreases mitochondrial respiration.
A possible mechanism to account for decreased respiration in CLD1
overexpressing cells is suggested by the observation that over 60% of cells became
cytoplasmic petites. The respiratory growth deficiency of the petites was not
complemented by crossing to ρ- tester strains, and mitochondrial DNA was not
observed in the petite cells stained with DAPI. As aconitase is required for mitochondrial
genome maintenance (Chen et al., 2005b), we tested the possibility that aconitase
activity might be decreased in cells overexpressing CLD1. In fact, the kinetics of
aconitase enzymatic activity in mitochondria from CLD1 overexpressing cells exhibited
a 60% decrease compared to cells overexpressing empty vector (Figure 2-5C). Taken
together, these studies indicate that increasing CL deacylation by constitutive
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overexpression of CLD1 impairs cell growth and respiration and decreases
mitochondrial DNA stability, suggesting that deacylation of CL is an important control
point for mitochondrial function.
Increased

fermentation

compensates

for

decreased

respiration

in

cells

overexpressing CLD1.
As respiration was decreased in cells overexpressing CLD1, we expected to see
a concomitant decrease in ATP synthesis. The contribution of mitochondria to cellular
ATP production can be estimated by the decrease in oxygen consumption resulting
from the addition of oligomycin, an inhibitor of ATP synthesis. Under basal conditions,
the decrease in respiration caused by oligomycin was significantly less in mitochondria
from CLD1 overexpressing cells than in controls (Figure 2-5B), suggesting that
mitochondrial ATP synthesis was decreased. Interestingly, however, total ATP levels
were actually higher in CLD1 overexpressing cells (Figure 2-6A). This suggested that
cells may compensate for the respiratory loss by increasing ATP generation from
fermentation. Consistent with this, ethanol production was significantly higher in CLD1overexpressing cells than in controls (Figure 2-6B). To determine if up-regulation of
genes in glycolysis/fermentation could account for increased ethanol production, we
analyzed expression of GAPDH and PGK1, which encode enzymes that catalyze key
steps in glycolysis (glyceraldehyde-3-P dehydrogenase and phosphoglycerate kinase,
respectively), as well as ADH1 and ADH2, which encode the fermentation enzyme
alcohol dehydrogenase. As seen in Figure 2-6C, expression of ADH1 and ADH2 was

39

A

B

C

Figure 2-5. Overexpression of CLD1 leads to increased ATP and ethanol.
(A) ATP levels in logarithmically growing cells overexpressing CLD1 or empty vector
(EV) were determined as described under “Experimental Procedures.” Data shown
are mean ± S.E. (n = 3). (B) Ethanol concentrations were determined as described
under “Experimental Procedures”. Data shown are mean ± S.E. (n = 6) (*p<0.05,
**p<0.01). (C) WT cells overexpressing CLD1 or EV grown to the logarithmic phase
were harvested for mRNA extraction. Expression of ADH1, ADH2, GAPDH, and
PGK1 was determined using RT-qPCR as described under “Experimental
Procedures”. Values of each gene were normalized to the internal control ACT1.
Transcripts normalized to ACT1 are represented as fold change relative to those in
control cells. Data shown are mean ± S.E. (n = 3)
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increased 2-fold, which most likely accounts for the increase in ethanol production.
Expression of GAPDH and PGK1 was not altered. These findings indicate that
overexpression of CLD1 leads to decreased mitochondrial respiration and ATP
synthesis, which is compensated by increasing glycolysis.
DISCUSSION
A deficiency in CL reacylation catalyzed by tafazzin is deleterious in eukaryotes
(Acehan et al., 2011; Gu et al., 2004; Schlame et al., 2003; Valianpour et al., 2002;
Vreken et al., 2000; Xu et al., 2006a), most notably in humans where it leads to the lifethreatening disorder BTHS (Barth et al., 1983; Barth et al., 2004; Barth et al., 1999a).
The loss of tafazzin results in perturbation of CL metabolism. Specifically, the CL/MLCL
ratio is decreased, as are the levels of unsaturated CL species. Although many studies
suggest that the deleterious effects of tafazzin deficiency result from the absence of
unsaturated CL (Schlame et al., 2003; Schlame and Ren, 2006; Schlame et al., 2002;
Valianpour et al., 2003; Xu et al., 2003), no reports to date have distinguished between
decreased unsaturated CL and decreased CL/MLCL as the cause of the cellular defects.
In the current study, we addressed this question by characterizing the effects of CLD1
deletion on tafazzin deficient yeast cells. The cld1Δ mutant has decreased unsaturated
CL (similar to the taz1Δ mutant), but the CL/MLCL ratio is not decreased. We report that
cld1Δ rescues growth and respiration defects of the taz1Δ mutant, indicating that the
decreased CL/MLCL ratio, and not decreased unsaturated CL, leads to the defects in
tafazzin-deficient cells.
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Interestingly, the double mutant cld1Δtaz1Δ exhibited defective growth in
glycerol/ethanol medium at 37˚C as reported in Beranek et al (Beranek et al., 2009). We
tested growth of WT, crd1Δ, cld1Δ, taz1Δ, and cld1Δtaz1Δ cells in media containing
glucose, glycerol, ethanol, or glycerol/ethanol as carbon sources. Indeed, we found that
the double mutant grew poorly compared to WT when glycerol/ethanol was used as
carbon source, similar to the observation of Beranek et al. However, in these carbon
sources, we did not observe respiratory growth defects in taz1Δ at 30˚C. Although
taz1Δ exhibited decreased growth in glycerol/ethanol at 37˚C, high temperature stress
complicates respiration defects. In marked contrast, we observed that taz1Δ cells
exhibit a significant respiratory growth defect in ethanol medium at 30˚C. Under these
conditions, we observed that the double mutant rescued the respiratory defects of taz1Δ.
As cld1Δ restores CL levels but not unsaturated CL species in taz1Δ, this finding
indicates that rescue of respiratory growth of taz1Δ by cld1Δ results from restoration of
CL levels.
While deletion of CLD1 does not appear to affect growth, expression of the gene
is deleterious in the absence of reacylation, as taz1Δ cells that have the wild type CLD1
gene are defective, while those carrying the cld1Δ mutation grow normally. To gain
insight into the mechanism underlying the deleterious effects of increased CLD1, we
characterized growth and mitochondrial function of cells overexpressing this gene.
Interestingly, overexpression of CLD1 resulted in increased ATP levels (Figure 2-6A)
despite a significant reduction in mitochondrial respiration (Figure 2-5B).
possibilities may explain this seemingly surprising finding.

Two

First, overexpression of
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CLD1 leads to growth slowdown, therefore less ATP is required and utilized to maintain
cellular functions. Second, CLD1 overexpression shifts metabolism from respiration
toward glycolysis and fermentation (Figure 2-7), compensating for defective oxidative
phosphorylation.

This indicates that regulation of Cld1-mediated deacylation of CL

influences energy metabolism by modulating the relative contribution of glycolysis and
respiration. CL is an essential component of oxidative phosphorylation complexes. For
example, it was identified in the crystal structure of cytochrome c oxidase (ShinzawaItoh et al., 2007), the proposed rate-limiting enzyme of the electron transport chain
(reviewed in (Huttemann et al., 2012)) and is required for optimal enzyme function and
activity (Koshkin and Greenberg, 2000). Therefore, reduced mitochondrial respiration in
CLD1 overexpressing cells would be expected if the CL pool is modified. (We
hypothesize that during stationary growth, when oxidative phosphorylation is used, CL
may be tuned towards increased membrane fluidity or association with the
supercomplexes). Furthermore, such alterations lead to mitochondrial DNA instability.
Apparently, there is yet another level of regulation of the CL metabolic pathway
intersecting with cytochrome c oxidase regulation. We show here that CLD1 gene
regulation is mediated by the Hap2/3/4/5p transcription factor complex (Figure 2-4E),
which is also a crucial regulator of cytochrome c oxidase subunit V isoforms Va and Vb
(Kwast et al., 1999). These isoforms result in an enzyme with higher affinity for oxygen
when the substrate is scarce.

Furthermore, overexpression of components of the

Hap2/3/4/5p complex rescues cytochrome c oxidase deficiencies (Fontanesi et al.,
2008).

In another example of coordinate control, regulation of COX4 translation
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requires Pgs1, the enzyme that catalyzes the committed step of CL synthesis (Su and
Dowhan, 2006). Taken together these findings suggest an integrated and concerted
response to environmental stress that affects the CL pathway and oxidative
phosphorylation, both of which are interconnected.
Our findings suggest that increased CLD1 is deleterious to cells because it
decreases respiration. However, CLD1 expression was increased during respiratory
growth and regulated by the HAP complex (Figure 2-4), the transcriptional activator that
responds to respiratory growth signals. This raises the question of what is the function
of the CL remodeling pathway, and the corollary question of why is CLD1 expression
increased in response to respiratory conditions. We speculate that the function of CL
remodeling is to remediate the deleterious effects of respiration (Figure 2-7). In support
of this possibility, superoxides generated by respiratory complex III cause peroxidation
of CL and decreased cytochrome c oxidase activity (Paradies et al., 2000; Paradies et
al., 2001; Paradies et al., 1998). Exogenous supplementation of CL, but not peroxidized
CL or other phospholipids, rescued both reduced activity of cytochrome c oxidase and
increased generation of ROS in reperfused heart (Paradies et al., 2001; Petrosillo et al.,
2007). In this light, CL remodeling may be a mechanism whereby damaged fatty acyl
chains are replaced. Although different approaches have been used, this proposed
model is similar to the model described in Baile et al (Baile et al., 2013), in which they
suggested a feedback loop between oxidative phosphorylation and CL remodeling.
Specifically, they found that CLD1 expression is regulated by carbon sources, and the
activity of Cld1 is increased by dissipating the mitochondrial membrane potential
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Figure 2-6. Proposed model.
Regulation
of
Cld1-mediated
deacylation
of
CL influences
energy
metabolism. CLD1 expression is upregulated in response to increased
respiration. Increased CLD1 expression modulates the relative contributions of
oxidative phosphorylation and glycolysis to cellular energy production. We speculate
that the function of CL deacylation, which is increased during respiratory conditions
that are known to increase oxidative stress, is to remove peroxidized acyl chains
from damaged CL.
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(Baile et al., 2013). They suggested that CL remodeling functions to increase oxidative
phosphorylation efficiency and/or replace peroxidized CL.
Our findings have implications for understanding the mechanism underlying
BTHS. Many studies of BTHS have concluded that the disorder is due to the complete
lack of the ‘normal’ unsaturated (tetralinoleoyl, or L4) CL in the heart (Schlame et al.,
2003; Schlame and Ren, 2006; Schlame et al., 2002; Valianpour et al., 2003; Xu et al.,
2003). However, the current study indicates that in yeast, a total lack of the ‘normal’
unsaturated CL species is not deleterious to cells. The large number of mammalian
phospholipases complicates the ability to distinguish between decreased CL/MLCL vs.
decreased unsaturated CL in human cells. Gross and co-workers (Kiebish et al., 2013b)
reported that ablation of phospholipase iPLA2g in the mouse reduced MLCL levels by
only ~50% indicating that other phospholipases deacylate CL. Mass spectrometry
analysis of phospholipase activity identified at least four phospholipases that deacylate
CL in vitro (Hsu et al., 2013). The identification of mammalian CL-specific
phospholipases may ultimately enable this question to be addressed.
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CHAPTER 3 LIPIDOMICS CHARACTERIZATION OF BIOSYNTHETIC
AND REMODELING PATHWAYS OF CARDIOLIPINS IN GENETICALLY
AND NUTRITIONALLY MANIPULATED YEAST CELLS
The work described in this chapter has been published in Tyurina* Y. Y., W. Lou*,
F. Qu*, V. A. Tyurin, D. Mohammadyani, J. Liu, M. Hüttemann, M. A. Frasso, P. Wipf, H.
Bayir, M. L. Greenberg, and V. E. Kagan. 2016. Lipidomics characterization of
biosynthetic and remodeling pathways of cardiolipins in genetically and nutritionally
manipulated yeast cells. ACS Chemical Biology. *Equal contributors
http://pubs.acs.org/doi/pdf/10.1021/acschembio.6b00995#notes-1
INTRODUCTION
The well-established tissue specificity of cardiolipins (CL)s (Kagan et al., 2015;
Schlame, 2008) has led to a paradigm that the molecular speciation of CLs – achieved
through the process of remodeling of the nascent species - is defined by the unique
mitochondrial demands of a particular tissue. This commonly accepted paradigm has
been recently challenged by a clear demonstration that unremodeled CLs are
functionally indistinguishable from remodeled CLs for yeast mitochondrial morphology
and major bioenergetic functions, such as in oxidative phosphorylation (OxPhos) (Baile
et al., 2014), where it is a required structural component of the individual OxPhos
complexes as well as supercomplexes (Eble et al., 1990; Mileykovskaya and Dowhan,
2014; Pfeiffer et al., 2003; Poyry et al., 2013; Sharpley et al., 2006; Shinzawa-Itoh et al.,
2007). Recent findings have demonstrated that respiratory supercomplexes are
destabilized by disturbed CL remodeling in heart mitochondria from tafazzin knockdown
mice, resulting in disruption of interactions between the electron transporting complexes
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and the fatty acid (FA) oxidation enzymes (Huang et al., 2015).
The two major reactions in the remodeling process are a phospholipase-driven
production of monolyso-CL (MLCL) intermediates followed by an acyltransferase
(tafazzin) dependent “rebuilding” of the molecule that reacylates MLCL via the acylCoA-independent transfer of an acyl group from a donor phospholipid (Baile et al., 2014;
Beranek et al., 2009; Gu et al., 2004).
Recent developments, elucidating the role of mitochondria as a platform
coordinating many metabolic processes as well as life and death decisions, imply that
essential functions not associated with bioenergetics may dictate the necessity for the
highly diversified molecular speciation of CLs in tissues with signaling functions (e.g., in
the brain). Not only has it been shown that mitochondria have functions other than
bioenergetics, but CL in particular has extra-bioenergetic functions. The first
demonstration of a role for CL in cell viability apart from bioenergetics was the
demonstration that the crd1Δ (CL synthase) mutant has a temperature-sensitive growth
defect, unlike yeast mitochondrial bioenergetics mutants which do not exhibit
temperature sensitivity (Jiang et al., 1999). Perturbation of CL synthesis has been
shown to affect MAPK signaling (Zhong et al., 2007; Zhou et al., 2009) and vacuolar
function in yeast (Chen et al., 2008). This is in sharp contrast to such tissues as cardiac
and skeletal muscles in which mitochondrial energy production dictates the dominance
of homo-acylated tetraoleoyl-CL ((C18:1)4-CL) or tetralinoleoyl-CL ((C18:2)4-CL)
species over a rich assortment of hetero-acylated CLs that may be required for
signaling purposes (Patil and Greenberg, 2013; Tyurina et al., 2014).
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CL signaling may be realized through the production of oxygenated lipid
mediators (Tyurina et al., 2014), thus requiring CL species containing polyunsaturated
fatty acids (PUFA). Therefore, the plasticity that is fine-tuned by adaptive changes in the
microenvironment – rather than a rigid constitutive program – is likely to define the
functions and mechanisms of CL remodeling. The machineries realizing these adaptive
responses may include the availability of polyunsaturated fatty acids as well as
enzymatic mechanisms involved in CL remodeling – including phospholipases A and
acyl-transferases (Lu and Claypool, 2015; Schlame, 2013).
Yeast cells may be ideal organisms for the exploration of these pathways
because they: i) can be grown on media completely devoid of PUFA or supplemented
with PUFA, ii) rely on only one CL-specific phospholipase A, Cld1, iii) utilize Taz1 as the
major tool for reacylation of MLCL, and iv) employ only one – Cld1/Taz1-dependent –
pathway for CL remodeling. With this in mind, in the current work we employed detailed
phospholipidomics analysis to explore the effects of PUFA supplementation as well as
cld1Δ and taz1Δ mutants on the molecular speciation of CLs in S. cerevisiae. Herein,
we report the results of differential phospholipidomics studies of S. cerevisiae that
provide new insights into CL remodeling and biosynthesis. Our findings identified the
roles of Cld1 and Taz1 as the major regulatory mechanisms, which are governed by the
availability of PUFA esterified into phospholipids that act as donors for the Taz1catalyzed reaction.
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METHODS AND MATERIALS
Yeast strains, media, and growth conditions—The Saccharomyces cerevisiae
strains used in this work are listed in Table 2-1. Single deletion mutants were obtained
from the yeast knock-out deletion collection (Invitrogen). Double mutants were obtained
by tetrad dissection. Complex media contained yeast extract (1%), peptone (2%), and
glucose (2%) (YPD) or glycerol (3%) and ethanol (1%) (YPGE). The effect of fatty acids
was determined in YPD or YPGE medium supplemented with 0.2% oleic, arachidonic,
linoleic, or docosahexaenoic acid solubilized in the media with tergitol (1%).
Unsupplemented controls contained only tergitol. Synthetic complete (SC) medium
contained all the essential components of Difco yeast nitrogen base, 2% glucose, 0.2%
ammonium sulfate, vitamins, adenine (20.25 mg/L), arginine (20 mg/L), histidine (20
mg/liter), leucine (60 mg/L), lysine (200 mg/liter), methionine (20 mg/L), threonine (300
mg/L), tryptophan (20 mg/L), uracil (20 mg/L), and inositol (75 μM). For solid medium, 2%
agar was added. For selection of cells carrying plasmids, appropriate amino acids were
omitted from the media. Yeast strains were grown at 30°C. E. coli strain DH5 was used
for plasmid maintenance and amplification. Bacteria were grown at 37°C in LB medium
(0.5% yeast extract, 1% tryptone, 1% NaCl), supplemented with ampicillin (100 μg/mL)
for selection purposes. Solid medium contained 1.5% agar. Growth in liquid cultures
was monitored spectrophotometrically. Cells were harvested and centrifuged at 4 oC
(4,300 rpm, 5 min). Supernatant was discarded and glass beads (0.3g) were added to
the centrifuge tubes. Samples were vortexed (5 X 1min intervals) and frozen at -80oC
for lipidomics analysis.
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Construction of plasmids and expression of His6-tagged CLD1 in S. cerevisiae—
To construct a His6-tagged CLD1 overexpression plasmid, a 1373-bp sequence
containing the entire open reading frame without stop codon of CLD1 was amplified
from yeast genomic DNA using an EcoRI-tagged forward primer CLD1_EcoRI_F3 (5’TGATTAATAAGAATTCAACACAATGTTCAAGTCAACTTTAAACTC-3’) and an XbaItagged

reverse

primer

(5’-

CLD1_XbaI_R3

ATTTTGAGATTCTAGATATTTTTTGCATTTCTTTCG-3’). The PCR products were
purified using the Wizard SV gel and PCR clean-up system (Promega). The purified
DNA fragments were ligated into pYES2/CT cut with EcoRI and XbaI downstream of the
GAL1 promoter. All the plasmids were amplified and extracted using standard protocols.
The plasmids were transformed into yeast strains using a one-step transformation
protocol.
Purification of His6-tagged Cld1—S. cerevisiae strain BY4741 was used to express
the recombinant His6-tagged Cld1. Cells were grown at 30°C in synthetic complete
raffinose medium lacking uracil. Galactose (2%) was added to induce expression of the
recombinant protein. Cell extracts were prepared by disrupting cells with glass beads
(0.5 mm diameter), vortexing for 5 min intermittently in disruption buffer containing 50
mM Tris-Cl (pH 8.0) and 300 mM NaCl. Protease inhibitor (cOmplete EDTA-free, Roche)
was added to the disruption buffer before breaking the cells. His 6-tagged Cld1 was
purified

with

Millipore®

PureProteome

nickel

magnetic

beads

following

the

manufacturer's instructions. Millipore® UFC503024 Amicon® Ultra-0.5 centrifugal filter
concentrator (30 KD) was used to concentrate the protein and remove imidazole.
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Protein concentration was determined with a BIO-RAD DC protein assay kit using
bovine serum albumin as the standard.
LC/MS assessment of phospholipids—Lipids were extracted from yeast using the
Folch procedure (Folch et al., 1957) and lipid phosphorus was determined by a micromethod (Boettcher et al., 1961). LC/MS of phospholipids was performed in negative
mode using a Dionex UltimateTM 3000 RSLCnano system coupled online Q-Exactive
hybrid quadrupole-orbitrap mass spectrometer (ThermoFisher Scientific, San Jose, CA).
Total lipids were separated on a normal phase column (Silica Luna 3 µm, 100A, 150x2
mm, (Phenomenex, Torrance CA)) with flow rate 0.2 mL/min using gradient solvents
containing 5 mM CH3COONH4 (A – n-hexane:2-propanol:water, 43:57:1 (v/v/v) and B n-hexane:2-propanol:water, 43:57:10 (v/v/v). The gradient conditions (all linear) were as
follows: 0-23 min (10%B to 32%B); 23-32 min (32%B to 65%B); 32-35 min (65%B to
100%B) 35-62 min (hold at 100%B); 62-64 min (100%B to 10%B); 64-80 min (10%B).
Flow rate was maintained at 200 microliters/min except for the 35-62 min time frame
where the flow rate was increase to 225 microliters/min. MS analysis was performed in
negative ion mode (profile) at a resolution of 140,000 for the full MS scan and 17,500 for
the MS2 scan in a data-dependent mode with appropriate inclusion and exclusion lists.
The scan range for MS analysis was 400-1800 m/z with a maximum injection time of
128 ms using 1 microscan. A maximum injection time of 500 ms was used for MS 2 (high
energy collisional dissociation (HCD)) analysis with collision energy set to 24. An
isolation window of 1.0 Da was set for the MS2 scans. Capillary spray voltage was set at
3.5 kV, and capillary temperature was 320 oC. The S-lens Rf level was set to 60 with a
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sheath gas flow of 8. To quantitatively assess phospholipids, PE-(17:0/17:0); PC(17:0/17:0); CL-(14:0/14:0/14:0/14:0); LPE-(17:1/0:0); LPC-(17:1/0:0) from Avanti Polar
Lipids have been used as internal standards. Reference standards PE-(18:1/18:1); PC(18:1/18:1); CL-(18:2/18:2/18:2/18:2); LPE-(18:0/0:0); LPC-(18:0/0:0) were used for
calibrations and were also from AvantiPolar Lipids. Both Internal and reference
standards

of

MLCLs

were

prepared

from

CL-(14:0/14:0/14:0/14:0)

CL-

(18:2/18:2/18:2/18:2), respectively as described (Kim and Hoppel, 2011). Precursor ions
[M-H]- were identified with mass accuracy less than 5ppm. Therefore, phospholipids,
including CL, were identified by accurate mass and MS2 fragmentation analysis. The
fragmentation pattern provided information on fatty acids but not on their position.
Assuming that sn-1 position in phospholipids is commonly occupied by saturated and
monounsaturated acids we used this information to identify PE and PC molecular
species. Clearly, this is a more difficult task for CL molecular species with four acyl
chains in the molecule. Therefore, we presented CL molecular species based on the
information provided in the paper by Liebisch et al.(Liebisch et al., 2013). Spectra
subtraction was done by Background Subtraction Module in Xcalibur (Thermo Fisher
Scientific). By defining one file as background (subtractor) and another file as
foreground (minuend), the difference can be evaluated from the differential spectra.
Since negative spectra cannot be calculated and exported from Xcalibur, we performed
swapping of the subtractor and the minuend which afforded the calculations and
presentation of the negative spectra.
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Respiration measurements—Oxygen consumption rate (OCR) of intact yeast cells
was analyzed via the polarographic method in a closed 500 L chamber equipped with
a micro Clark-type oxygen electrode (Oxygraph Plus System, Hansatech Instruments)
at 30°C. Yeast cells were grown in synthetic YPD media supplemented with oleic acid,
linoleic acid, or arachidonic acid. Cells were harvested during the stationary phase.
Cells were mixed in fresh media using a final protein concentration of 0.5 mg/mL
following measurements of respiration. KCN (0.2 mM) was added at the end of the
experiment to inhibit cytochrome c oxidase to correct for cytochrome c oxidaseindependent oxygen utilization. Oxygen consumption was recorded on a computer and
analyzed with the Oxygraph plus software. Oxygen consumption rate (ORC) is defined
as consumed O2 (nmol)/min/total protein (mg).
Synthesis of Cardiolipins—General Experimental Conditions. All air and moisture
sensitive reactions were carried out under a nitrogen or argon atmosphere. All reactions
carried out above room temperature were performed using an oil bath set to the
specified temperature and monitored with an external thermometer. THF and diethyl
ether were distilled from sodium/benzophenone ketyl. Dichloromethane was distilled
from CaH2. Diisopropylethylamine (DIPEA) and diisopropylamine were distilled from and
stored over KOH. Pyridine was filtered through activated basic alumina and stored over
freshly activated 4 Å molecular sieves for at least 24 h prior to use. Amberlite-IR120H
resin was activated by stirring with 6 N HCl for 30 min, filtering, and rinsing once with
equal volumes of water and methanol. All other reagents were used as received.
Concentrating under reduced pressure refers to removing solvents by the use of a
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rotary evaporator connected to a PIAB Lab Vac H40. Reactions were monitored by thin
layer chromatography analysis (pre-coated silica gel 60 F254 plates, 250 μm layer
thickness) and visualized with a 254 nm UV light or by staining with a KMnO4 solution.
Flash chromatography on SiO2 (Silicycle, 40-63 μm) was used for purification where
indicated. All products were placed under high vacuum to remove trace solvents.
Melting points were determined using a Laboratory Devices Mel-Temp II and are
uncorrected. Infrared spectra were obtained from neat solids or oils on a Perkin Elmer
ATR IR or Smiths Detection IdentifyIR FT-IR spectrometer. High-resolution mass
spectra were obtained on a Thermo Scientific Exactive Orbitrap mass spectrometer
using electrospray ionization. Low-resolution mass spectra were obtained on an Advion
Expression L compact mass spectrometer using electrospray ionization.

1H

NMR

spectra were obtained on a Bruker Avance at 300 MHz, 400 MHz, or 500 MHz in CDCl 3,
CD2Cl2, or CD3OD. Chemical shifts were reported in parts per million with the residual
solvent peak used as an internal standard 1H /

13C

(solvent): 7.26 / 77.00 (CDCl3);

5.32/53.84 (CD2Cl2). 1H NMR spectra were obtained and are tabulated as follows:
chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, dd = doublet of
doublets, m = multiplet, bs = broad singlet), number of protons, and coupling constant(s).
13C

NMR spectra were recorded using a proton-decoupled pulse sequence run at 100

MHz or 125 MHz and are tabulated by observed peaks.

31P

NMR spectra were recorded

using a complete decoupled pulse sequence run at 162 MHz.
OH
C15H 31

O
O

OH
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1-O-Palmitoylglycerol (1a) (Lok et al., 1985; Mori, 2012). General Procedure A. A
solution of palmitic acid (5.5 g, 21.4 mmol, 1.0 eq.), 50% glycidol in CH 2Cl2 (3.0 mL,
22.8 mmol, 1.06 eq.) and tributylamine (0.1 mL, 0.4 mmol, 0.02 eq.) was heated to
85 °C and stirred for 5 h. The crude product was recrystallized from i-Pr2O:Et2O (1:1) to
yield 1-O-palmitoylglycerol (1a, 4.88 g, 14.8 mmol, 69%) as a colorless solid: Mp 71.972.5 °C; IR 3293, 2913, 2848, 1728 cm-1; 1H NMR (CDCl3, 300 MHz) 4.22 (dd, 1 H, J =
4.8, 11.7 Hz), 4.15 (dd, 1 H, J = 6.0, 11.4 Hz), 3.97-3.90 (m, 1 H), 3.70 (dd, 1 H, J = 4.2,
11.7 Hz), 3.60 (dd, 1 H, J = 5.7, 11.4 Hz), 2.35 (t, 2 H, J = 7.7 Hz), 1.66-1.58 (m, 2 H),
1.28-1.25 (m, 25 H), 0.85 (t, 3 H, J = 6.8 Hz);

13C

NMR (CDCl3, 100 MHz) 174.4, 70.3,

65.2, 63.3, 34.1, 31.9, 29.7-29.6 (multiple peaks), 29.4, 29.3, 29.1, 24.9, 22.7, 14.1.
OH
C17H 35

O

OH

O

1-O-Stearoylglycerol (1b) (Lok et al., 1985; Mori, 2012). According to General
Procedure A but using stearic acid, 1-O-stearoylglycerol (1b, 4.36 g, 12.2 mmol, 71%)
was obtained as a colorless solid: 1H NMR (CDCl3, 300 MHz) 4.21 (dd, 1 H, J = 4.8,
11.7 Hz ), 4.14 (dd, 1 H, J = 5.7, 11.4 Hz), 3.96-3.90 (m, 1 H), 3.70 (dd, 1 H, J = 3.9,
11.4 Hz), 3.60 (dd, 1 H, J = 6.0, 11.4 Hz), 2.71 (bs, 2 H), 2.35 (t, 2 H, J = 7.7 Hz), 1.651.60 (m, 2 H), 1.28-1.25 (m, 29 H), 0.88 (t, 3 H, J = 6.6 Hz).
C15H 31
O
O

C15H 31

O
ODMT

O

1,2-O-Dipalmitoyl-3-O-dimethoxyltriylglycerol (2a). General Procedure B. To a solution
of 1a (4.57 g, 13.8 mmol, 1.0 eq.) in pyridine:CH2Cl2 (1:2, 35 mL) at 0 °C was added
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dimethoxyltrityl chloride (DMTCl, 4.82 g, 14.1 mmol, 1.0 eq.) and dimethylaminopyridine
(DMAP, 0.177 g, 1.43 mmol, 0.1 eq.) The orange solution was stirred at this
temperature for 15 min., then warmed to room temperature and stirred for 13 h. The
orange reaction mixture was quenched with water (30 mL) and extracted with CH2Cl2
(2x50 mL). The organic portion was rinsed with water (40 mL), brine (40 mL), dried
(MgSO4), and concentrated. The residue was then concentrated from toluene (2x20 mL)
and the resulting orange oil used without further purification. A solution of 1-ethyl-3-(3dimethylaminopropyl) carbodiimide (EDCI, 2.93 g, 15.3 mmol, 1.1 eq.), palmitic acid
(3.91 g, 15.3 mmol, 1.1 eq.) and DMAP (0.851 g, 6.90 mmol, 0.5 eq.) in CH 2Cl2 (60 mL)
was allowed to stir at room temperature under nitrogen for 15 min. Then, a solution of
the previously obtained oil from the dimethoxyltrityl protection (8.77 g, 13.9 mmol 1.0 eq)
in CH2Cl2 (30 mL) was added and stirring was continued for 4 h. The reaction mixture
was diluted with water (50 mL) and the organic layer was rinsed with water (50 mL),
brine (50 mL), dried (MgSO4), and concentrated. Purification by filtration through SiO 2
(9:1 CH2Cl2:hexanes) gave 1,2-O-dipalmitoyl-3-O-dimethoxyltriylglycerol (2a, 7.94 g,
9.11 mmol, 66%) as a colorless solid. Pure 2a can also be obtained by repeated
trituration with MeOH. Mp 64.5-66.0 °C; IR 2915, 2846, 1729 cm-1; 1H NMR (CDCl3, 300
MHz) 7.42 (d, 2.0 H, J = 2 Hz), 7.40-7.20 (m, 7 H), 6.82 (d, 4 H, J = 8.7 Hz), 5.28-5.22
(m, 1 H), 4.34 (dd, 1 H, J = 3.6, 11.7 Hz), 4.25 (dd, 1 H, J = 6.6, 11.7 Hz), 3.79 (s, 6 H),
3.22 (d, 2 H, J = 5.1 Hz), 2.33 (t, 2 H, J = 7.5 Hz), 2.23 (t, 2 H, J = 7.5 Hz), 1.65-1.53 (m,
4 H), 1.28-1.25 (m, 48 H), 0.91 (t, 3 H, J = 6.6 Hz);

13C

NMR (CDCl3, 125 MHz) 173.4,
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173.0, 158.5, 144.5, 135.7, 130.0, 128.1, 127.8, 126.8, 113.1, 86.0, 70.5, 62.9, 62.0,
55.1 34.4, 34.1, 31.9, 29.7-29.1 (multiple peaks), 25.0, 24.8, 22.7, 14.1.
C17H 35
O
O

C17H 35

O
ODMT

O

1,2-O-Distearoyl-3-O-dimethoxyltriylglycerol (2b). According to General Procedure B but
using 1b and purification by trituration with MeOH gave 1,2-O-distearoyl-3-Odimethoxyltriylglycerol (2b, 6.68 g, 6.48 mmol, 53%) as a colorless solid: Mp 67-68.4 °C;
IR 2915, 2848, 1730 cm-1; 1H NMR (CDCl3, 300 MHz) 7.45 (d, 2 H, J = 7.2 Hz), 7.357.24 (m, 7 H), 6.85 (d, 4 H, J = 9.0 Hz), 5.29-5.28 (m, 1 H), 4.35 (dd, 1 H, J = 8.1, 11.7
Hz), 4.25 (dd, 1 H, J = 6.6, 11.7 Hz), 3.82 (s, 6 H), 3.25 (d, 2 H, J = 3.3 Hz), 2.36 (t, 2 H,
J = 7.5 Hz), 2.27 (t, 2 H, J = 7.5 Hz), 1.69-1.56 (m, 4 H), 1.29 (m, 58 H), 0.91 (t, 3 H, J =
6.6 Hz);

13C

NMR (CDCl3, 125 MHz) 173.4, 173.0, 158.5, 144.6, 135.8, 130.1, 128.1,

127.8, 126.8, 113.1, 113.0, 86.1, 70.5, 62.9, 62.1, 55.2, 34.4, 34.1, 31.9, 29.7-29.1
(multiple peaks), 25.0, 24.8, 22.7, 14.1.
C15H 29
O
O

C15H 31

O
ODMT

O

1-O-Palmitoyl-2-O-palmitoleoyl-3-O-dimethoxyltriylglycerol (2c). According to General
Procedure B but using 1a and purification by chromatography on SiO2 (95:5,
hexanes:ethyl acetate) gave 1-O-palmitoyl-2-O-palmitoleoyl-3-O-dimethoxyltriylglycerol
(2c, 0.619 g, 0.712 mmol, 65%) as a clear colorless oil: IR 2923, 2853, 2093, 1741,
1250 cm-1; 1H NMR (CDCl3, 300 MHz) 7.43 (d, 2 H, J = 8.4 Hz), 7.31-7.25 (m, 7 H), 6.82
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(d, 4 H, J = 8.7 Hz), 5.40-5.30 (m, 2 H), 5.29-5.22 (m, 1 H), 4.34 (dd, 1 H, J = 3.6, 11.7
Hz), 4.23 (dd, 1 H, J = 6.6, 12.0 Hz), 3.79 (s, 6 H), 3.23-3.21 (m, 2 H), 2.33 (t, 2 H, J =
7.5 Hz), 2.23 (t, 2 H, J = 7.7 Hz), 2.02-2.00 (m, 4 H), 1.67-1.53 (m, 4 H), 1.29 (m, 40 H),
0.88 (t, 6 H, J = 6.8 Hz); 13C NMR (CDCl3, 125 MHz) 173.4, 173.0, 158.5, 144.6, 135.8,
135.7, 130.0, 129.7 128.1, 127.8, 126.8, 113.1, 86.1, 70.5, 62.9, 62.0, 55.2, 34.4, 34.1,
31.9, 31.8, 29.8-29.0 (multiple peaks), 27.2, 25.0, 24.9, 22.7, 22.6, 14.1.
C15H 31
O
O

C15H 31

O
OH

O

1,2-O-Dipalmitoylglycerol (3a) (Roodsari et al., 1999). General Procedure C. To a
solution of 2a (7.94 g, 9.11 mmol, 1.0 eq.) in CHCl3:MeOH (1:1, 90 mL) was added
Amberlite IR-120H (4.0 g). The reaction mixture was stirred for 2.5 h, then filtered
through basic alumina (EtOAc). The resulting yellow oil was precipitated from
Et2O:hexanes (3:1) and filtered to give 1,2-O-dipalmitoylglycerol (3a, 3.75 g, 5.50 mmol,
60%, purity by 1H NMR: 90%) as a colorless solid: 1H NMR (CDCl3, 400 MHz) 5.10-5.06
(m, 1 H), 4.32 (dd, 1 H, J = 4.8, 12.0 Hz), 4.24 (dd, 1 H, J = 6.0, 12.0 Hz), 3.74-3.73 (m,
2 H), 2.33 (apparent q, 4 H, J = 8 Hz), 1.65-1.58 (m, 4 H), 1.28-1.25 (m, 48 H), 0.88 (t, 3
H, J = 6.6 Hz).
C17H 35
O
O

C17H 35

O
OH

O

1,2-O-Distearoylglycerol (3b) (Lee et al., 2007). According to General Procedure C but
using 2b, and purification by trituration with Et2O:hexanes (3:1) gave 1,2-O-
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distearoylglycerol (3b, 2.08 g, 3.39 mmol, 72%) as a colorless solid: 1H NMR (CDCl3,
500 MHz) 5.10-5.06 (m, 1 H), 4.32 (dd, 1 H, J1 = 4.5 Hz, J2 = 12 Hz), 4.24 (dd, 1 H, J1 =
5.5 Hz, J2 = 12 Hz), 3.79-3.72 (m, 2 H), 2.34 (m, 4 H), 1.99 (t, 1 H, J = 4.0 Hz), 1.641.54 (m, 4 H), 1.29-1.25 (m, 56 H), 0.88 (t, 3 H, J = 7.0 Hz).
C15H 29
O
O

C15H 31

O
OH

O

1-O-Palmitoyl-2-O-palmitoleoylglycerol (3c). According to General Procedure C but
using 2c and purification by chromatography on SiO2 (1:0 to 5:1, CH2Cl2:ethyl acetate)
gave 1-O-palmitoyl-2-O-palmitoleoylglycerol (3c, 64 mg, 0.113 mmol, 98%) as a light
yellow oil: IR 3502, 2919, 2850, 2093, 1737, 1163 cm -1; 1H NMR (CDCl3, 300 MHz)
5.40-5.30 (m, 2 H), 5.10-5.05 (m, 1 H), 4.32 (dd, 1 H, J = 4.8, 12.3 Hz), 4.24 (dd, 1 H, J
= 5.4, 11.7 Hz), 3.73 (m, 2 H), 2.33 (apparent q, 4 H, J = 7.3 Hz), 2.02-2.00, (m, 4 H),
1.64-1.54 (m, 4 H), 1.30-1.27 (m, 40 H), 0.88 (t, 6 H, J = 6.7 Hz); 13C NMR (CDCl3, 125
MHz) 173.8, 173.4, 130.0, 129.7 128.1, 72.1, 62.0, 61.6, 34.3, 34.1, 31.9, 29.7-29.0
(multiple peaks), 27.2, 25.0, 24.9, 22.7, 22.6, 14.1; HRMS (ESI +) m/z calculated for
C35H67O5 [M+H] 567.4983, found 567.4960.

N, N-Diisopropylamidomethylchlorophosphite (4) (Stadlbauer et al., 2009). To a solution
of PCl3 (3.2 mL, 36 mmol, 1.04 eq.) and pyridine (2.9 mL, 36 mmol, 1.04 eq.) in Et 2O
(120 mL) at -78 °C under argon was added dry MeOH (1.4 mL, 35 mmol, 1.0 eq.) in
Et2O (4 mL) over 30 min. The reaction mixture was stirred for 3 h at room temperature.
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diluted with Et2O (40 mL) and cooled to 0 °C. Diisopropylamine (9.6 mL, 67.9 mmol, 2.0
eq.) was added over 0.5 h and stirring was continued for 22 h at room temperature. The
salts were filtered off under argon, rinsed with Et2O (50 mL) and the solvent was
distilled off. The resulting yellow oil was purified by vacuum distillation to give N,Ndiisopropylamidomethylchlorophosphite (4, 3.73 g, 18.9 mmol, 56%) as a clear colorless
oil: Bp 88 °C (12 Torr); 1H NMR (CD2Cl2, 400 MHz) 3.74-3.64 (m, 2 H), 3.51 (d, 3 H, J =
14.4 Hz), 1.20-1.16 (m, 12 H); 31P NMR (CD2Cl2, 162 MHz) 183.8.
O
BnO

O

4-((Benzyloxy)methyl)-2,2-dimethyl-1,3-dioxolane (5). (Lee et al., 2007) A slurry of 60%
NaH in mineral oil (360 mg, 9.00 mmol, 1.2 eq.) in THF (10 mL) at 0 °C under nitrogen
was added to a solution of 2,2-dimethyl-1,3-dioxolane-4-methanol (1.0 mL, 7.8 mmol,
1.0 eq.) in THF (5 mL). The reaction mixture was stirred for 30 min, then BnBr (0.98 mL,
1.4 mmol, 1.05 eq.) was added in a drop wise fashion. The reaction mixture was
warmed to room temperature and stirred for 2.5 h. The reaction was quenched with
water (8 mL), diluted with Et2O (20 mL), and the layers were separated. The aqueous
layer was extracted with Et2O (25 mL) and the combined organic layers were rinsed with
brine (10 mL), dried (MgSO4), and concentrated. Purification by chromatography on
SiO2 (95:5 to 9:1 to 85:15, hexanes:ethyl acetate) gave 4-((benzyloxy)methyl)-2,2dimethyl-1,3-dioxolane (5, 1.15 g, 5.17 mmol, 67%) as a clear colorless oil: 1H NMR
(CDCl3, 400 MHz) 7.35-7.29 (m, 5 H), 4.59, 4.56 (AB, 2 H, J = 12.0 Hz), 4.34-4.28 (m, 1
H), 4.06 (dd, 1 H, J = 6.4, 8.0 Hz), 3.75 (dd, 1 H, J = 6.4, 8.4 Hz), 3.56, 3.45 (ABd, 2 H,
J = 5.6, 9.6 Hz), 3.46 (dd, 1 H, J = 5.6, 9.6 Hz), 1.42 (s, 3 H), 1.37 (s, 3 H).
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BnO

OTBS
OTBS

1-O-Benzyl-2,3-O-bis(tert-butyldimethylsilyl)glycerol (6). A solution of 5 (1.15 g, 5.17
mmol, 1.0 eq.) in THF:H2O (2:1, 10 mL) was treated with 12 M HCl (2.1, 25 mmol, 4.9
eq.), and the reaction mixture was stirred for 1 h at room temperature, poured into sat.
NaHCO3 (30 mL) and extracted with Et2O (3x 25 mL). The combined organic layers
were rinsed brine (25 mL), dried (MgSO4), and concentrated. The resulting yellow oil
was dissolved in CH2Cl2 (8.7 mL) at 0 °C under nitrogen and treated with Et3N (1.4 mL,
9.9 mmol, 2.3 eq.) and TBSOTf (2.2 mL, 9.5 mmol, 2.2 eq.). The cloudy white reaction
mixture was then stirred for 3 h at room temperature, quenched with H 2O (8 mL) and
diluted with CH2Cl2 (10 mL). The organic layer was rinsed with brine (8 mL), dried
(MgSO4), and concentrated. Purification by chromatography on SiO 2 (99:1 to 95:5,
hexanes:ethyl acetate) gave 1-O-benzyl-2,3-O-bis(tert-butyldimethylsilyl)glycerol (6,
1.72, 4.31 mmol, 83% over 2 steps) as a clear colorless oil: 1H NMR (CDCl3, 500 MHz)
7.35-7.33 (m, 4 H), 7.28-7.26 (m, 1 H), 4.54 (s, 2 H), 3.89-3.84 (m, 1 H), 3.61 (dd, 1 H, J
= 6.0, 10.0 Hz), 3.57-3.52 (m, 2 H), 3.42 (dd, 1 H, J = 5.5, 10.0 Hz), 0.87 (s, 18 H),
0.070 (d, 6 H, J = 1.5 Hz), 0.042 (s, 6 H).
HO

OTBS
OTBS

2,3-O-Bis(tert-butyldimethylsilyl)glycerol (7). (Harried et al., 2009) To a solution of 6
(1.62 g, 4.06 mmol, 1.0 eq.) in ethyl acetate (20 mL) was added 10% Pd/C (0.161 g,
0.152 mmol, 0.037 eq.). The reaction mixture was submitted to hydrogenation on a Parr
hydrogenator under H2 (5 atm) for 1 h, filtered through Celite (ethyl acetate) and
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concentrated to give 2,3-O-bis(tert-butyldimethylsilyl)glycerol (7, 1.15 g, 3.59 mmol,
88%) as a clear colorless oil that was used without further purification. An analytically
pure sample was obtained by chromatography on SiO2 (95:5 to 9:1, hexanes:ethyl
acetate): 1H NMR (CDCl3, 300 MHz) 3.79-3.74 (m, 1 H), 3.69-3.53 (m, 4 H), 2.10 (bs, 1
H), 0.90 (s, 18 H), 0.1-0.06 (m, 12 H).
C15H 31
O
O

C15H 31
O

O
O

O
O
P
OMe

OTBS
OTBS

3-(((2,3-Bis((tert-butyldimethylsilyl)oxy)propoxy)(methoxy)phosphoryl)oxy)propane-1,2diyl dipalmitate (8a).7 General Procedure D. To a solution of 3a (1.73 g, 2.89 mmol, 1.0
eq.) and diisopropylethylamine (DIPEA, 0.53 mL, 3.2 mmol, 1.1 eq.) in CH2Cl2 (30 mL)
under nitrogen was added 7 (6.0 mL, 3.0 mmol, 1.1 eq.). The reaction mixture was
stirred for 1 h, and treated dropwise with a solution of 6 (0.921 g, 2.87 mmol, 0.99 eq.)
and 4,5-dicyanoimidazole (0.700 g, 5.80 mmol, 2 eq.) in THF (4.9 mL). The solution was
stirred for 1 h, cooled to 0 °C, treated with Bu4NIO4 (1.46 g, 3.36 mmol, 1.2 eq.), and
stirring was continued for 30 min. The mixture was diluted with water (15 mL) and the
combined organic layers were rinsed with sat. Na2S2O3 (15 mL), sat. NaHCO3 (15 mL),
and brine (15 mL), dried (MgSO4), and concentrated. The crude residue was filtered
through a plug of SiO2 (1:1, hexanes:ethyl acetate) and concentrated. Purification by
chromatography on SiO2 (5:1 to 3:1, hexanes:ethyl acetate) gave 3-(((2,3-bis((tertbutyldimethylsilyl)oxy)propoxy)(methoxy) phosphoryl)oxy)propane-1,2-diyl dipalmitate
(8a, 1.42 g, 1.47 mmol, 51%) as a clear colorless oil: IR 2922, 2854, 1741, 1252, 835
cm-1; 1H NMR (CDCl3, 300 MHz) 5.25-5.19 (m, 1 H), 4.36-4.30 (m, 1 H), 4.19-4.09 (m, 4
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H), 3.97-3.83 (m, 2 H), 3.76 (d, 3 H, J =11.1 Hz; diasteromers), 3.56-3.54 (m, 2 H),
2.34-2.27 (m, 4 H), 2.23 (t, 2 H, J = 7.5 Hz), 1.61-1.56 (m, 4 H), 1.28-1.25 (m, 48 H),
0.88-0.85 (m, 24 H), 0.08 (s, 3 H), 0.07 (s, 3 H), 0.05 (s, 6 H);

13C

NMR (CDCl3, 125

MHz) 173.2, 172.7, 72.0 (d, J = 7.5 Hz), 69.4 (d, J = 7.5 Hz), 69.1 (d, J = 6.5 Hz), 65.465.3 (multiple peaks), 64.0, 61.6, 55.4 (d, J = 6.3 Hz) 34.1, 34.0, 31.9, 31.6, 29.7-29.1
(multiple peaks), 25.8, 25.7, 24.8, 22.6, 18.3, 18.1,14.1, -4.7, -4.8, -5.5; HRMS (ESI+)
m/z calculated for C51H106O10PSi2 [M+H]+ 965.7057, found 965.7086.
C17H 35
O
O

C17H 35
O

O
O

O
O
P
OMe

OTBS
OTBS

3-(((2,3-Bis((tert-butyldimethylsilyl)oxy)propoxy)(methoxy)phosphoryl)oxy)propane-1,2diyl distearate (8b). (Harried et al., 2009) According to General Procedure D but using
3b and purification by chromatography on SiO2 (5:1, hexanes:ethyl acetate) gave 3(((2,3-bis((tert-butyldimethylsilyl)oxy)propoxy)(methoxy)phosphoryl)oxy)propane-1,2-diyl
distearate (8b, 0.605 g, 0.592 mmol, 67%) as a waxy colorless solid: Mp 31.0-31.9 °C;
IR 2923, 2852, 1743, 1252, 835 cm-1; 1H NMR (CDCl3, 300 MHz) 5.24-5.20 (m, 1 H),
4.37-4.31 (m, 1 H), 4.22-4.09 (m, 4 H), 3.97-3.84 (m, 2 H), 3.76 (d, 3 H, J =11.1 Hz;
diasteromers), 3.57-3.54 (m, 2 H), 2.31 (apparent q, 4 H, J = 7.0 Hz), 1.61-1.57 (m, 4 H),
1.28-1.25 (m, 56 H), 0.88-0.86 (m, 24 H), 0.09 (s, 3 H), 0.08 (s, 3 H), 0.05 (s, 6 H);

13C

NMR (CDCl3, 125 MHz) 173.2, 172.2, 72.0 (d, J = 8.8 Hz), 69.4 (d, J = 7.5 Hz), 69.269.1 (m), 65.4-65.3 (m), 64.0, 61.6, 54.4 (d, J = 5.0 Hz), 34.2, 34.0, 31.9, 29.7-29.1
(multiple peaks), 25.9, 25.7, 24.8, 22.7, 22.6, 18.3, 18.1,14.1, -4.7, -4.8, -5.4, -5.5;
HRMS (ESI+) m/z calculated for C55H114O10PSi2 [M+H]+ 1021.7688, found 1021.7766.
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C15H 31
O
O

C15H 31

O

O
O
P
OMe

O

O

OTBS
OH

3-(((2-((Tert-butyldimethylsilyl)oxy)-3-hydroxypropoxy)(methoxy)phosphoryl)oxy)
propane-1,2-diyl dipalmitate (9a). General Procedure E. To a solution of 8a (800 mg,
0.829 mmol, 1.0 eq.) in CH2Cl2:MeOH (1:1, 8.3 mL) at 0 °C was added camphorsulfonic
acid (195 mg, 0.823 mmol, 1.0 eq.). The reaction mixture was maintained between -5
and 5 °C and stirred for 5.5 h. The solution was filtered through a small plug of basic
alumina (ethyl acetate) and concentrated. Purification by chromatography on SiO 2 (3:1
to

1:1,

hexanes:ethyl

acetate)

gave

3-(((2-((tert-butyldimethylsilyl)oxy)-3-

hydroxypropoxy)(methoxy)phosphoryl)oxy)propane-1,2-diyl dipalmitate (9a, 435 mg,
0.511 mmol, 62%) as a colorless solid: Mp 27.8-28.0 °C; IR 2922, 2854, 1741, 1252,
835 cm-1; 1H NMR (CDCl3, 400 MHz) 5.29-5.20 (m, 1 H), 4.33 (dd, 1 H, J = 4.4, 12.0 Hz),
4.21-4.14 (m, 3 H), 4.06-4.01 (m, 2 H), 3.93-3.89 (m, 1 H), 3.80-3.76 (m, 3 H), 3.67-3.50
(m, 2 H), 2.35-2.31 (m, 5 H), 1.62-1.60 (m, 4 H), 1.28-1.25 (m, 48 H), 0.90-0.86 (m, 15
H), 0.11 (s, 6 H);

13C

NMR (CDCl3, 100 MHz) 173.2, 172.8, 71.1 (d, J = 7.0 Hz), 69.4-

69.3 (multiple peaks), 67.7 (m), 65.6-65.5 (multiple peaks), 63.0, 61.6, 54.6 (multiple
peaks), 34.1, 34.0, 31.9, 29.7-29.1 (multiple peaks), 25.7, 24.8, 22.7, 18.0, 14.1, -4.8, 4.9; HRMS (ESI+) m/z calculated for C45H92O10PSi [M+H]+ 851.6192, found 851.6180.
C17H 35
O
O

C17H 35
O

O
O

O
O
P
OMe

OTBS
OH
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3-(((2-((Tert-butyldimethylsilyl)oxy)-3-hydroxypropoxy)(methoxy)phosphoryl)oxy)
propane-1,2-diyl distearate (9b). According to General Procedure E but using 8b and
purification by chromatography on SiO2 (4:1 to 1:1, hexanes:ethyl acetate) gave 3-(((2((tert-butyldimethylsilyl)oxy)-3-hydroxypropoxy)(methoxy)phosphoryl)oxy)propane-1,2diyl distearate (9b, 470 mg, 0.518 mmol, 55%) as a waxy colorless solid: Mp = 41.241.7 °C; IR 3535, 2921, 2850, 1739, 733 cm-1; 1H NMR (CDCl3, 300 MHz) 5.25-5.22 (m,
1 H), 4.34 (dd, 1 H, J = 4.2, 12.0 Hz), 4.19-4.11 (m, 3 H), 4.05-4.02 (m, 2 H), 3.95-3.90
(m, 1 H), 3.78 (d, 3 H, J = 11.4 Hz; diasteromers), 3.67-3.60 (m, 2 H), 2.36-2.29 (m, 5
H), 1.62-1.58 (m, 4 H), 1.28-1.25 (m, 56 H), 0.90-0.86 (m, 15 H), 0.11 (s, 6 H);

13C

NMR

(CDCl3, 125 MHz) 173.3, 172.8, 71.1 (d, J = 7.1 Hz), 69.4 (multiple peaks), 67.7
(multiple peaks), 65.6 (multiple peaks), 63.0, 61.6, 54.6 (multiple peaks), 34.2, 34.0,
31.9, 29.7-29.1 (multiple peaks), 25.7, 24.8, 22.7, 18.0, 14.1, -4.7, -4.9; HRMS (ESI+)
m/z calculated for C49H100O10PSi [M+H]+ 907.6818, found 907.6785.
C15H 31

C15H 31
O
O

C15H 31
O

O

O
O
O
P
OMe

OTBS
O
O
O
P
OMe

O

O
O

C15H 31
O

3-(((3-(((2,3-(Palmitoyloxy)propoxy)(methoxy)phosphoryl)oxy)-2-((tertbutyldimethylsilyl)oxy)propoxy)(methoxy)phosphoryl)oxy)propane-1,2-diyl

dipalmitate

(10a). (Harried et al., 2009) To a solution of 9a (322 mg, 0.378 mmol, 1.0 eq.) in CH2Cl2
(3.7 mL) at 0 °C under nitrogen was added DIPEA (0.069 mL, 0.42 mmol, 1.1 eq.) and a
0.5 M solution of 7 in CH2Cl2 (0.83 mL, 0.42 mmol, 1.1 eq.). The reaction mixture was
warmed to room temperature, stirred for 1.5 h, and treated with a solution of 3a (364 mg,
0.416 mmol, 1.1 eq.) and 4,5-dicyanoimidazole (90 mg, 0.76 mmol, 2.0 eq.) in THF (1.5
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mL) in a drowpwise fashion. The reaction mixture was stirred for 2 h, cooled to 0 °C,
treated with Bu4NIO4 (186 mg, 0.429 mmol, 1.1 eq.) and stirred for 40 min. The mixture
was diluted with water (3 mL) and CH2Cl2 (5 mL) and and the organic layer was rinsed
with sat. Na2S2O3 (3 mL) and brine (3 mL), dried (MgSO4), and concentrated. The crude
product was filtered through a plug of SiO2 (1:1 hexanes:ethyl acetate) and
concentrated. Purification by chromatography on SiO2 (3:1 to 2:1 to 1:1, hexanes:ethyl
acetate) gave 3-(((3-(((2,3-(palmitoyloxy)propoxy)(methoxy) phosphoryl)oxy)-2-((tertbutyldimethylsilyl)oxy)propoxy)(methoxy)phosphoryl)oxy)propane-1,2-diyl

dipalmitate

(10a, 381 mg, 0.255 mmol, 67%) as a colorless solid: Mp 36.5-37.5 °C; IR

2913,

2848, 1737, 1465, 913, 744 cm-1; 1H NMR (CDCl3, 400 MHz) 5.25-5.22 (m, 2 H), 4.364.31 (m, 2 H), 4.22-4.12 (m, 6 H), 4.05-3.97 (m, 5 H), 3.78 (d, 6 H, J = 11.2 Hz;
diasteromers), 2.32 (apparent q, 8 H, J = 7.9 Hz), 1.61-1.57 (m, 8 H), 1.28-1.25 (m, 96
H), 0.89-0.86 (m, 21 H), 0.11 (s, 6 H);

13C

NMR (CDCl3, 125 MHz)

173.1, 172.7, 69.8

(multiple peaks), 69.4 (d, J = 6.3 Hz), 67.8 (2, J = 6.3 Hz), 65.7 (multiple peaks), 61.6,
54.6 (d, J = 6.3 Hz), 34.2, 34.0, 31.9, 29.7-29.1 (multiple peaks), 25.6, 24.9, 22.7, 18.0,
14.1, -4.9; HRMS (ESI+) m/z calculated for C81H161O17P2Si [M+H]+ 1496.0973, found
1496.0903.
C17H 35
O
O

C17H 35
O

C17H 35

O
O

O
O
P
OMe

OTBS
O
O
O
P
OMe

O

O
O

C17H 35
O

3-(((3-(((2,3-(Stearoyloxy)propoxy)(methoxy)phosphoryl)oxy)-2-((tertbutyldimethylsilyl)oxy)propoxy)(methoxy)phosphoryl)oxy)propane-1,2-diyl

distearate

(10b). General Procedure F (Abe et al., 2011). To a solution of 3b (356 mg, 0.570 mmol,
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1.0 eq.) and DIPEA (0.10 mL, 0.63 mmol, 1.1 eq.) under nitrogen was added a 0.5 M
solution of 7 (1.2 mL, 0.63 mmol, 1.1 eq.) in CH2Cl2. The reaction was mixture stirred for
1 h, and treated drowpwise with a solution of 9b (470 mg, 0.518 mmol, 1.0 eq.) and 4,5dicyanoimidazole (125 mg, 1.04 mmol, 2.0 eq.) in THF (1.5 mL). The mixture was
stirred for 3 h, cooled to 0 °C, treated with Bu4NIO4 (173 mg, 0.399 mmol, 1.2 eq.),
stirred for 45 min and diluted with water (2 mL) and CH2Cl2 (5 mL). The organic layer
was rinsed with sat. Na2S2O3 (2x3 mL), sat. NaHCO3 (3 mL), and brine (3 mL), dried
(MgSO4), and concentrated. The crude residue was filtered through a plug of SiO 2 (1:1,
hexanes:ethyl acetate), concentrated, dissolved in CH2Cl2 (4 mL) and treated with
TBSCl (43 mg, 0.29 mmol 0.5 eq.), imidazole (21 mg, 0.31 0.6 eq.) and DMAP (3 mg,
0.024 mmol 0.04 eq.). The reaction mixture was stirred for 4.5 h, quenched with water
(4 mL) and diluted with CH2Cl2 (4 mL). The organic layer was rinsed with brine (4 mL),
dried (MgSO4), and concentrated. Purification by chromatography on SiO 2 (5:1 to 3:1 to
1:1,

hexanes:ethyl

acetate)

gave

3-(((3-(((2,3-

(stearoyloxy)propoxy)(methoxy)phosphoryl)oxy)-2-((tert-butyldimethylsilyl) oxy)propoxy)
(methoxy)phosphoryl)oxy)propane-1,2-diyl distearate (10b, 335 mg, 0.208 mmol, 40%)
as a waxy colorless solid: Mp 48.1-48.2 °C; IR 2918, 2851, 1741, 1043 cm-1; 1H NMR
(CDCl3, 300 MHz) 5.25-5.22 (m, 2 H), 4.35-4.30 (m, 2 H), 4.29-4.04 (m, 11 H), 3.78 (d,
6 H, J = 11.4 Hz; diasteromers), 2.32 (apparent q, 8 H, J = 7.2 Hz), 1.61-1.57 (m, 8 H),
1.25 (m, 112 H), 0.89-0.86 (m, 21 H), 0.11 (s, 6 H);

13C

NMR (CDCl3, 125 MHz) 173.2,

172.8, 69.7 (multiple peaks), 69.4 (multiple peaks), 67.9 (multiple peaks), 65.6 (multiple
peaks), 61.6, 54.6 (d, J = 5.9 Hz), 34.1, 34.0, 31.9, 29.7-29.1 (multiple peaks), 25.6,
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24.8, 22.7, 18.0, 14.1, -4.9; HRMS (ESI+) m/z calculated for C89H177O17P2Si [M+H]+
1608.2225, found 1608.2190.
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O
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O
O
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3-(((3-(((2-Palmitoleoyloxy-3-(palmitoyloxy)propoxy)(methoxy)phosphoryl)oxy)-2-((tertbutyldimethylsilyl)oxy)propoxy)(methoxy)phosphoryl)oxy)propane-1,2-diyl

dipalmitate

(10c). According to General Procedure F using 3c and 9c and a purification by
chromatography on SiO2 (5:1 to 3:1 to 1:1, hexanes:ethyl acetate) gave 3-(((3-(((2palmitoleoyloxy-3-(palmitoyloxy)propoxy)(methoxy)phosphoryl)oxy)-2-((tertbutyldimethylsilyl)oxy)propoxy) (methoxy)phosphoryl)oxy)propane-1,2-diyl dipalmitate
(10c,145 mg, 0.0970 mmol, 39%) as a clear colorless oil: IR 2919, 2850, 1741, 1465,
1034 cm-1; 1H NMR (CDCl3, 300 MHz) 5.35-5.33 (m, 2 H), 5.25-5.22 (m, 2 H), 4.36-4.32
(m, 2 H), 4.23-4.12 (m, 6 H), 4.05-4.00 (m, 5 H), 3.78 (d, 6 H, J = 11.4 Hz; diasteromers
visible), 2.32 (apparent q, 8 H, J = 7.2 Hz), 2.02-2.00 (m, 4 H), 1.61-1.54 (m, 8 H), 1.301.26 (m, 88 H), 0.89-0.86 (m, 21 H), 0.11 (s, 6 H);

13C

NMR (CDCl3, 125 MHz) 173.2,

172.8, 130.0, 129.7, 69.7 (m), 69.4 (d, J = 6.5 Hz), 67.8 (d, J = 5.5 Hz), 65.6 (m), 61.6,
54.6 (d, J = 6.0 Hz), 34.1, 34.0, 31.8, 29.7-29.0 (multiple peaks), 25.6, 24.8, 22.7, 22.6
18.0, 14.1, -4.9; HRMS (ESI+) m/z calculated for C81H159O17P2Si [M+H]+ 1494.0816,
found 1494.0825.

70

Tetrapalmitoylcardiolipin diammonium salt (11a). General Procedure G. A solution of
10a and NaI (24 mg, 0.16 mmol, 4 eq.) in 2-butanone (0.8 mL) was heated at reflux for
13.5 h and concentrated. The crude waxy yellow solid was dissolved in 1 M
HCl:THF:H2O (0.1:2:1, 1 mL) and the resulting yellow solution was stirred for 12 h, and
quenched with 30% NH4OH (2 mL). The resulting white slurry was extracted with CHCl3
(3x5 mL), concentrated, and triturated with Et2O to give tetrapalmitoylcardiolipin
diammonium salt (11a, 40 mg, 0.029 mmol, 73%) as a colorless solid containing 5-7%
(ESI-MS) monolyso (tripalmitoyl) cardiolipin as an impurity that was removed by thin
layer chromatography: 1H NMR (CDCl3, 400 MHz) 7.46 (bs, 8 H), 5.21(bs, 2 H), 4.37 (m,
2 H), 4.17-4.13 (m, 2 H), 3.91 (bs, 9 H), 2.29 (apparent q, 8 H, J = 8.5 Hz), 1.58 (m, 8 H),
1.28-1.25 (m, 98 H), 0.87 (t, 12 H, J = 6.8 Hz); HRMS (ESI-) m/z calculated for
C73H141O17P2 [M-H]- 1351.9639, found 1351.9648.
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Tetrastearoylcardiolipin diammonium salt (11b) (Abe et al., 2011), According to General
Procedure G using 10b and purification by precipitation from hot THF gave
tetrastearoylcardiolipin diammonium salt (11b, 53 mg, 0.035 mmol, 38%) as a colorless
powder containing 5-7% (ESI-MS) monolyso (tristearoylcardiolipin) cardiolipin as an
impurity that was removed by thin layer chromatography: 1H NMR (CDCl3, 400 MHz)
7.44 (bs, 8 H), 5.21 (bs, 2 H), 4.37-4.35 (m, 2 H), 4.17-4.13 (m, 2 H), 3.92 (bs, 9 H),
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2.30 (apparent q, 8 H, J = 8.3 Hz), 1.59-1.58 (m, 8 H), 1.28-1.25 (m, 112 H), 0.88 (t, 12
H, J = 6.8 Hz); MS (ESI-) m/z calculated for C81H156O17P2 [M-2H]2- 731.5, found 731.8.
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Tripalmitoyl-monopalmitoleoylcardiolipin diammonium salt (11c). According to General
Procedure G using 10c and purification by trituration with Et2O gave tripalmitoylmonopalmitoleoylcardiolipin diammonium salt (11c, 83 mg, 0.060 mmol, 70%) as a
colorless powder containing 5-7% (ESI-MS) monolyso-11c as an impurity that was
removed by thin layer chromatography: 1H NMR (CDCl3, 400 MHz)

7.44 (bs, 8 H),

5.35-5.32 (m, 2 H), 5.21 (bs, 2 H), 4.39-4.35 (m, 2 H), 4.17-4.13 (m, 2 H), 3.84 (bs, 9 H),
2.30 (apparent q, 8 H, J = 8.1 Hz), 2.01-1.99 (m, 4 H), 1.66-1.58 (m, 8 H), 1.28-1.25 (m,
106 H), 0.88 (t, 12 H, J = 6.4 Hz); MS (ESI-) m/z calculated for C73H138O17P2 [M-2H]2674.5, found 674.7.
Assessment of Substrate Specificity of Purified Cld1—Activity of Cld1 was detected
in liposomes by accumulation of MLCL after CL hydrolysis. Liposomes containing
DOPC and CL (10 µM, 1:1) were prepared by sonication (Ultrasonic Homogenizer 4710
series, Cole-Parmer Instrument Co., Chicago, IL) and treated with Cld1 (0.1−0.5 μg of
protein per 250µl sample) in 50 mM HEPES pH 7.45, containing 100 μM DTPA for 20
min at 37°C. After incubation with CLD1, lipids were extracted by Folch procedure and
analysis of MLCL was performed using LC−ESI-MS. Internal standards of MLCLs were
prepared from respective CLs in PLA2 (porcine pancreatic, Sigma) driven reaction as
described by Kim and Hoppel (2011) (Kim and Hoppel, 2011) with slight modifications.
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Molecular modeling—The homology model of CLD1 was built using I-TASSER (Yang
et al., 2015) webserver. Hsad, a steroid-degrading hydrolase from Mycobacterium
Tuberculosis (PDB ID: 2VF2 (Lack et al., 2008)), was utilized as a template. C-score for
the constructed model was equal to 1.78. The C-score is a confidence score to estimate
the quality of predicted models by I-TASSER, in the range of [-5,2], where a C-score of
higher value defines a model with a high confidence (Yang et al., 2015). The model
showed a TM-score equal to 0.5. TM-score is a scale for measuring the structural
similarity of two protein models, with lower sensitivity to the local error compared to
RMSD (a TM-score >0.5 indicates a model of correct topology independent from protein
length) (Zhang and Skolnick, 2004). The overlay of the cavities and cartoon
representations was employed to explore the active site and a possible channel
facilitating access of CL acyl chain to the hydrolase domain of CLD1. Three homoacylated-CL species, including (C14:0)4-CL, (C16:0)4-CL and (C18:2)4-CL were
docked to the predicted structure of CLD1 using default settings by AutoDock Vina
(http://vina.scripps.edu) (Trott and Olson, 2010). The pdb into pdbqt format conversion
of lipids and protein structures was performed using MGL Tools. A grid box was
centered at coordinates 39.861, 40.057, 74.975 with 100Å, 80Å and 90Å units in x, y
and z directions, respectively, to cover the entire protein structure. AutoDock Vina
reports the 9 lowest energy conformations, which were inspected using PyMOL
software (www.pymol.org).
Statistical Analysis—The results are presented as mean ± S.D. values from at least
three experiments, and statistical analyses were performed by paired/unpaired
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Figure 3-1. LC/MS analysis of CL in S. cerevisiae.
A. 3D-mass spectra (left panels) and MS maps (right panels) of CL obtained from
wild type and cld1Δ, taz1Δ, cld1Δ/taz1Δ mutants before and after supplementation
with different fatty acids. (OA, oleic acid C18:1; LA, linoleic acid C18:2, DHA,
docosahexaenoic acid C22:6, AA, arachidonic acid C20:4). Insert: Mass spectrum of
CL from yeast supplemented with C20:4 (AA). MS signals of C20:4 containing CL
molecular species with m/z 1393.92, 1395.92, 1421.95, 1423.95, 1445.95, 1447.95,
1449.98, 1471.98, 1473.98, 1500.00 identified as C16:1/C16:1/C16:1/C20:4,
C16:1/C16:1/C16:0/C20:4, C16:1/C16:1/C18:1/C20:4, C16:0/C16:1/C18:1/C20:4,
C16:0/C16:1/C20:4/C20:4, C16:0/C16:0/C20:4/C20:4, C16:1/C18:1/C18:1/C20:4,
C16:1/C18:1/C20:4/C20:4, C16:0/C18:1/C20:4/C20:4 and C18:1/C18:1/C20:4/C20:4,
respectively and shown in blue. B. Quantitative assessment of hetero- and homoacylated molecular species of CLs in wt yeast cells before and after supplementation
with different FAs.
Student's t-test. The statistical significance of differences was set at p< 0.05.
RESULTS
Exogenous FAs define the molecular speciation of CLs in wt and mutant S.
cerevisiae cells.
In wt S. cerevisiae cells grown without FA supplementation, there is an
assortment of CL molecular species with different FA residues ranging from C10 to C18.
Among those, only singly-unsaturated CL species were present whereas PUFA were
not detected (Figure 3-1A). To gain insight into the mechanisms of CL remodeling and
biosynthesis, we chose to expose yeast cells to FAs with different chain lengths as well
as unsaturation. In particular, we employed oleic (18:1), linoleic (18:2), arachidonic
(20:4) and docosahexaenoic (22:6) acids as components of the growth medium and
established their effects on the phospholipidomes of S. cerevisiae cells.
Supplementation of the growth medium with either 18:1 or 18:2 FAs caused
dramatic changes in CLs composition (Figure 3-1B). Only CL molecular species
containing from one to four 18:1 or C18:2 were detectable, while essentially all other
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molecular species of CLs with shorter chains and devoid of C18-containing species
were not found (Figure3- 1). Notably, a huge preponderance of homo-acylated –
(18:1)4-CL- and (18:2)4-TLCL species – was observed (Figure 3-1B). The second
largest cluster of CLs included hetero-acylated - tri-C18:1 and tri-C18:2-species,
respectively (Figure 3-1). These robust effects of exogenously added C18 FAs in wt
cells were much less pronounced when C20:4 was used (Figure 3-1). In fact, only
singly- and doubly- 20:4-acylated CL species were detectable; no tri- or tetra-20:4-CL
species were observed (Figure 3-1B, Supplementary Figure 4). Upon treatment with
22:6, CLs speciation remained unchanged vs untreated w/t cells (Figure 3-1B); 22:6contaning CL species were not detectable. Overall, these data indicate that the
remodeling and biosynthetic pathways for CLs are very specific and favor the synthesis
of C18-containing molecular species. The balance of natural processes of CL hydrolysis
and re-acylation yields only very low concentrations of MLCLs – as intermediates of
these reactions. Supplementation with FAs did not significantly affect the MLCL content
in wt cells (Figure 3-2).
CL remodeling from MLCL in yeast cells occurs via a single metabolic reaction
catalyzed by Taz1 (Ren et al., 2014):
PL-2FA + MLCL-3FA  LPL-1FA + CL-4FA
where PL-2FA is a donor di-acylated phospholipid, MLCL-3FA is an acceptor MLCL,
LPL is lyso-phospholipid formed, and CL-4FA is a remodeled CL. For CL reacylation,
the enzyme utilizes donor phospholipids, particularly PC and PE. Therefore, we also
studied the effects of C18:1 and C18:2 supplementations on the phospholipidome of
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Figure 3-2. LC/MS analysis of mono-lyso-CL (MLCL) in S. cerevisiae.

A. Mass spectra of MLCL obtained from wt (left panel) yeast cells and cld1Δ, taz1Δ,
cld1Δ/taz1Δ mutants supplemented with C18:1 (OA) (middle panel) and C18:2 (LA)
(right panel). B. Quantitative assessments of MLCL performed for wild type yeast
cells and cld1Δ, taz1Δ, cld1Δ/taz1Δ mutants.
these cells. We found no changes in the total content of phosphatidylcholine (PC) and
phosphatidylethanolamine (PE) in supplemented cells. However, supplementation with
18:1 resulted in the accumulation of PE and PC species containing 18:1 FA residues
(Figure 3-3). Similarly, addition to the medium of 18:2 was associated with higher levels
of 18:2-containing PE and PC (Figure 3-3). The enrichment with C18 FA residues was
at the expense of the decreased contents of PE and PC species containing 16:0 and
16:1 (Figure 3-3). Further, we found that supplementation of cells with either 18:1 or
18:2 resulted in the accumulation of homo-acylated PC and PE molecular species
(containing either 18:1 or 18:2 in both sn-1 and sn-2 positions). Subsequently, we
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Figure
3-3.
LC/MS
analysis
and
quantitative
assessment
of
phosphatidylcholine (PC) and phosphatidylethanolamine (PE) as well as their
hydrolysis products – lyso-PC (LPC) and lyso-PE (LPE) - in S. cerevisiae.
A. Mass spectra of PC (left panels) and LPC (right panels) for wild type yeast cells
before and after supplementation with either C18:1 (OA) or C18:2 (LA). B. A. Mass
spectra of PE (left panels) and LPE (right panels) for wild type yeast cells before
and after supplementation with either C18:1 (OA) or C18:2 (LA). C, D. Heat maps of
PC, PE, LPC and LPE for wild type yeast cells before and after supplementation
with either C18:1 (OA) or C18:2 (LA). Values in heat maps pixels show the fold
change in phospholipid content in supplemented yeast cells compared to nonsupplemented wild type cells. Red pixels without numbers inside designate lipid
species produced only after LA supplementation (but not detectable in non-C18:2supplemented cells).
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detected

an

increased

content

of

18:1-LPC/LPE

and

18:2-LPC/LPE

after

supplementation of cells with these FAs. This suggests that homo-acylated species of
PC and PE were effectively utilized by Taz1 as preferred substrates for the re-acylation
of MLCL. It is also possible that these FAs were readily incorporated via de novo
biosynthesis (presumably of phosphatidic acid (PA)). Direct experimental assessment of
the contribution of these alternative pathways can be deduced from our lipidomics data
obtained from wt and mutant cells supplemented with FA, as shown below.
Both Cld1 and Taz1 modify the cardiolipinome.
Cld1 is a critical participant of the CL remodeling process, as it catalyzes
phospholipid hydrolysis with a significant selectivity towards 16:0 and 16:1-containing
molecular species (Beranek et al., 2009). This suggests that disruption of this process in
the cld1Δ mutant should result in an altered molecular speciation of CLs, particularly
with regards to longer-chain (C16 and C18) species. However, according to a recently
reported shotgun lipidomics study, the lipid profile of cld1Δ was similar to that of wt,
whereas taz1Δ had a reduction of CL and an accumulation of MLCL (Baile et al., 2014).
To resolve this apparent conundrum, we performed detailed LC-MS based
characterization of cardiolipinomes in wt and mutant S. cerevisiae cells. We found that
composition of CL from wt cells was different from that detected in either cld1Δ, taz1Δ
or cld1Δ/taz1Δ mutants. In addition, cld1Δ contained slightly (but significantly) higher
levels of CLs compared to wt cells (Figure 3-1B). In line with published data, the
changes in the total content of CL and MLCL found in taz1Δ mutants were no longer
detectable in cld1Δ/taz1Δ mutants. Indeed, dramatic accumulation of MLCL was
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detected in taz1Δ but not in cld1Δ or cld1Δ/taz1Δ mutants (Figure 3-2). However
molecular speciation of CLs in wt cells vs double-mutant cells were markedly different.
Similar results were obtained with wt cells and mutants supplemented with OA or LA
(Figure 3-2). These data are compatible with the role of Cld1 in “preparing” CLs for
remodeling via hydrolysis/reacylation, and suggest that elimination of the hydrolytic
pathway by deletion of Cld1 would lead to “conservation” of CLs. Consistent with this
prediction, cld1Δ mutant cells were essentially unable to produce remodeled tetra- and
tri-18:1 species of CLs (Figure 3-1B). Instead, their CLs were enriched with 16:0 and
16:1 containing molecular species (Figure 3-1B).
Assuming that Cld1 is a participant in the only remodeling process in S.
cerevisiae cells, one can distinguish between the contribution of de novo biosynthesis
vs remodeling processes in the overall diversification of CLs. In wt cells, both the
biosynthesis and de novo remodeling reactions contribute to the overall diversity and
content of CLs. Deletion of Cld1 would eliminate the remodeling process, thus revealing
the nascent CL species generated via its de novo biosynthesis. Thus, two categories of
CLs can be determined by comparison of LC-MS spectra of CLs from wt and cld1Δ cells
(Figure 3-4), including: i) those produced by the biosynthetic pathway, revealed in the
cld1Δ mutant, ii) those generated as products (increased) or utilized as substrates by
the remodeling pathway (decreased). These latter respective categories of CLs can be
identified in the LC-MS spectra of CLs in ± (wt minus cld1Δ) by the differential analysis.
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Figure 3-4. Contribution of de novo biosynthesis vs remodeling processes to
the diversification of CLs in S. cerevisiae.
Mass spectra of CL obtained from wild type yeast cells and cld1Δ mutant cells with
or without oleic/linoleic acid (OA/LA) supplementation. The resulting differential
mass spectra of CL species produced and consumed by the remodeling process
were obtained, as shown in the positive and negative spectra of w/t minus cld1Δ
mutants, respectively. A. Mass spectra of CL obtained from non-supplemented wild
type yeast cells and cld1Δ mutant. CL molecular species were identified as
C10:0/C16:1/C16:1/C16:1 (m/z 1261.8249); C10:0/C16:0/C16:0/C16:1 (m/z
1265.8593); C10:0/C16:1/C16:1/C18:1 (m/z 1289.8574); C12:0/C16:0/C16:0/C16:1
(m/z1293.8904);
C12:0/C16:1/C16:1/C18:1
(m/z
1317.8840);
C12:0/C16:0/C16:1/C16:1 (m/z 1321.9176); C16:1/C16:1/C16:1/C16:1 (m/z
1343.9041); C12:0/C16:1/C18:1/C18:1 (m/z 1345.9184); C12:0/C16:0/C16:1/C18:0
(m/z
1347.9318);
C16:1/C16:1/C16:1/C18:1
(m/z
1371.9380);
C16:0/C16:1/C16:0/C18:1 (m/z 1375.9669); C16:1/C18:1/C16:1/C18:1 (m/z
1399.9688); C16:0/C18:1/C16:0/C18:1 (m/z 1403.9988); C16:1/C18:1/C18:1/C18:1
(m/z
1428.0015);
C16:0/C18:1/C18:0/C18:1
(m/z
1432.0336);
C18:1/C18:1/C18:1/C18:1 (m/z 1456.0292). B. Mass spectra of CL obtained from
OA supplemented w/t yeast cells and cld1Δ mutant. Major CL species are annotated
on mass spectra. C. Mass spectra of CL obtained from LA supplemented w/t yeast
cells and cld1Δ mutant. Major CL species are annotated on mass spectra
By applying these differential (subtraction) protocols1, we found significant differences in
molecular speciation of CLs in wt and mutant cells. In cld1Δ cells (lacking the
remodeling pathway), CLs formed in the reaction catalyzed by CL synthase were
mainly represented by molecular species containing 16:0, 16:1 and 18:1 FA residues
(Figure 3-4). This was supported by LC/MS analysis of the CL biosynthesis precursor, –
phosphatidylglycerol (PG). We found that PGs were predominantly represented by
16:1/18:1, 16:1/18:1 and 16:0/16:1 molecular species in wt cells (Figure 3-5). On the
other hand, during the remodeling, esterified 16:0 was substituted with the 16:1 fatty
acid residue (Figure 3-5). These data suggest that in non-FA-supplemented w/t cells,

1

Please note that the specific feature of the software utilized for the subtraction disallows plotting of the negative
spectra; therefore -(WT- cld1Δ) plots were used as explained in detail in Materials and Methods.
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Figure 3-5. LC/MS analysis of phosphatidylglycerol (PG) in wild type S.
cerevisae before and after supplementation with different fatty acids.
Mass spectra and quantitative assessments (inserts) of PG obtained from control wild
type yeast cells and wild type yeast cells supplemented with C18:1 (OA), C18:2 (LA),
C20:4 (AA) and C22:6 (DHA).
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Cld1 predominantly hydrolyzed 16:0-containing CLs that were then remodeled with 16:1
by Taz1-catalyzed re-acylation.
We further applied the same approach to distinguish between the CL species
formed through either biosynthetic or remodeling pathways in wt cells supplemented
with either 18:1 or 18:2. This analysis revealed that the remodeling route was entirely
accountable for the replacement of fatty acid residues in CLs yielding predominantly
homo-acylated tetra-18:1 or tetra-18:2 molecular species of CLs, respectively (Figure 31B, Figure 3-4B, C). Based on these newly developed protocols for the assessment of
biosynthetic vs remodeling origins of the CL species, we compared the relative
contributions of these two pathways to all CLs in determining the pool of homo-acylated
species. We found that biosynthesis was the major (wt cells, 18:2-treated cells) or
significant (C18:1-treated cells) contributor to the entire pool of CLs. Interestingly, the
remodeling process was, by far, the most important contributor to the pool of homoacylated CLs.
product

Specifically, we found that CL(18:1/18:1/18:1/18:1) was the major

(Figure

3-4B,

WT-cld1Δ),

while

CL(16:1_18:1_16:1_18:1)

and

CL(16:0_18:1_18:1_18:1) were the major substrates of the remodeling process (Figure
3-4B, -(WT-cld1Δ)). Based on the cld1Δ spectra, we determined that both major
substrates of the remodeling originated from CL biosynthesis. For LA-supplemented
cells, we found that CL (18:2/18:2/18:2/18:2) was the major product (Figure 4C, WTcld1Δ), while CL(16:0/18:2/16:0/18:2) and CL(16:0/18:2/18:2/18:2) were the major
substrates of the remodeling process (Figure 3-4C, -(WT-cld1Δ)).

Similar to OA-

supplementation, both major remodeling substrates represented the products of CL
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biosynthesis. Further, the differential analysis demonstrated that after OA- or LAsupplementation, Cld1 had preferentially hydrolyzed C16:0- and C16:1-fatty acid
residues over C18:1- and C18:2-containing CL species. As a result, the remodeling
process tended to convert hetero-acylated CL to homo-acylated CLs, provided C18:1 or
C18:2 were available.
As all major phospholipids can serve as acyl sources for Taz1-catalyzed
remodeling, we further looked at the content of several phospholipids as well as their
monolyso-forms in wt and taz1Δ mutant cells. Included in our phospholipidomics
analyses were several major classes of phospholipids: i) a biosynthetic precursor of CL,
phosphatidylglycerol (PG); ii) two major phospholipids present in both mitochondria and
extra-mitochondrial compartments, PE and PC, and iii) an extra-mitochondrial
phospholipid, phosphatidylserine (PS). We found that the effects of taz1Δ deletion were
CL specific. Other phospholipids such as PC, PG, PS were not sensitive to taz1Δ
deletion.
Exogenous FAs do not affect molecular speciation of CL in remodeling of mutant
S. cerevisiae cells.
While Cld1 and Taz1 represent the two major components of the machinery
involved in the CL remodeling process, the immediate motive force(s) triggering the
process remain unknown. As exogenously added C18 FAs caused efficient remodeling
of CL to generate mostly homo-acylated tetra-18:1 and tetra-18:2 molecular species in
wt cells, we further explored the CL composition in mutant cells. The dramatic changes
in molecular speciation of CLs induced by exogenous C18-FAs in wt cells were
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essentially not found in any of the remodeling mutant cells, including cld1Δ, taz1Δ, and
cld1Δ/taz1Δ (Figure 3-1).
Because Cld1 is specific for the hydrolysis and remodeling of CLs but Taz1 can
participate in remodeling of other phospholipids (Ye et al., 2014), we were interested in
assessing the effects of deletion of Cld1 as well as Taz1 on the phospholipidomes of
the mutant cells grown in the presence of 18:1 and 18:2 FAs. Our findings clearly
demonstrate that deletion of cld1Δ did not cause any changes in PE and PC molecular
species in either 18:1- or 18:2-supplemented cells. The absence of Taz1 also did not
substantially affect the content or molecular speciation of PC and PE (except for the
accumulation of 16:0/16:1 and 16:1/16:1 PC molecular species but in cells
supplemented with C18:1).
Specificity of Cld1 for different molecular species of CLs.
Because of the apparent preference of CL remodeling triggered by exogenous
fatty acids for C18 species, we further investigated the specificity of Cld1 in the
hydrolysis of different molecular species of CLs. We used commercially available homoacylated CLs - (14:0)4-CL, (18:1)4-CL, (18:2)4-CL and also synthesized several
molecular species of CL - (16:0)4-CL, (18:0)4-CL, and (16:1) (16:0)3-CL. The multistep
preparations of (16:0)4-CL, (18:0)4-CL and (16:1) (16:0)3-CL followed a modular
approach to achieve optimal synthetic efficiency. Selectively protected glycerol building
blocks were loaded with palmitoate, stearate, and palmitoleoate in the presence of 1ethyl-3-(3-dimethyl-aminopropyl)
aminopyridine

(DMAP)

and

carbodiimide
then

condensed

(EDCI)
with

and

N,

N-dimethyl-4-

1-chloro-N,N-diisopropyl-1-
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Figure 3-6. Effect of Cld1 isolated from S. cerevisiae on accumulation of
mono-lyso-CLs after hydrolysis of different CLs in a biochemical system in
vitro.
#

$

*p<0.05 vs (14:0)3, p<0.002 vs. (18:1)3, p<0.005 vs (18:2)3, (n=4-10).
methoxyphosphinamine. The formation of the second phosphoester bond utilized 4,5dicyanoimidazole, and the resulting phosphite was subsequently peroxidized to the
phosphate with tetrabutylammonium periodate. Iterative couplings generated a fully
protected CL precursor that was O-demethylated with sodium iodide to release the
phosphate anions and O-desilylated under mild, carefully controlled acidic conditions to
generate the secondary alcohol in the glycerol moiety. Ammonium hydroxide was used
to prepare the final CL diammonium salts that were used for biological analysis.
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Figure 3-7. Typical LC-ESIMS spectrum of CL isolated
from cld1Δ mutants
(A), LC-MS profiles (B) and
MS/MS spectra (C) of MLCLs
after CL hydrolysis by Cld1 and
heat map of mono-lyso-CLs
molecular species (D) after the
release fatty acids from CLs
induced by Cld1 in the CLs
isolated from cld1Δ mutants
and from the heart of Northern
Red
Snapper
(Lutjanus
campechanus).
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We found that (14:0)4-CL, (18:1)4-CL, (18:2)4-CL were very poor substrates for Cld1
(Figure 3-6). Both (16:0)4-CL and (16:1) (16:0)3-CL and also (18:0)4-CL were readily
hydrolyzed by Cld1 (Figure 3-6). To verify the specificity of Cld1 toward CL containing
palmitic acid, we performed experiments using several types of mixtures of different CLs.
In particular, we were interested in testing Cld1 substrate specificity towards different
CL species present in S. cerevisiae cells as well as long-chain polyunsaturated CL
species “unusual” for these cells. To this end, we prepared two types of liposomes,
DOPC liposomes containing either CLs isolated from cld1Δ yeast mutant (to obtain the
most diversified set of yeast CLs in conditions of suppressed remodeling process) or
long chain polyunsaturated CLs isolated from fish heart (Northern Red Snapper,
Lutjanus campechanus) (Figure 3-7). These experiments provided interesting details
regarding the specificity of Cld1 towards different molecular species of CLs as
substrates. We found that hydrolysis of yeast CLs by Cld1 resulted in the release of
predominantly palmitic acid (16:0) and the formation of four major MLCL species such
as 12:0_14:0_18:1; (14:0_14:0__18:1; 16:0_16:1_18:1 and 18:1_18:1_18;1. We did not
observe significant accumulation of MLCL and free fatty acids or decreased CL content
when liposomes containing fish heart CLs (with highly diversified CLs containing C22:5
and C22:6 fatty acid residues) were treated with Cld1. Thus, Cld1 specifically
hydrolyzed CL species containing palmitic acid.
Computational studies of the interactions of homo-acylated-CL with Cld1.
To get insights into specifics of Cld1 hydrolysis of CL and its molecular species, a
homology model of full-length structure of the protein was generated using Hsad, a
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Figure 3-8. A homology model of Cld1, generated using iTassar server.
A. A full-length structure of Cld1 and its N-terminus region called mitochondrial
228
232
target signal (MTS). B. The known lipase motif ( AHSLG ). C. Acyl transferase
424
429
motif ( HHLYLD ). D. The catalytic triad, including S230, D392 and H424,
introduced by Baile et al.
steroid-degrading hydrolase, from Mycobacterium tuberculosis as a template (Figue 38A) (Lack et al., 2008). The choice was based on the sequence analysis using the
Protein BLAST tool (Altschul et al., 1990). This resulted in five templates with the
highest levels of identities to Cld1. Accordingly, five homology models of Cld1 were built
using I-TASSER 31 webserver. The model based on Hsad, a steroid-degrading
hydrolase from Mycobacterium Tuberculosis (PDB ID: 2VF2 13), demonstrated the
greatest C-score (C-score was equal to -1.78). Therefore, it was selected for molecular

90

Figure 3-9. Interactions of (C16:0)4-CL with Cld1 structure, generated using
homology modeling.
A. One of the acyl chains of TPCL aligned toward the active site. B. A channel
represents the CL acyl chain to the active site, which may define the specificity of
Cld1 toward particular fatty acids based upon its size.

docking modeling. The known lipase motif (228AHSLG232) and acyl transferase motif
(424HHLYLD429) are shown in Figure 3-8B-C, respectively. According to Baile et al.
(Baile et al., 2014), S230, H424 and D329 are the catalytic triad of Cld1 (Figure 3-8D).
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Intriguingly, the overlay of cavity and cartoon representation of the model structure
revealed a channel toward the catalytic site. Subsequently, molecular docking method
was utilized to investigate the interactions of three homo-acylated-CL species - (14:0)4CL, (16:0)4-CL and (18:2)4-CL. Notably, a palmitoyl residue (16:0) perfectly fit in this
cavity (Figure 3-9). However, neither chains of tetra-myristoyl CL, nor chains of tetralinoleoyl CL penetrated the active site channel. This indicates that the channel can
introduce a CL acyl chain to the active site. Moreover, the length of the channel may
function as a “ruler” defining the specificity of Cld1 towards particular molecular species
of CLs – in reasonable agreement with the experimentally tested homo- and heteroacylated CLs.
Effects of C18:1, C18:2 and C20:4 FAs supplementation on mitochondrial
bioenergetic function in S. cerevisiae cells.
As CL is an essential structural component of the OxPhos machinery, we tested one
possible effect of fatty acid supplementation on intact cell respiration of yeast cells.
Interestingly, yeast cells analyzed in stationary phase in YPD media showed 45% and
21% increased respiration rates when the media was supplemented with linoleic acid
and arachidonic acid, respectively, but not with oleic acid, where respiration was
decreased by -26% compared to control (Figure 3-10). These data suggest that CL
composition plays an important role for mitochondrial function at the level of the
oxidative phosphorylation system, and that linoleic acid supplementation produces
highest respiration rates.
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Figure 3-10. Yeast cells were grown in synthetic fermentable (YPD) media
supplemented with tergitol alone (control), or tergitol plus oleic acid, linoleic
acid, or arachidonic acid.
Respiration of intact cells was analyzed via the polarographic method. *p<0.05
versus control (n=3).
DISCUSSION
Predominantly

localized

in

mitochondria,

CLs

interact

with

numerous

mitochondrial proteins (Eble et al., 1990; Mileykovskaya and Dowhan, 2014; Pfeiffer et
al., 2003; Poyry et al., 2013; Sharpley et al., 2006; Shinzawa-Itoh et al., 2007) thus
defining their role and significance in mitochondrial structural organization and
metabolic/signaling functions. Similar to other phospholipids, CLs are subject to
continuous turnover, resulting in changes in their molecular species that may be
associated with their modified interactions with proteins. The molecular mechanisms
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and the significance of these changes – also called remodeling – in normal physiology
and disease conditions are the subject of intensive investigation (Barth et al., 2004). We
discovered that nutritional “pressure” by high levels of free FAs in the growth medium
triggered massive synthesis of unusual homo-acylated di-oleoyl- and di-linoleoylmolecular species in all major classes of phospholipids, including direct CL precursors
as well as donors of acyl-groups for the remodeling reactions. Not surprisingly, this
resulted in the preponderant accumulation of the respective homo-acylated CL species.
By employing detailed phospholipidomics analysis, this work established that the
availability of specific FA precursors is the major factor defining the diversity and
molecular speciation of CLs in S. cerevisiae. Supplementation with C18 FAs resulted in
the predominant accumulation of homo-tetra-acylated 18:1 and 18:2 species of CL.
Based on the engagement of only one biosynthetic and one remodeling pathway for
CLs in S. cerevisiae, the specific contributions of these respective mechanisms to the
overall molecular diversification/speciation of CLs in different growth conditions as well
as in mutant forms can be established. For example, we established that the remodeling
process is the major contributor to the pool of homo-acylated (C18:1)4-CL and (C18:2)4CL in cells supplemented with these FAs.
The hydrolase is a major part of the remodeling pathway. To convert nascent CL,
containing short saturated FA, to homo-acylated CL with log chain polyunsaturated FAs,
CL first has to undergo deacylation. In yeast, Cld1 fulfills this function and has been
identified as a CL-specific hydrolase enzyme. Modeling data revealed the presence of a
channel adjacent to the active site of Cld1, which may introduce a fatty acid of CL to the
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active site to be hydrolyzed. In line with LC/MS data demonstrating preferable
hydrolysis of 16:0 fatty acids by Cld1, and modeling results revealing most likely
interactions of 16:0 fatty acid with the channel it is tempting to speculate that the
channel acts as a “molecular ruler” defining the specificity of Cld1 to particular fatty acid
residues in CLs.
By appropriately designing genetic manipulations (e.g., creating and producing
appropriate deletion mutants such as cld1Δand targeted transfection with mammalian
remodeling genes such as iPLA2β or iPLA2 γ ), yeast cells supplemented with desired
PUFA can be used as effective models in studies of mammalian CL metabolism.
Similarly, the taz1Δ mutant transfected with acyltransferases alcat1 or mlcat1 may lead
to the elucidation of their specific contributions to CL metabolic processes. In all these
cases, the approach based on differential (subtractive) lipidomics analysis may be
particularly powerful in examination of remodeling and biosynthesis.
Supplementation with exogenous C18 FAs stimulated CL remodeling. As FAs
can be integrated into yeast CLs only via MLCL/Taz1-driven reactions, the acyl-CoAdependent pathways are not utilized to remodel CL. However, it has been reported that
acyl-CoAs are essential for reacylation of other phospholipids (Rijken et al., 2009).
Thus, detailed lipidomic analyses of other phospholipids in addition to CL are essential
for comprehensive analysis of CL remodeling pathways.
It has been well established that taz1Δ cells are characterized by lower levels of
CLs and markedly increased content of MLCL relative to wt cells (Ye et al., 2014). Our
results are in full agreement with these earlier studies. In terms of molecular speciation
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of CLs, the same altered features of CLs molecular speciation were also characteristic
of taz1Δ mutant and double mutant cld1Δtaz1Δ cells, suggesting that the selectivity of
Cld1 for C16-containing CLs is the major factor defining the overall molecular speciation
and remodeling of CLs in S. cerevisiae. This is clearly illustrated by the analysis of
MLCL molecular species that accumulate in taz1Δ cells, in which 16:1_16:1_16:0,
16:1_16:0_18:1, and 16:1_18:1_18:1 individual species dominated. Only minimal
amounts of MLCLs were detected in cld1Δ and cld1Δ/taz1Δ mutant cells, reconfirming
that

the

Taz1-catalyzed

reaction

was

the

major

contributor

to

the

re-

acylation/remodeling of CLs in S. cerevisiae.
A recent study demonstrated that simultaneous deletion of cld1Δ and taz1Δ
provided protection against mitochondrial injury triggered by single deletion of taz1Δ (Ye
et al., 2014). However, molecular speciation of CLs in w/t and double mutant cells
cld1Δ/taz1Δ was markedly different. This suggests that the accumulated MLCL – rather
than the changed CL speciation – are the major contributors to mitochondrial
dysfunction. A recent study demonstrated that unremodeled CLs are functionally
indistinguishable from remodeled CLs for yeast major bioenergetic functions (Baile et al.,
2014). In contrast, we found that mitochondrial respiration rates were altered in the
presence of different FA. Surprisingly, monounsaturated oleic acid had a small inhibitory
effect on intact cell respiration whereas the PUFAs - linoleic acid and arachidonic acid significantly increased mitochondrial respiration. This may give yeast cells a survival
advantage by shifting metabolism from glycolysis to the much more efficient OxPhos
process under non-proliferating conditions. Interestingly, CL with four linoleic acid
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chains is the primary CL species in some mammalian tissues including cow heart
(Schlame et al., 1993), a tissue that fully depends on aerobic energy production,
suggesting that linoleic acid is the evolutionarily preferred CL side chain to support
optimal high levels of oxidative phosphorylation. It should be noted that the effect of the
studied fatty acids on mitochondrial function can be the result of several independent
mechanisms. One primary mechanism is likely through changes in CL fatty acid
composition (i.e., length and saturation versus unsaturation state), which will affect the
structure of the OxPhos complexes. Another mechanism may be through cell signaling.
For example, it is known that arachidonic acid, a well-studied signaling molecule in
higher organisms, also affects cell signaling in yeast, where it leads to changes in the
phosphorylation state of many proteins and in particular protein kinase C (PKC)
signaling (Kuo et al., 1994). PKC has been shown to regulate mitochondrial respiration
by acting on OxPhos complexes both in mammals and yeast (Machida et al., 1998;
Ogbi and Johnson, 2006), suggesting that cell signaling may contribute to the observed
changes in the presence of arachidonic acid.
Interestingly, these general considerations can be applied to specific pathogenic
pathways in disease conditions such as, for example, the one likely operating in patients
suffering from the X-linked disease Barth syndrome (BTHS) leading to a rare childhood
cardiomyopathy with cyclic neutropenia (Barth et al., 2004). Recent detailed studies
have identified seven functional classes of BTHS mutations with several distinct loss-offunction mechanisms leading to a partial or total loss of catalytic activity (Claypool et al.,
2011; Whited et al., 2013). It has also been demonstrated that accumulation of MLCL
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(decreased CL/MLCL ratio) rather than deficiency of “correct” unsaturated CL species is
the major reason of mitochondrial dysfunction in yeast cells (Ye et al., 2014). Based on
our data on the effective remodeling of CLs supplemented with PUFA, one may wonder
whether the supplementation with C18:2 may be of therapeutic value, particularly in
cases with a partial loss of TAZ catalytic activity (Valianpour et al., 2003).
It has been long believed that remodeling of PUFA phospholipids is driven, at
least in part, by their peroxidation with subsequent hydrolysis of oxidatively modified FA
residues and re-acylation (Kagan et al., 1978; Salgo et al., 1993; Vankuijk et al., 1987).
The results of this work clearly indicate that the remodeling process occurs even in the
absence of peroxidizable PUFA. This suggests that different mechanisms, independent
of peroxidation, may drive the CL recycling process yielding the molecular species of CL
optimized in response to specific cell/tissue demands. Our results are compatible with
the dominant role of Taz in re-acylation of Cld1-hydrolyzed CLs and explain the high
selectivity of the overall remodeling process towards homo-acylated 18:2 species of
CLs and the role of the tazΔ mutations in the pathogenesis of Barth syndrome. However,
further detailed studies of the specificity and the role of PLAs in the re-acylation of
peroxidized vs non-peroxidized polyunsaturated CL species may be necessary to better
understand these intriguing and important general mechanisms of biological adaptation.
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CHAPTER 4 EXPRESSION OF ∆12-DESATURASE PROMOTES
CARDIOLIPIN PEROXIDATION IN SACCHAROMYCES CEREVISIAE: A
MODEL FOR CL SIGNALING
INTRODUCTION
The dimeric mitochondrial phospholipid cardiolipin (CL) is most abundant in the
mammalian heart, where it was first discovered (Pangborn, 1942); however, it is present
in nearly all mammalian tissues and throughout the eukaryotic kingdom (Schlame et al.,
2000b). The cellular and subcellular functions of CL have been studied for decades
using the powerful yeast genetic model, Saccharomyces cerevisiae (Schlame and
Greenberg, 2017). Yeast genes encoding the CL biosynthetic enzymes (Figure 4-1)
have been identified, and well-characterized mutants are available for each step of the
pathway, enabling in vivo studies of CL function that are not easily carried out in
mammalian cells (Joshi et al., 2009b). The yeast model has, thus, been pivotal in
demonstrating the critical role of CL in mitochondrial bioenergetics (Claypool et al.,
2008b; Gohil et al., 2004; Jiang et al., 2000; Patil et al., 2013; Raja et al., 2017),
mitochondrial protein import (Gebert et al., 2009), mitochondrial dynamics (Joshi et al.,
2016; Joshi et al., 2012), cell cycle progression (Chen et al., 2010), cellular aging (Zhou
et al., 2009), mitophagy (Shen et al., 2017), and apoptosis (Gonzalvez and Gottlieb,
2007; Schug and Gottlieb, 2009), among other essential functions.
CL that is synthesized de novo undergoes remodeling, in which it is deacylated
to monolysocardiolipin (MLCL), which is reacylated by the transacylase tafazzin, t hus
forming CL species that are more highly unsaturated (Baile et al., 2013; Beranek et al.,
2009; Brandner et al., 2005; Gu et al., 2004; Testet et al., 2005).

Unsaturated
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tetralinoleoyl-CL is the major CL species detected in the heart, skeletal muscle and liver;
however, the physiological significance of tetralinoleoyl-CL remains unclear. It is absent
in cells from patients with Barth syndrome (BTHS), an X-linked recessive disorder
associated with variable cardiomyopathy, skeletal myopathy, neutropenia, and organic
aciduria (Barth et al., 1983). BTHS is caused by mutations in the TAZ gene that codes
for tafazzin (Bione et al., 1996). Accordingly, BTHS patient cells accumulate MLCL and
are devoid of tetralinoleoyl-CL, owing to a loss in the final step of the CL remodeling
pathway (Shen et al., 2015). In yeast, unremodeled and remodeled CL are thought to
be functionally indistinguishable (Baile et al., 2014), and deletion of the CL-specific
phospholipase, Cld1, was found to rescue the defects caused by loss of the CLtransacylase, Taz1 (Ye et al., 2014). This raises the question of why cells remodel CL,
and how CL-enriched with polyunsaturated fatty acid (PUFA) is functionally distinct from
that of saturated or mono-unsaturated fatty acyl CL species. Recent studies implicate
peroxidation of CL, yielding CLOX, in the cellular signaling events that initiate apoptosis,
as enzymatic hydrolysis of CLOX results in the release of lipid mediators with diverse
signaling properties (Kagan et al., 2014; Kagan et al., 2005a).
In the wild, yeast cells proliferate in diverse environments (Huffnagle and Noverr,
2013; Spencer and Spencer, 2013; Spencer and Spencer, 1997; Vadkertiova et al.,
2012), from which PUFAs may be readily incorporated into CL. We previously
demonstrated that yeast cells supplemented with PUFAs linoleic acid

(C18:2) or

arachidonic acid (C20:4) readily incorporate these fatty acids into CL (Tyurina et al.,
2017), suggesting that the yeast model may be exploited to dissect the mechanisms
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underlying the generation and function of CLOX. Cipak and co-workers demonstrated
that yeast cells expressing the H. brasiliensis Δ12-desaturase synthesize PUFA and
exhibit sensitivity to oxidative stress (Andrisic et al., 2015; Cipak et al., 2006). In the
current study, we show that S. cerevisiae yeast cells that express the H. brasiliensis
Δ12-desaturase synthesize CL acyl species containing PUFA. Furthermore, multiple
species of CLOX, including CL-hydroperoxides and CL-dihydroperoxides, are present in
these cells. Peroxidized species of mitochondrial phospholipids PC and PE were also
detected, but peroxidized PS (which is largely non-mitochondrial) was not. Importantly,
the presence of PUFA-containing CL and the production of CLOX were not associated
with major growth defects under optimum conditions. However, mild temperature
sensitivity and increased sensitivity to mitochondral lipid peroxidation were observed.
Thus, our findings illustrate that yeast cells synthesizing PUFA readily generate
phospholipid hydroperoxides and dihydroperoxides, including various CLox species,
within the mitochondira. Moreover, yeast provides a powerful genetic model that can be
exploited to elucidate mechanisms underlying the generation and function of CL
peroxidation.
METHODS AND MATERIALS
Strains, Media, and Growth Conditions—The S. cerevisiae strain used in this work is
BY4741(MATa his31 leu20 met150 ura30). The plasmids pYES2-EV and pYES2desa employed in this study were kindly given by Dr. Ana Cipak Gasparovic from the
Rudjer Boskovic Institute in Zagreb, Croatia. Expression of the Δ12-desaturase is
controlled by a Gal promoter and is induced by growth on galactose-containing media.
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Complex media contained yeast extract (1%), peptone (2%), and glucose (2%) (YPD).
The solid medium contained agar (2%) in addition to the ingredients mentioned above.
Synthetic complete (SC) ura- medium contained adenine (20.25 mg/liter), histidine (20
mg/liter), arginine (20 mg/liter), lysine (200 mg/liter), leucine (60 mg/liter), methionine
(20 mg/liter), tryptophan (20 mg/liter), threonine (300 mg/liter) all the essential
components of yeast nitrogen base without amino acids (Difco), 0.2% ammonium
sulfate, and glucose/galactose (2%). Yeast strains were grown at 30°C. E. coli strain
DH5 was used for plasmid maintenance and amplifications. Bacteria were grown at
37°C in LB medium (0.5% yeast extract, 1% tryptone, 1% NaCl), supplemented with
ampicillin (100 μg/ml) for selection purposes. For growth on plates, media were
supplemented with 1.5 and 2% agar for E. coli and yeast, respectively. Growth in liquid
cultures was monitored spectrophotometrically. Cells were harvested and centrifuged at
4°C (4,300 rpm, 5 min). The supernatant was discarded, and glass beads (0.3g) were
added to the centrifuge tubes. Samples were vortexed (5 X 1 min intervals) and frozen
at -80 ℃ for lipidomic analysis.
Chronological Life Span—As described in Chapter 2
Spotting Assay—As described in Chapter 2
Determination of mitochondrial membrane potential (MMP)—Cells were grown in
SC Gal Ura- medium to log phase and incubated with 500 nM TMRM for 30 min at 30°C.
Cells were washed, resuspended in warm medium and divided in half. One group was
treated with 6 µM FCCP and the other group was untreated. The TMRM fluorescence
intensity was determined in 30,000 cells from each group using LSR II flow cytometer at
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the Wayne State University Microscopy, Imaging and Cytometry Resources Core.
Median fluorescence intensity was calculated after correcting for background TMRM
fluorescence (values obtained after treatment with FCCP) using FlowJo v10.2.
Determination of O2 consumption—Cells were grown in SC Gal Ura- medium to the
mid-log phase to obtain a suspension containing 1.4 x 10 7 cells/ml. Cell respiration was
measured in a 5 mL glass chamber using a Clark-type electrode (YSI 5300) operated by
TracerDAQ software at 30 °C. After measurements of basal respiration, 5 µM FCCP
was added to measure maximal respiration. KCN (0.2 mM) was added to measure
cytochrome c oxidase-independent oxygen consumption.
Synthesis of Mito-AAPH—

NaOH
-NaCl; - H2O

1

2

SOCl2; DMF
-HCl; -SO2

3

4

5

2-[(E)-(2-amino-2-imino-1,1-dimethyl-ethyl)azo]-2-methyl-propanamidine

hydrochloride

(2; yield, 82%): In ice-cold methanol (100 mL), 2,2’-azobis-2-methyl-propanimidamide
(AAPH; 2,2’-azobis-2-methyl-propanimidamide, 1; 1 g; 3.7 mmol) was neutralized with
NaOH (0.3 g; 7.4 mmol). The solvent was rotor-evaporated (25 oC; 10 torr) and the
crystals formed were suspended in chloroform (100 mL). Undissolved 1 and NaCl were
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filtered off. Rotor-evaporation of the filtrate afforded 2 (0.6 g; 3 mmol), which was used
immediately for the preparation of 5.
(4-chloro-4-oxo-butyl)-triphenyl-phosphonium

bromide

(4;

yield,

65%):

3-

carboxypropyl(triphenyl)phosphonium bromide (3, 1 g; 2.3 mmol) was dissolved in
chloroform (50 mL) containing thionyl chloride (3 g; 25 mmol) and dimethylformamide
(DMF; 0.05 g; 0.68 mmol), and the reaction solution was refluxed for 4 hours. The
volume of the solvent was reduced to ~ 5 mL (rotor-evaporation; 25 oC; 150 torr) and
trituration with n-hexane afforded 4 (0.68 g), which was dried under vacuum (40 oC; 10
torr) for 1 hour.
[2-[(E)-[2-imino-1,1-dimethyl-2-(4-triphenylphosphaniumylbutanoylamino)ethyl]azo]-2methyl-propanimidoyl]ammonium chlorobromide (5; yield 45%): Chloroform (50 mL)
containing 2 (0.5 g; 2.5 mmol) and 4 (1.12 g; 2.5 mmol) was incubated for 24 hours at 0
oC.

Thereafter, the solvent was rotor-evaporated (20 oC; 10 torr) and the dry residue

was redissolved in minimal volume of ethanol. Trituration of the solution with diethyl
ether afforded 5 (0.69 g), which was filtered and dried under vacuum (20 oC; 1 torr) for
30 min. ESI MS calculated for the triphenylphosphonium cation of 5 (C30H38N6OP+), 529.64;
found, 529.80.

Mito-AAPH Treatment—Mito-AAPH was diluted with ethanol to make a 50 mM stock.
For the spotting assay, 50 µM Mito-AAPH was directly spread on the plate before the
experiment. For liquid culture, 50 µM Mito-AAPH was added at log phase (A550≈0.5).
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Statistical Analysis—All results are presented as mean ± S.D. from at least three
experiments. Statistical analyses were performed by paired and unpaired Student's ttests, and the level of statistical significance was set at p< 0.05.
LC/MS assessment of phospholipids—Lipids were extracted from yeast and LC/MS
of phospholipids was performed as previously described (Tyurina et al., 2017). Briefly,
phospholipids were analyzed in negative mode using a Dionex UltimateTM 3000
RSLCnano system coupled online to Q-Exactive hybrid quadrupole-orbitrap mass
spectrometer (ThermoFisher Scientific, San Jose, CA). Lipids were separated on a
normal phase column (Silica Luna 3 µm, 100A, 150x2 mm, (Phenomenex, Torrance
CA)) with flow rate 0.2 mL/min using gradient solvents containing 5 mM CH3COONH4 (A
– n-hexane:2-propanol: water, 43:57:1 (v/v/v) and B - n-hexane:2-propanol: water,
43:57:10 (v/v/v). MS lipid standards used in this study were from Avanti polar lipids
(Alabaster, AL). Analysis of LC-MS data was performed using software package
Compound DiscovererTM (ThermoFisher Scientific) with an in-house generated analysis
workflow and peroxidized phospholipid database.
RESULTS
Expression of the H. brasiliensis Δ12-desaturase alters the molecular speciation of
CL in S. cerevisiae cells
Yeast cells that are not supplemented with exogenous fatty acids produce only
saturated and Δ9-mono-unsaturated fatty acyl residues, as these cells cannot
synthesize PUFA (Tyurina et al., 2017). To construct a yeast model with PUFA-
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Figure 4-1 Cardiolipin biosynthesis and remodeling in S. cerevisiae.
Yeast cells readily produce 16:0-CoA and 18:0-CoA, which can be converted to 16:19
12
CoA and 18:1-CoA via endogenous  -desaturase activity or the expressed D desaturase. 16:1-CoA and 18:1-CoA can be further converted to 16:2-CoA and 18:2CoA following a second, complementary desaturation. All available acyl-CoA species
can be incorporated into PA and used in the de novo synthesis of CL via CL synthase
(Crd1). Newly synthesized CL contains predominantly unsaturated fatty acyl chains.
Nascent CL may undergo Cld1-catalyzed deacylation to form MLCL. The
transacylase, Taz1, utilizes donor phospholipids, particularly PC and PE, to reacylate
MLCL to CL. PC and PE are also synthesized from PA. Multiple cycles of
deacylation-reacylation generate CL that contains mainly unsaturated acyl chains.
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containing CL, we expressed the H. brasiliensis ∆12-desaturase gene in yeast (Cipak et
al., 2006) and established its effect on the phospholipidome of these cells.
As described in Figure 4-1, yeast readily produces 16:0-CoA and 18:0-CoA,
which can be converted to 16:1-CoA and 18:1-CoA via endogenous 9-desaturase
activity. These acyl-CoA species can be incorporated into phosphatidic acid (PA) and
used in the de novo synthesis of CL via the CL synthase (Crd1)-catalyzed reaction to
form nascent CL, which contains predominately unsaturated fatty acyl chains (Chang et
al., 1998b; Jiang et al., 1997; Tamai and Greenberg, 1990; Tuller et al., 1998). Nascent
CL is deacylated by the phospholipase Cld1 to form monolysocardiolipin (MLCL) (Baile
et al., 2013; Beranek et al., 2009). The transacylase Taz1 utilizes donor phospholipids,
particularly PC and PE, to acylate MLCL to form CL (Brandner et al., 2005; Gu et al.,
2004; Testet et al., 2005). Multiple cycles of deacylation-reacylation lead to the
synthesis of mature CL containing mainly unsaturated acyl chains (Beranek et al., 2009;
Gu et al., 2004; Vaz et al., 2003). As we showed previously, Cld1 has a greater affinity
for C16-containing acyl chains than for C18-containing acyl chains (Tyurina et al., 2017).
Accordingly, the predominant CL species detected in yeast contain C18 acyl chains.
The expression of ∆12-desaturase results in the production of 16:2-CoA and 18:2CoA, which are incorporated into CL through de novo synthesis or via CL remodeling.
As shown in Figure 4-2A-B, expression of the ∆12-desaturase caused dramatic changes
in CL composition. WT yeast cells have predominantly CL64:3, CL66:4, CL68:4, CL70:4
and CL72:4, while cells expressing the ∆12-desaturase contained predominantly CL66:5,
CL68:5, CL70:6 and CL72:8. The CL species detected in WT and ∆ 12-desaturase-
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Figure 4-2. CL species synthesized in ∆ -desaturase-expressing cells.
(A) Mass spectra of CL obtained from wild type yeast cells expressing the empty
12
vector (EV) or ∆ -desaturase (desa). Major CL molecular species are identified:
CL58:3 (m/z 1261.8241); CL60:3 (m/z 1289.8578); CL62:3 (m/z 1317.8895); CL64:3
(m/z 1345.9180); CL66:4 (m/z 1371.9358); CL68:4 (m/z 1399.9666); CL70:4 (m/z
1427.9991); CL72:4 (m/z 1456.0305); CL60:4 (m/z 1287.8410); CL62:4 (m/z
1315.8712); CL64:4 (m/z 1343.9119); CL66:5 (m/z 1369.9176); CL68:5 (m/z
1397.9476); CL70:6 (m/z 1423.9635); CL72:7 (m/z 1449.9794). (B) A differential
mass spectra of CL species was obtained by highlighting individual CL species that
12
were increased [+(desa-EV)] or decreased [-(desa-EV)] by the expression of the D desaturase. (C) Heat map of CL quantified from wild type yeast cells expressing the
12
empty vector (EV) or ∆ -desaturase (desa). (D) Quantitative comparison of CL
12
molecular species in cells expressing the empty vector (EV) or ∆ -desaturase
(desa).

expressing cells are shown in Figure 4-2C. Quantitative comparison of individual
CL species indicates that ∆12-desaturase expression resulted in the production of
multiple PUFA-containing CL species and a concomitant reduction in the abundance of
CL species containing saturated or monounsaturated fatty acids (Figure 4-2C-D).
MLCL species were also altered by ∆12-desaturase expression (Figure 4-3). Total MLCL
was significantly reduced in ∆12-desaturase-expressing cells when compared to WT.
Furthermore, quantitative comparison of individual MLCL species indicates that ∆12desaturase expression resulted in the reduction of MLCL species containing saturated
or monounsaturated fatty acids. Additionally, PUFA-containing MLCL species were
detected (in low abundance) in the ∆12-desaturase-expressing cells.
Because phosphatidylglycerol (PG) is the precursor of nascent CL produced via de
novo synthesis (Chang et al., 1998b; Jiang et al., 1997; Osman et al., 2010; Tamai and
Greenberg, 1990; Tuller et al., 1998), we also examined the effect of ∆12- desaturase
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Figure 4-3. MLCL species in ∆ -desaturase-expressing cells.

(A) Mass spectra of MLCL. Major MLCL molecular species are identified: MLCL50:2
(m/z 1137.7310); MLCL50:3 (m/z 1135.7225); MLCL50:4 (m/z 1133.7018); MLCL52:2
(m/z 1165.7626); MLCL52:3 (m/z 1163.7540); MLCL52:4 (m/z 1161.7366); MLCL52:5
(m/z 1159.7208). (B) Heat map of MLCL. (C) Quantitative assessment of total MLCL.
(D) Quantitative comparison of MLCL molecular species.
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Figure 4-4. PG in ∆ -desaturase-expressing cells.
(A) Mass spectra of PG. Major PG molecular species identified: PG32:1 (m/z
719.5); PG32:2 (m/z 717.5); PG34:1 (m/z 747.5); PG34:2 (m/z 745.5); PG34:3 (m/z
743.5). (B) Heat map of PG. (C) Quantitative assessment of PG.
expression on PG (Figure 4-4). In WT cells, the predominant PG species (34:1 and
32:1) contain one saturated acyl chain and one mono-unsaturated acyl chain. The
expression of ∆12-desaturase resulted in a significant reduction of PG34:1 and PG32:1.
Furthermore, when compared to WT, ∆12-desaturase-expressing cells had significantly
increased PG32:2 and PG34:2. Additionally, PG34:3 was detected in ∆ 12-desaturase-
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Figure 4-5. Oxygenated CL (CLOX) in ∆ -desaturase-expressing cells.
(A) Heat map of CLox. (B) Quantitative assessment of total. (C) Quantitative
assessment of CLox molecular.
expressing cells but not WT cells.
∆12-desaturase expression leads to accumulation of peroxidized CL.
The accumulation of CLOX was readily observed in cells expressing the ∆12desaturase (Figure 4-5A-C). CL-hydroperoxide and CL-dihydroperoxide species were
observed in these cells. As anticipated, peroxidized CL species were not detected in
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Figure 4-6. PC, PE, and PS in ∆ -desaturase-expressing cells.
Heat map of PC (A), PE (B), and PS (C).
WT cells.

Neither peroxidized MLCL nor peroxidized PG was detected in the ∆12-

desaturase-expressing cells. As the lipid profile has been altered in ∆12-desaturase
expression yeast cells, we next sought to determine if presence of PUFA-containing or
peroxidized CL species affected yeast growth
Detection of other peroxidized phospholipids in ∆12-desaturase-expressing cells.
The effects of ∆12-desaturase expression on PC, PE, and PS (Figure 4-6) were
determined. All phospholipids analyzed in these cells contained C16:2 and/or C18:2
fatty acyl chains. Peroxidized species of PC and PE were readily detected in ∆12desaturase-expressing cells. Interestingly, however, peroxidized PS species were not
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detected. Given that PC and PE species are enriched within mitochondrial membranes
while PS species contribute minimally to the mitochondrial phospholipidome (Carman
and Zeimetz, 1996; Wright and McMaster, 2002), this finding suggests that phospholipid
peroxidation observed in ∆12-desaturase-expressing cells likely occurs within the
mitochondrial subcellular compartment.
∆12-desaturase expression results in a mild growth phenotype and increased
sensitivity to mitochondria-targeted lipid peroxidation.
In accordance with the findings of Cipak and coworkers (Andrisic et al., 2015;
Cipak et al., 2006), we observed a mild growth phenotype in the ∆12-desaturase cells,
characterized by a prolonged lag phase and a slower rate of growth during stationary
phase in liquid growth medium (Figure 4-7A). Growth on solid medium was unaffected
at 30℃ but was decreased at 39℃ (Figure 4-7B). Interestingly, chronological lifespan
was largely unaffected by ∆12-desaturase expression at 30℃ (Figure 4-7C). The
expression of ∆12-desaturase resulted in an increase in the mitochondrial membrane
potential, which was associated with minimal changes in basal mitochondrial respiration
(Figure 4-7D-E). We next used the mitochondria-targeted lipid peroxidation reagent,
mito-AAPH, to further examine how CL peroxidation and growth are affected in ∆12desaturase-expressing cells. We determined that ∆12-desaturase-expressing cells
exhibit increased sensitivity to mito-AAPH (Figure 4-8A). Exposure to mito-AAPH
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Figure 4-7. Physiologic phenotype in desaturase-expressing cells.
(A) Cell growth. Cells were inoculated at an initial A550 of 0.05, and A550 was
measured at the indicated times. The growth curves shown are representative of
three experiments. (B) Serial 10-fold dilutions of cells were spotted on SC medium
containing 2% glucose or 2% galactose as carbon source. Plates were incubated at
the indicated temperature for 5 days. (C) Chronological life span. The data depicted
are representative of three experiments. (D) Membrane potential was determined in
logarithmically growing cells by measuring the TMRM fluorescence intensity in
30,000 cells from each group using LSR II flow cytometer. (E) Oxygen consumption
was measured in logarithmically growing cells using a Clark-type electrode.
resulted in an increased generation of specific CL-dihydroperoxide species, including
CL(62:6)+2[O], CL (64:8)+2[O], CL(66:7)+2[O], CL(66:8)+2[O], CL(68:8)+2[O] (Figure 48B). PC(36:4)+2[O] (Figure 4-8C), PE(32:4)+2[O], and PE(34:4)+2[O] (Figure 4-8D)
were also increased. CL(66:7)+2[O] and PE(34:3)+2[O] were found only in desaturase-
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Figure 4-8. Effect of mito-AAPH on desaturase-expressing cells.
(A) Serial 10-fold dilutions of cells were spotted on SC medium containing 2%
galactose as carbon source. Mito-AAPH was spread on the plates immediately
before spotting. Plates were incubated at 30°C for 3 days. (B) Quantitative
12
assessment of CLox molecular species in cells expressing the ∆ -desaturase (desa)
treated with or without mito-AAPH. (C) Quantitative assessment of PCox molecular
12
species in cells expressing the ∆ -desaturase (desa) treated with or without mitoAAPH. (D) Quantitative assessment of PEox molecular species in cells expressing
12
the ∆ -desaturase (desa) treated with or without mito-AAPH.
expressing cells exposed to mito-AAPH. Oxygenated mCL, PG, and PS were not found
in desaturase-expressing cells exposed to mito-AAPH. These results suggest that the
increased mitochondrial lipid peroxidation contributes to the overall growth defects
observed in the ∆12-desaturase-expressing cells.
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DISCUSSION
This study demonstrates for the first time that ∆12-desaturase expression in yeast
promotes the formation of PUFA-containing CL species that are readily peroxidized in
vivo. To date, the study of processes governing CL peroxidation and the various cellular
signaling functions of CLOX and CLOX-derived lipid mediators has not been carried out
using yeast model systems. We have confirmed that 16:2-CoA and 18:2-CoA produced
by yeast expressing the ∆12-desaturase are incorporated into CL. This likely occurs, in
part, during de novo synthesis of CL from PUFA-containing PG and CDP-diacylglycerol
by CL synthase. Subsequent enrichment of CL with PUFA occurs during CL remodeling.
Consistent with our previous observations in yeast cells supplemented with exogenous
PUFA (Tyurina et al., 2017), in the current study, MLCL levels were significantly
decreased in ∆12-desaturase-expressing cells compared to WT. This may suggest that
CL remodeling is down-regulated in cells containing PUFA. Alternatively, the relative
activities of Cld1 and Taz1 may be altered by the availability of PUFA. Nonetheless, the
enrichment of PUFA-containing CL combined with reduced detection of the CL
remodeling intermediate, MLCL, in ∆12-desaturase-expressing cells supports a model in
which a major role of CL remodeling is to generate PUFA-enriched CL, which may
serve to increase mitochondrial membrane potential.
This is the first report of CL peroxidation in the yeast S. cerevisiae.

CL

peroxidation provides a critical signal for the initiation of apoptosis (Kagan et al., 2004;
Mao et al., 2016; Nakagawa, 2004), and therapeutic reduction of CL peroxidation is
being explored to treat human diseases associated with apoptosis (Jiang et al., 2014;
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Maddalena et al., 2017; Zhong et al., 2017). Additionally, hydrolysis of CLOX likely
serves as a key mitochondrial source of peroxidized fatty acid lipid signaling molecules
(Tyurina et al., 2014). Given that in their natural environments, yeast cells likely
encounter PUFA, it is reasonable to speculate that yeast may readily synthesize CLenriched with PUFA in these environments and produce CLox in the absence of
stressors. The ∆12-desaturase-expressing yeast provides a powerful tool for the study of
CL peroxidation and CLOX signaling Future studies will explore potential inducers of CL
peroxidation as well as functions of CLox using this model system.
The expression of exogenous desaturase enzymes in yeast has variable effects
on cellular function and viability depending on the yeast strain and growth conditions
used (Andrisic et al., 2015; Cipak et al., 2006; Cipak et al., 2008; Johansson et al.,
2016). Johansson and coworkers observed severe growth defects in cells expressing
both 12 and 6-desaturase enzymes (Johansson et al., 2016). Cipak and coworkers
report distinct effects of ∆12-desaturase expression depending on the yeast strain used
(Andrisic et al., 2015; Cipak et al., 2006; Cipak et al., 2008). The current study is the
first to perform unbiased lipidomic analysis of yeast cells expressing an exogenous
desaturase enzyme. Our findings indicate that CL OX is readily detected in the ∆12desaturase-expressing yeast under normal growth conditions, suggesting that CL
peroxidation may occur in the absence of cytotoxic stressors.
The accumulation of CLOX may be subject to factors beyond the rate of CL
peroxidation. Peroxidized forms of other phospholipids known to localize within the
mitochondrial membranes (PC and PE) were detected in the ∆ 12-desaturase-expressing
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cells. As Taz1, the yeast CL-transacylase transfers fatty acids from phospholipids to
MLCL without specificity (Xu et al., 2006b), CLOX may be formed in a Taz1-dependent
manner during the transmission of a peroxidized fatty acid residue from a donor
phospholipid. However, because PCOX and PEOX are relatively non-abundant, this
mechanism likely contributes minimally to the total pool of CL OX.
Increased sensitivity to lipid peroxidation were previously reported using this
genetic yeast model (Andrisic et al., 2015). However, our comprehensive lipidomic
approach provides compelling evidence to implicate mitochondrial free radicals and CL
peroxidation in contributing to the growth defects observed in ∆ 12-desaturaseexpressing cells. Excessive generation of CLOX in response to mitochondrial oxidative
stress likely contributes to the small but significant growth defect observed under these
conditions. In the current study, we found that ∆12-desaturase-expressing cells exhibit
increased sensitivity to mito-AAPH (Figure 4-8A), and treatment with mito-AAPH was
associated with an increase in specific CLOX species (Figure 4-8B). The absence of
peroxidized PS supports a model of mitochondria-localized phospholipid peroxidation.
PS species are confined almost exclusively to the cell membrane and secretory vesicles
(Zinser et al., 1991). Although PS is imported into mitochondrial membranes, its
intramitochondrial transport is linked to enzymatic conversion to PE by PS
decarboxylase (Atkinson et al., 1980; Carman and Henry, 1989; Simbeni et al., 1993).
Thus, the relative abundance of PS within the mitochondrial membranes is minimal
when compared to PC and PE (Zinser et al., 1991). Peroxidation of CL, PC, and PE but
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not PS suggests that phospholipid peroxidation observed in ∆ 12-desaturase-expressing
cells likely occurs within the mitochondrial subcellular compartment.
While hydrolysis of CL may be driven, at least in part, by CL peroxidation (Kagan
et al., 1978), in the current study, we detected decreased MLCL in the ∆12-desaturaseexpressing cells containing CLOX, indicating that some degree of CLOX can be tolerated
in yeast. Future in vitro studies will focus on the specificity of CL hydrolysis for
peroxidized vs. non-peroxidized CL substrates. Additionally, using the in vivo ∆12desaturase expression system, the relationship between CL remodeling and CL
peroxidation will be further explored.
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CHAPTER 5 LOSS OF CLD1 IN Δ12-DESATURASE EXPRESSION
CELLS LEADS TO INCREASED PEROXIDIZED CL SPECIES THAT
DECREASES CELLULAR MEMBRANE POTENTIAL AND
CHRONOLOGICAL LIFE SPAN
INTRODUCTION
As the signature lipid of mitochondria, cardiolipin (CL) plays a critical role in
mitochondrial bioenergetics (Claypool et al., 2008b; Gohil et al., 2004; Jiang et al.,
2000), mitochondrial protein import (Gebert et al., 2009), cell cycle progression (Chen et
al., 2010), cellular aging (Zhou et al., 2009) and apoptosis (Gonzalvez and Gottlieb,
2007; Schug and Gottlieb, 2009). Following de novo synthesis, CL undergoes
remodeling in which acyl chains are exchanged. Cld1 is the only known CL-specific
phospholipase in yeast and is required to initiate the CL remodeling pathway. In this
process, CL is deacylated by Cld1 on the matrix side of the inner mitochondrial
membrane to form monolysocardiolipin (MLCL) (Baile et al., 2013; Beranek et al., 2009).
The transacylase, Taz1, reacylates MLCL to reform CL using acyl groups from donor
phospholipids, particularly PC and PE (Brandner et al., 2005; Gu et al., 2004; Testet et
al., 2005). In addition to its role in CL remodeling, deacylation of CL results in the
generation of mitochondria-derived free fatty acids, which may modulate various cellular
functions. Peroxidation of CL, yielding CLOX, has been implicated in the cellular
signaling events that initiate apoptosis, and CLOX can undergo enzymatic hydrolysis,
resulting in the release of various lipid mediators with diverse signaling properties
(Kagan et al., 2014; Kagan et al., 2005a).

Cancer cells evade apoptosis through

modulation of CL oxidation and subsequent formation of reactive lipid electrophiles,
especially 4-hydroxy-nonenal (4-HNE) (Zhong et al., 2017). Attenuating CL peroxidation
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is being explored as a potential treatment to manage the clinical effects of aberrant
apoptosis. For instance, 3-hydroxypropyl-triphenylphosphonium-conjugated imidazolesubstituted oleic acid (TPP-IOA) was developed as an apoptosis-specific inhibitor that
prevents CL oxidation (Maddalena et al., 2017).
Previous studies showed that unremodeled and remodeled CL are functionally
indistinguishable in the yeast S. cerevisiae (Baile et al., 2014; Ye et al., 2014). However,
the CL species of unsupplemented yeast contain only saturated and Δ 9-monounsaturated fatty acids, enriched primarily with palmitic (C16:0), stearic (C18:0),
palmitoleic (C16:1) and oleic acids (C18:1) (Tyurina et al., 2017). In the wild, yeast
proliferate in diverse environments (Huffnagle and Noverr, 2013; Spencer and Spencer,
2013; Spencer and Spencer, 1997; Vadkertiova et al., 2012), from which
polyunsaturated fatty acids (PUFA)’s may be readily incorporated into CL. Yeast
supplemented

with

PUFA-containing

CL

readily

synthesize

peroxidized

CL

(unpublished). However, the functions of PUFA-containing CL and peroxidized CL are
not clear. A recent study showed that the mammalian CL phospholipase iPLA2γ
deacylates peroxidized CL, initiating diverse signaling pathways, including activation of
caspase-3, expression of stress response genes, accumulation of ceramide, loss of
mitochondrial membrane potential, and induction of apoptosis (Song et al., 2014).
Accordingly, we speculated that Cld1 may function to deacylate peroxidized CL and
regulate cellular signaling in yeast. We demonstrated that cells expressing the H.
brasiliensis Δ12-desaturase synthesize C16:2 and C18:2 fatty acids, which are readily
incorporated into CL. Multiple species of CLox, including CL-hydroperoxides and CL-
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dihydroperoxides, were detected in these cells (unpublished). However, the specific
functions of Cld1 and CL remodeling in yeast cells with PUFA-containing CL have not
been explored.
In this study, we compared the CL profiles of Δ12-desaturase-expressing WT and
cld1 cells to determine if Cld1 removes peroxidized CL. Δ12-desaturase-expressing
cld1 cells contain increased amount of discrete peroxidized CL species, which leads to
decreased growth, chronological life span and membrane potential. Furthermore,
purified Cld1 protein exhibits higher affinity for peroxidized CL than non-peroxidized CL
(C18:2)4. These results indicate a novel role for Cld1 in mitigating the effects of CL
peroxidation. Additionally, MLCL levels were increased in desaturase-expressing cld1
cells, suggesting the existence of an alternate, unidentified CL phospholipase that is
capable of deacylating PUFA-containing CL. The findings from this study will serve as
the basis on which we will improve our understanding of CL remodeling and its
mechanistic roles in mitigating oxidative stress.
METHODS AND MATERIALS
Strains, Media, and Growth Conditions— The S. cerevisiae strain used in this work is
BY4741(MATa his31 leu20 met150 ura30). The plasmids pYES2-EV and pYES2desa employed in this study were kindly given by Dr. Ana Cipak Gasparovic (Rudjer
Boskovic Institute, Zagreb, Croatia). Expression of the Δ12-desaturase is controlled by a
Gal promoter and is induced by growth on galactose-containing medium. Complex
medium contained yeast extract (1%), peptone (2%), and glucose (2%) (YPD). Solid
medium contained agar (2%) in addition to the ingredients mentioned above. Synthetic
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complete (SC) ura- medium contained adenine (20.25 mg/liter), histidine (20 mg/liter),
arginine (20 mg/liter), lysine (200 mg/liter), leucine (60 mg/liter), methionine (20 mg/liter),
tryptophan (20 mg/liter), threonine (300 mg/liter), all the essential components of yeast
nitrogen

base

without

amino

acids

(Difco),

0.2%

ammonium

sulfate,

and

glucose/galactose (2%). Yeast strains were grown at 30°C. E. coli strain DH5 was used
for plasmid maintenance and amplifications. Bacteria were grown at 37°C in LB medium
(0.5% yeast extract, 1% tryptone, 1% NaCl), supplemented with ampicillin (100 μg/ml)
for selection purposes. For growth on plates, media were supplemented with 1.5 and 2%
agar for E. coli and yeast, respectively. Growth in liquid cultures was monitored
spectrophotometrically. For lipidomic analysis, cells were harvested and centrifuged at
4°C (4,300 rpm, 5 min). The supernatant was discarded, and glass beads (0.3g) were
added to the centrifuge tubes. Samples were vortexed (5 X 1 min intervals) and
centrifuged again at 4°C (4,300 rpm, 5 min). Supernatants were collected and frozen at
-80 ℃ for lipidomic analysis.
Construction of Plasmids and Expression of Yeast His6-tagged Cld1 in S.
cerevisiae—As described in Chapter 3
Purification of His6-tagged Cld1—As described in Chapter 3.
Chronological Life Span—As described in Chapter 2
Spotting Assay—As described in Chapter 2
Real Time Quantitative PCR (RT-qPCR) Analysis—As described in Chapter 2
Determination of mitochondrial membrane potential (MMP)—As described in
Chapter 4
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Determination of O2 consumption— As described in Chapter 4
Mito-AAPH Treatment—Mito-AAPH was diluted with ethanol to make a 50 mM stock.
For the spotting assay, 50 µM Mito-AAPH was directly spread on the plate before the
experiment. For liquid culture, 50 µM Mito-AAPH was added at log phase (A550≈0.5).
Statistical Analysis—The results are presented as mean ± S.D. values from at least
three experiments, and statistical analyses were performed by paired/unpaired
Student's t-test. The statistical significance of differences was set at p< 0.05.
LC/MS assessment of phospholipids—Lipids were extracted from cells and LC/MS of
phospholipids was performed as previously described (Tyurina et al., 2017). Briefly,
phospholipids were analyzed in negative mode using a Dionex UltimateTM 3000
RSLCnano system coupled online to Q-Exactive hybrid quadrupole-orbitrap mass
spectrometer (ThermoFisher Scientific, San Jose, CA). Lipids were separated on a
normal phase column (Silica Luna 3 µm, 100A, 150x2 mm, (Phenomenex, Torrance
CA)) with flow rate 0.2 mL/min using gradient solvents containing 5 mM CH3COONH4 (A
– n-hexane:2-propanol: water, 43:57:1 (v/v/v) and B - n-hexane:2-propanol: water,
43:57:10 (v/v/v). MS lipid standards used in this study were from Avanti polar lipids
(Alabaster, AL). Analysis of LC-MS data was performed using software package
Compound DiscovererTM (ThermoFisher Scientific) with an in-house generated analysis
workflow and peroxidized phospholipid database. LC/MS was carried out by
collaborators from Dr. Valerian Kagan’s lab from Pittsburgh University.
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RESULTS
Expression of Δ9-desaturase in cld1 cells leads to increased levels of specific
peroxidized CL species
We have previously shown that expression of CLD1 is highest when cells are
actively respiring (Ye et al., 2014). These conditions lead to increased generation of
ROS and, concomitantly, increased oxidation of lipids.

Increased CLD1 in these

conditions suggests the possibility that this phospholipase deacylates peroxidized CL, in
which case the loss of CLD1 would lead to increased peroxidized CL. Yeast cells can
synthesize only saturated and Δ9-mono-unsaturated fatty acids, but when engineered to
express Δ12-desaturase, they can synthesize PUFAs (Andrisic et al., 2015; Cipak et al.,
2006).

Furthermore, when supplemented with PUFA, they can synthesize PUFA-

containing phospholipid species (Tyurina et al., 2017). To investigate the role of Cld1 in
deacylating peroxidized CL, we expressed the Δ12-desaturase in cld1 cells. PUFAcontaining CL species were detected in the 12-desaturase-expressing cld1 cells, likely
because some incorporation of PUFA into CL occurs during de novo CL biosynthesis.
However, the level of PUFA-containing CL was significantly decreased in cld1 cells
expressing ∆12-desaturase (cld1+desa) compared to WT cells expressing the
desaturase (Figure 5-1). Surprisingly, although cld1+desa cells had decreased total
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Figure 5-1. Oxygenated CL (CLOX) in ∆12-desaturase-expressing cells.
(A) Heat map of all CLox species quantified. (B) Quantitative assessment of specific
12
molecular species of CLox that are increased in cld1 yeast cells expressing ∆ desaturase (desa). (C) Mitochondrial membrane potential was determined in
logarithmically growing cells by measuring the TMRM fluorescence intensity. Analysis
of 30,000 cells from each group demonstrated that mitochondrial membrane potential
12
is significantly affected by the presence of ∆ -desaturase expression. (D)
Chronological life span of wt and cld1 yeast cells expressing ∆12-desaturase (desa)
or empty vector (EV). The data depicted are representative of three experiments.

levels of peroxidizable CL, they contained significantly more CLox species within highly
unsaturated CL species (64:7, 66: 7, 68:7, 68:8, 70:8) (Figure 5-2A-B).
The expression of 12-desaturase increased the incorporation of PUFA not only into CL
but also into other phospholipids known to localize to the mitochondrial membranes (e.g.
PG and PC) in both wt and cld1 cells (need data for cld1). Interestingly, while
desaturase expression increased the mitochondrial membrane potential in wt cells, the
membrane potential in cld1 cells was decreased (Figure 5-2C). These results suggest
that mitochondrial membrane potential is directly affected by the extent to which CL is
enriched with PUFA and/or peroxidized.
Increased MLCL in cld1 cells expressing12-desaturase indicate a novel CL
phospholipase that prefer to deacylate PUFA-containing CL.
Cld1 is the only known CL phospholipase capable of deacylating CL to form MLCL
(Baile et al., 2013; Beranek et al., 2009; Ye et al., 2014). Although cld1 cells have
decreased levels of MLCL compared to wt cells, small amounts of MLCL were
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Figure 5-2. Cld1 exhibits greater affinity for oxidized than non-oxidized CL in
vitro.
(A) Mixture of 10 μM cardiolipin (TLCL/TLCLox) in HEPES buffer pH 7.45 was
incubated at 37℃ for 45 min with an increasing amount of Cld1. Total TLCL was
extracted by the Folch procedure and TLCL, TLCLox, and MLCL were quantified by
LCMS. Hydrolysis of CL was evident by an accumulation of MCL and concomitant
reduction of CL. (B) Isolated Cld1 was incubated with non-oxidized TLCL (CL), TLCL
containing one hydroperoxy-LA residue (CLOOH), or TLCL containing two
hydroperoxy-LA residues (CL2OOH). In the presence of oxygenated CL (CLOOH or
CL2OOH) Cld1 generated significantly increased free hydroperoxy-LA (m/z 311) than
non-oxidized-LA (m/z 279). (C) Isolated Cld1 was incubated with increasing ratios of
oxidized TLCL (CLOX) to non-oxidized TLCL (CL). As the CL: CLOX ratio was
increased from 1:1 to 1:2, the generation of free hydroperoxy-LA (m/z 311) increased
by nearly 50%. Further increasing the CL: CLOX ratio (1:4) had little effect on the
generation of free hydroperoxy-LA. As the CL: CLOX ratio was increased, the
generation of free non-oxidized-LA (m/z 279) was also increased.
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Figure 5-3. Expression of desaturase increases the sensitivity of cells to mitoAAPH.
Serial 10-fold dilutions of wt and cld1 yeast cells expressing ∆12-desaturase (desa)
or empty vector (EV) were spotted on SC medium containing 2% galactose as
carbon source. Mito-AAPH was spread on the plates immediately before spotting.
Plates were incubated at 30°C for 3 days.

Figure 5-4. CLD1 expression is increased by exposure to H2O2.
WT cells were grown to the mid-logarithmic phase and treated with 1 mM H2O2 for 1
h. Analyses CLD1 expression in H2O2-treated cells and non-treated cells was
determined using RT-qPCR.
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12

Figure 5-5. MLCL species in ∆ -desaturase-expressing cells.
(A) Heat map of all MLCL species quantified. (B) Quantitative assessment of total
12
MLCL in wt and cld1 yeast cells expressing ∆ -desaturase (desa) or empty vector
(EV).
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detectable in the mutant (Figure 5-3). Interestingly, the expression of 12-desaturase in
cld1 cells increased MLCL levels by more than 100%, suggesting that an alternate,
unidentified CL phospholipase may exist that is capable of deacylating PUFA-containing
CL.
Cld1 mitigates the effects of CL peroxidation
In vitro experiments revealed that Cld1 exhibits greater affinity for peroxidized
than non-peroxidized CL (Figure 5-4). Thus, (18:2)4-CL was a poor substrate for Cld1,
but peroxidized (18:2)4-CL was an excellent substrate.
We have previously shown that CLD1 expression is increased during respiratory
growth and regulated by the HAP complex (Ye et al., 2014). It is plausible that
increased CLD1 expression during respiratory growth mitigates the effects of
superoxides generated by respiratory complex III, which likely contribute to the
peroxidation of CL. Consistent with this possibility, wt cells treated in the log phase with
H2O2 for 1 hr exhibited a 2-fold increase in CLD1 expression (Figure 5-5). Furthermore,
the expression of desaturase increased the sensitivity of cld1cells to mito-AAPH
(Figure 5-6), which has been shown to generate CLox (unpublished). The chronological
life span of cld1was dramatically decreased by expression of desaturase (Figure 52D), while the life span of wt cells expressing the desaturase was not affected.
Taken together, these findings support a role for Cld1 in mitigating the effects of
CL peroxidation.
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DISCUSSION
This study demonstrates, for the first time, a role for Cld1 in mitigating the effects
of CL peroxidation. Previously, we demonstrated that deletion of CLD1 rescues the
respiratory growth defect of tafazzin deficient yeast cells, indicating that an increased
MLCL/CL ratio, not decreased CL with unsaturated fatty acyl chains, is detrimental in
tafazzin deficient cells (Ye et al., 2014). Similarly, a study by Baile and colleagues
illustrated that unremodeled and remodeled cardiolipin are functionally indistinguishable
in yeast (Baile et al., 2014). An interesting question arises from these observations: why
do yeast require CL remodeling if there is no adaptive advantage of accumulating CL
dominated by unsaturated fatty acyl chains. A clue to this question comes from our
findings, it further indicate that expression of CLD1 is increased in response to
respiratory growth conditions, and this increase is mediated by the HAP and Mig1
transcriptional factors. Baile and coworkers revealed that Cld1 protein level and function
are decreased in glucose and increased in lactate (Baile et al., 2013). They observed
that CL remodeling is regulated by available carbon source and membrane potential.
Mitochondria are the major producer of cellular ROS, and CL-hydroperoxides are known
to reduce oxidative metabolism by inactivating complex IV (Musatov, 2006). Similarly,
respiratory chain defects have been shown to increase ROS production and decrease
the membrane potential (Grivennikova and Vinogradov, 2006; Minners et al., 2007).
These findings support a model in which decreased membrane potential resulting from
the accumulation of CL-hydroperoxides serves as a signal to activate CL remodeling.
This model is further supported by the notion that CL remodeling may function to
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remove peroxidized fatty acyl residues from CL, thereby mitigating the downstream
consequences of mitochondrial CL-hydroperoxide accumulation, possibly including
mitophagy or apoptosis. However, it is unclear if this model applies to yeast cells
because loss of CLD1 does not cause any detectable functional defects (Baile et al.,
2014). CL-hydroperoxides are not produced in either WT or cld1Δ cells unless PUFA is
supplied in the growth medium or an exogenous-desaturase is expressed (Tyurina et al.,
2017). WT yeast cells readily incorporate PUFA into CL, which suggests that CL
enriched with PUFA may influence cellular function in S. cerevisiae. In the current study,
we used 12-desaturase-expressing cells to study the functions of Cld1 and CL
remodeling in the presence of PUFA-containing CL, and reveal that loss of Cld1 causes
an accumulation of specific CLox species, decreased membrane potential, and
decreased chronological life span (Figure 2). These results suggest that Cld1 is
involved in removing specific CLox species. This is supported by the demonstration that
purified Cld1 has a higher affinity for peroxidized than non-peroxidized (C18:2)4CL
(Figure 3). This may explain the previous observation that CLD1 expression is
upregulated during stationary phase and that CLD1 upregulation is respiration
dependent (Ye et al., 2014). Consistent with this model, H2O2 treatment increases
CLD1expression, which suggests that increased oxidative stress upregulates CLD1
expression.
We previously demonstrated that expression of 12-desaturase enables WT S.
cerevisiae cells to make C16:2- and C18:2- containing phospholipids, including CL, PC,
PE, and PS, and CLox (Chapter 4, unpublished). The LC-MS data showed that cld1
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cells exhibit decreased PUFA-containing CL, but increased levels of specific CLox
species. In our previous study, we showed that WT yeast cells expressing 12desaturase readily accumulate CLox, yet these cells do not exhibit detectable defects
under optimum growth conditions (Chapter 4, unpublished). In this study, we showed
that Cld1 is involved in removing specific CLox species, and that loss of CLD1 in 12desaturase-expressing cells led to severe physiological defects, including decreased
mitochondrial membrane potential and decreased chronological life span.
As Cld1 functions to removed CLox, we speculate that CLD1 expression is
regulated by the cellular ROS level. This is supported by the finding that treatment of
H2O2 increased CLD1 expression (Figure 5). This observation is consistent with the
previous finding that CLD1 expression is upregulated in stationary phase, as cellular
ROS are accumulated during respiration and reach high concentrations during this
phase. Furthermore, upregulation of CLD1 expression is respiration dependent, and the
transcription factor Mig1 is required for CLD1 upregulation. Mig1 has been shown to
sense ROS and regulate gene expression in response to increased ROS production.
Although Cld1 is the only known phospholipase that deacylates CL in yeast,
MLCL was still detectable in cld1, and the MLCL level was significantly increased in
12-desaturase-expressing cld1 cells. This observation suggests the existence of an
unidentified phospholipase capable of deacylating CL containing PUFA.
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CHAPTER 6 LOSS OF CARDIOLIPIN REMODELING RESULTS IN
DECREASED C2C12 MYOBLAST DIFFERENTIATION: A MYOBLAST
MODEL FOR BARTH SYNDROME AND CARDIOLIPIN DEFICIENCY
INTRODUCTION
Cardiolipin (CL) is a dimeric mitochondrial membrane phospholipid with multiple
functions that are conserved from yeast to humans (Acehan et al., 2011; Chen et al.,
2008; Gebert et al., 2009; Jiang et al., 2000; Joshi et al., 2009a; Koshkin and
Greenberg, 2000; Koshkin and Greenberg, 2002; McKenzie et al., 2006; Pfeiffer et al.,
2003; Soustek et al., 2011; Xu et al., 2006a). Newly synthesized CL contains
predominately saturated fatty acyl chains, and acyl remodeling of CL is required to
produce “mature”, highly unsaturated CL species. Deficient CL remodeling causes Barth
syndrome (BTHS), a rare X-linked genetic disorder associated with a broad range of
clinical manifestations, including cardiomyopathy, skeletal myopathy, neutropenia, and
3-methylglutaconic aciduria (Barth et al., 1983; Mazzocco et al., 2007b). Specifically,
BTHS results from mutations in the tafazzin gene (TAZ) encoding the transacylase
responsible for remodeling of CL. Mutations in TAZ lead to reduced total CL content and
an accumulation of monolyso-CL (MLCL), an intermediate of the CL remodeling
pathway.
Most patients diagnosed with BTHS exhibit pronounced skeletal myopathy, low
muscle mass, delayed gross motor development, exercise intolerance, muscle
weakness, and focal myofibrillar degeneration (Barth et al., 1999b; Spencer et al.,
2006b). Consistent with decreased mitochondrial function, skeletal muscle O 2 utilization
and peak work rate are significantly lower in BTHS patients than control participants
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(Spencer et al., 2011). While it is widely accepted that skeletal myopathy associated
with BTHS stems from mitochondrial dysfunction, the mechanisms linking defective CL
remodeling and skeletal myopathy have not been clearly elucidated and likely extend
beyond compromised ATP generation. Myogenic differentiation is largely controlled by
myogenic transcription factors and is accompanied by major changes in mitochondrial
metabolism (Abdel Khalek et al., 2014; Hamai et al., 1997; Philp et al., 2011; Zhu et al.,
2013), mitochondrial energy production (Abdel Khalek et al., 2014; Murray and Huss,
2011), and mitochondria-mediated activation of apoptotic pathways (Camara et al.,
2007; Ciavarra and Zacksenhaus, 2011; Griffiths et al., 2015). Given the central role of
mitochondria in regulating myoblast differentiation, we hypothesized that mitochondrial
defects associated with BTHS may contribute to skeletal myopathy by interfering with
normal myocyte differentiation.
To determine the effect of defective CL remolding on myogenic determination,
we sought to develop a tafazzin-deficient mammalian skeletal myoblast model. The
C2C12 cell line was derived from murine skeletal myoblast cells and represents a
widely used model for the study of skeletal muscle development (Burattini et al., 2004),
skeletal myopathy (Arya et al., 2013; Bathe et al., 2007; Mullen et al., 2010), and
skeletal muscle differentiation (Ardite et al., 2004; Jasmer and Kwak, 2006; Wallace et
al., 2016). The cells readily proliferate in high-serum conditions, and differentiate and
fuse in low-serum conditions. Tafazzin-deficient C2C12 myocytes would provide a
metabolic model for which isogenic cells are available as controls, in contrast to
currently used BTHS patient-derived lymphoblast cells. Furthermore, they are
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experimentally easier and cheaper to manipulate than tafazzin-deficient induced
pluripotent stem cells (iPSCs) (Dudek et al., 2013b).
In this study, we constructed a CRISPR-generated stable tafazzin knockout
(TAZ-KO) C2C12 myocyte cell line. The TAZ-KO cell line exhibits an increased
MLCL/CL ratio, decreased mitochondrial respiratory capacity, increased mitochondrial
ROS production, and defective myocyte differentiation. These results indicate that loss
of CL remodeling influences myogenic determination and form the foundation for future
studies exploring potential mechanisms by which CL remodeling is required for
regulating myocyte differentiation. Although BTHS is the only known genetic disorder
directly linked to CL, aberrant myocyte differentiation may contribute to the development
of skeletal myopathy associated with other mitochondrial diseases.
METHODS AND MATERIALS
Cell line and growth conditions—Wild type C2C12 cell lines were kindly provided by
Dr. Steven Cala, Wayne State University. Growth medium consisted of DMEM (Gibco)
containing 10% FBS (Hyclone), 2 mM glutamine (Gibco), penicillin, (100 units/ml) and
streptomycin (100 μg/ml) (Invitrogen). Cells were grown at 37°C in a humidified
incubator with 5% CO2. C2C12 myoblast differentiation was induced by shifting cells to
DMEM medium containing 2% horse serum (Gibco).
Construction of TAZ-KO C2C12 cell line using CRISPR—A gRNA targeting mouse
TAZ exon 3 was identified using the clustered regulatory interspaced short palindromic
repeats (CRISPR) design tool at crispr.mit.edu (G2: TCCTAAAACTCCGCCACATC). To
express Cas9 and guide RNA in the mouse-derived C2C12 myoblast cells,
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complementary oligonucleotides containing the gRNA sequence preceded by a G (for
expression from the U6 promoter) were cloned into the BbsI site of plasmid pX330
(Cong et al., 2013) (a gift from Feng Zhang; Massachusetts Institute of Technology,
Cambridge, Massachusetts, USA) [Addgene plasmid # 42230]). The sequence was
verified using oligonucleotide primer 330/335 (ACTATCATATGCTTACCGTAAC). The
plasmid pPGKpurobpa (a gift from Allan Bradley; Wellcome Trust Sanger Institute,
Cambridge, UK) was co-transfected to allow selection under puromycin. Cells were
transfected with plasmid pX330-TAZ and pPGKpurobpa using Lipofectamine 2000 (Life
Technologies, Inc.). Cells were selected in puromycin-containing DMEM with 10% FBS.
Cells were then diluted and put into 96-well plates. Single colonies were picked for
screening. To screen for insertions or deletions at the target sites, the following
oligonucleotide

primers

flanking

CCAACCACCAGTCTTGCATG.

mouse

REV:

Taz

exon

3

were

ATCCCTGCCTCCAAGACTTC.

used:
Wild

FOR:
type

genomic DNA generates a product of 547 bp. Cells that did not generate this product
were selected for further analysis.
Real Time Quantitative PCR (RT-qPCR) Analysis—As described in Chapter 2
Mitochondria extraction—Cells were grown to 100% confluency in 150 mm dishes,
and collected by scraping followed by centrifugation at 800 rpm for 5 min. The cell
pellets were washed with cold PBS and suspended in mitochondrial isolation buffer (280
mM sucrose, 0.25 mM EDTA, 20 mM Tris-HCl, pH 7.2). Cells were manually
homogenized with a glass homogenizer. Cell debris was removed by centrifugation at
800 rpm for 5 min. Mitochondria were subsequently collected by centrifugation at
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11,500 rpm for 10 min. Protein concentration was determined using the DC protein
assay kit (BIO-RAD).
Determination of CL by mass spectrometry—Transacylation products were
quantified by MALDI-TOF mass spectrometry using the method of Sun et al. (Sun et al.,
2008). Lipid extracts were dissolved in chloroform/methanol (1:1) and mixed 1:1 with
matrix solution containing 20 g/L 9-aminoacridine in 2-propanol/acetonitrile (3:2, v/v). An
aliquot of 1 μL or less of this mixture was spotted on a target plate. Measurements were
performed with a MALDI Micro MX mass spectrometer (Waters) operated in reflectron
mode. The pulse voltage was set to 2000 V, the detector voltage was set to 2200 V, and
the TLF delay was set to 700 ns. The nitrogen laser (337 nm) was fired at a rate of 5 Hz
and 10 laser shots were acquired per sub-spectrum. The instrument was operated in
negative ion mode with a flight tube voltage of 12 kV, a reflectron voltage of 5.2 kV, and
a negative anode voltage of 3.5 kV, and calibrated daily. We typically acquired 100 subspectra (representing 1000 laser shots) per sample in a mass range from 400 to 2000
Da. Spectra were only acquired if their base-peak-intensity was within 10–95% of the
saturation level. Data were analyzed with the MassLynx 4.1 software.
Western Blot—Mitochondrial protein concentration was measured using the DC
Protein Assay Kit (BIO-RAD). Cell extract corresponding to 30 μg protein was analyzed
by SDS-PAGE on a 10% gel. Immunoblotting was performed using primary antibodies
against tafazzin, NDUFB6, and corresponding secondary antibodies conjugated to
horseradish

peroxidase.

Immunoreactivity

chemiluminescence (ECL) substrate (Thermo).

was

visualized

using

enhanced
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MTT assay—3000 cells were suspended in 100 μL of growth medium and seeded into
96-well plates. Viable cells were measured in triplicate using MTT (Fisher) after 3, 24,
and 48 h. In brief, 10 µL of 5 mg/mL MTT were added to each well. Inclusion of an
additional set of wells treated with MTT but containing no cells served as a negative
control. The plate was incubated for 4 h at 37°C in a culture hood. The medium was
carefully removed and 150 µL DMSO were added to dissolve the MTT product. The
plate was covered with foil and incubated for 10 min at 37°C. Samples from each well
were mixed well with a pipette, and absorbance was read at 570 nm.
Mitochondrial respiration measurements— Intact cell respiration was analyzed in a
closed 500 μL chamber equipped with a micro Clark-type oxygen electrode (Oxygraph Plus
System, Hansatech Instruments) at 35 °C as described (Lee et al., 2010). Cells were cultured in
high glucose DMEM medium (100 units/mL penicillin-streptomycin, 10% fetal bovine serum),
trypsinized, and washed with PBS. Cells were then suspended in measuring buffer (120 mM
KCl, 3 mM Hepes, 3 mM MgSO4 5 mM KPi), to a final protein concentration of 2 mg/mL.
Following measurements of basal cell respiration, 0.5 μM FCCP was added to analyze
uncoupled respiration. Oxygen consumption was recorded on a computer and analyzed with the
Oxygraph plus software. Oxygen consumption rate (OCR) is defined as nM consumed
O2/min/mg protein).

Measurement of mitochondrial membrane potential via TMRM florescence—Cells
were plated at 40% confluency in 96-well plates in growth medium. After 24 h, the
mitochondrial membrane potential was measured using the fluorescent dye
Tetramethylrhodamine methyl ester (TMRM) as described previously (Brown, 1999).
Briefly, cells were treated with 150 nM TMRM in growth medium for 30 min at 37°C. The
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cells were then washed 3 times in PBS and TMRM fluorescence was measured on a
microplate reader (Excitation: 544 nm and Emission: 590 nm). Each assay was
performed

in

parallel

with

samples

(trifluoromethoxy)phenylhydrazone

containing

(FCCP),

which

10

μM

collapses

carbonyl-cyanide-4the

mitochondrial

membrane potential. All data were expressed as the total TMRM fluorescence minus
the FCCP treated TMRM fluorescence.
Measurement of ROS production using MitoSOX—ROS production was measured
with MitoSOX™ mitochondrial superoxide indicator (M36008) (Fisher Scientific)
following the manufacture ’s guide. In brief, the 5 mM MitoSOX™ reagent stock solution
was diluted in growth medium to make a 5 μM MitoSOX™ reagent working solution. 1.0
mL of 5 μM MitoSOX™ reagent working solution was applied to cover cells adhering to
coverslips. Cells were incubated for 10 min at 37˚C, protected from light, then washed
gently three times with warm buffer, counterstained with DAPI, and imaged using a Z1
AxioObserver inverted fluorescence microscope equipped with an AxioVision MRm
camera (Zeiss). Images were taken using a 20X objective. MitoSOX fluorescence was
quantified in all cells within five randomly selected fields of view from three biological
replicates using florescence density analysis with ZenPro software (Zeiss).
Immunofluorescence imaging of myotubes—Cells were seeded on gelatin and
fibronectin coated glass coverslips at 40% confluency. Following overnight culture, the
growth media containing 10% FBS were replaced with differentiation media containing 2%
horse serum. At the indicated times, the cells were fixed with 4% paraformaldehyde.
The coverslips were washed three times in buffer (PBS + 0.3% Triton) and then blocked
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using 10% horse serum (Invitrogen). Coverslips were incubated with primary antibody,
mouse anti-MHC (Novus Biologicals; MAB4470), diluted in PBS supplemented with 10%
horse serum for 24 h. After washing with PBS, coverslips were incubated with an
AlexaFluor 488®-conjugated donkey anti-mouse secondary antibody (1:1000, Jackson
ImmunoResearch Laboratories) overnight. Fluorescence microscopy was performed
using a Z1 AxioObserver inverted fluorescence microscope equipped with an AxioVision
MRm camera (Zeiss) operated by ZenPro software (Zeiss). All images were taken using
a 20X objective.
RESULTS
Construction of a tafazzin knockout C2C12 cell line using CRISPR technology.
We generated a TAZ-KO C2C12 myocyte cell line in order to interrogate a
potential link between CL remodeling and myocyte differentiation. C2C12 is a well
characterized myoblast cell line that exhibits a high metabolic demand, similar to
skeletal muscle cells (Burattini et al., 2004). These cells proliferate as undifferentiated
myoblast cells when grown in media containg high concentrations of serum (10%), and
terminally differentiate into multinucleated myotubes when cultured in low serumcontaining media. We used the CRISPR approach to generate tafazzin-deficient C2C12
myoblast cells. The pX330-TAZ and pPGKpurobpa plasmids were transfected into
C2C12 myoblasts, which were grown in selective medium. Following serial dilution,
cultures derived from single cells were picked and PCR was used to identify the gene
knockout. Tafazzin mRNA levels were measured using RT-qPCR. The TAZ-KO C2C12
myoblast cells exhibited a 90% decrease in tafazzin mRNA levels (Figure 6-1A).
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Figure 6-1. Construction of TAZ-KO C2C12 cells.
Mouse C2C12 myoblast cells were transfected with CRISPR plasmid targeting the
tafazzin gene. (A) Genomic TAZ is altered in TAZ-KO cells. Cells were selected in
puromycin-containing DMEM with 10% FBS. The knockout strain was identified by
PCR using the 547 bp region of the tafazzin gene targeted by the Cas9 gRNA
followed by a T7 endonuclease digestion. (B) Tafazzin mRNA levels were
decreased in TAZ-KO cells. WT and TAZ-KO cells were grown in DMEM with 10%
FBS and harvested for mRNA extraction. Tafazzin mRNA levels were quantified by
RT-qPCR and normalized to mRNA levels of the internal control GAPDH (three
independent experiments with three replicates each). (C) Tafazzin protein was not
detectable in TAZ-KO cells. Cells were grown in DMEM with 10% FBS, harvested,
and lysed for protein extraction. 30 μg of total cell extract from each sample were
subjected to Western blot analysis using 10% polyacrylamide gels. The
mitochondrial protein NDUFB6 was used as a loading control.
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Figure 6-2.CL profile of TAZ-KO cells.
(A) MLCL/CL ratio of TAZ-KO cells was increased compared to WT controls. WT and
TAZ-KO cells grown in DMEM to confluence were extracted for CL and MLCL content
analysis by MALDI-TOF mass spectrometry. (B) CL saturation of TAZ-KO cells is
increased, consistent with defective CL remodeling.
Tafazzin protein was not detectable via Western blot analysis (Figure 6-1B).
Increased MLCL/CL ratio in TAZ-KO cells.
The most direct biochemical phenotype associated with tafazzin deficiency is an
accumulation of MLCL and a concomitant reduction in CL species containing
unsaturated fatty acyl chains. Using MALDI-TOF mass spectrometry we confirmed the
TAZ-KO C2C12 myoblast cells exhibit reduced tafazzin function, as indicated by the
characteristic CL profile of tafazzin deficiency. The MLCL/CL ratio was significantly

147

increased in TAZ-KO cells compared to controls, and the degree of CL unsaturation
was significantly reduced (Figure 6-2).
Characterization of tafazzin-deficient C2C12 cells.
We measured the proliferative growth of TAZ-KO myoblast cells using the MTT
assay to determine if loss of tafazzin directly affects myoblast proliferation. Deletion of
tafazzin did not significantly influence the doubling time of C2C12 cells (Figure 6-3A). In
other BTHS models, including BTHS patient-derived lymphoblast cells and iPSCs, loss
of tafazzin results in decreased mitochondrial respiration, increased mitochondrial ROS
production and decreased mitochondrial membrane potential (Dudek et al., 2013b; Xu
et al., 2005). We assayed these parameters in the TAZ-KO myoblast cells.
Mitochondrial respiration was measured in intact cells using a Clark-type electrode.
Basal mitochondrial respiration was not significantly affected by tafazzin deficiency in
the myoblast cells; however, maximal respiratory capacity of the TAZ-KO myoblast cells
was significantly decreased compared to controls (Figure 6-3B). This observation
contrasts with other BTHS models in which both basal and maximal mitochondrial
respiration is compromised by tafazzin deficency (Dudek et al., 2013b). Assessment of
mitochondrial membrane potential using TMRM fluorescence indicated a significant
reduction in membrane potential in TAZ-KO myoblasts compared to controls (Figure 63C). To quantify mitochondrial ROS production in the myoblast cells, we employed
MitoSOX fluorescence staining. Mitochondrial ROS production was significantly
increased

in

TAZ-KO

myoblast

cells

compared

to

controls

(Figure

6-4).
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Figure 6-3. Mitochondrial function is decreased in TAZ-KO cells.
(A) C2C12 myoblast proliferation was not affected by tafazzin deficiency. WT and
TAZ-KO cell proliferation in DMEM media with 10% FBS was measured using the
MTT assay. (B) Mitochondrial respiratory capacity is decreased in TAZ-KO cells.
Oxygen consumption was measured in intact cells using a Clark-type electrode.
While basal mitochondrial respiration was not affected by tafazzin deficiency,
maximal respiratory capacity was significantly decreased in TAZ-KO compared to
control cells (p=<0.05). (C) Mitochondrial membrane potential is significantly
reduced in TAZ-KO cells. Membrane potential of growing WT and TAZ-KO cells was
determined by fluorescence quantification of the Δψ dependent dye TMRM.
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Figure 6-4. Mitochondrial ROS production is increased in TAZ-KO cells.
(A) An increase of mitochondrial ROS was observed in TAZ-KO cells. ROS
production was measured via MitoSOX fluorescence using a Z1 AxioObserver
inverted fluorescence microscope equipped with an AxioVision MRm camera (Zeiss).
(B) Quantitative assesment of MitoSOX fluorescence was performed in all cells
within five randomly selected fields of view from three biological replicates using
fluorescence density analysis with ZenPro software (Zeiss).
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Figure 6-5. Myogenic differentiation is reduced in TAZ-KO cells.
Myogenic differentiation was initiated in cells reaching confluence by switching the
cells to DMEM medium containing 2% horse serum. Cells were cultured for 1, 3, or 7
days. Antibody detection of skeletal muscle contractile protein myosin heavy chain
(MHC) was used for immunofluorescent staining of differentiated myotubes.
CL remodeling is required for myocyte differentiation.
C2C12 myoblast cells are routinely used to study skeletal muscle differentiation.
These cells grow as undifferentiated myoblasts in growth medium containing 10% fetal
bovine serum and myogenic differentiation can be initiated in cells reaching confluence
by shifting the cells to medium containing 2% horse serum (Travaglione et al., 2005). To
investigate how myocyte differentiation is affected by the loss of tafazzin, we initiated
myogenic differentiation using the widely-used protocol outlined above. As shown by
fluorescence microscopy (Figure 6-5), control myoblast cells morphologically responded
to the serum depletion and expressed the skeletal muscle contractile protein myosin
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heavy chain (MHC). In striking contrast, TAZ-KO myoblast cells exhibited severely
impaired phenotypic differentiation into myotubes.
DISCUSSION
Previous studies have utilized TAZ-KO or BTHS patient-derived iPSCs to
generate

cardiomyocytes

for

studying

the

pathophysiology

underlying

the

cardiomyopathy in BTHS (Acehan et al., 2009; Dudek et al., 2013a; Moffat et al., 2014).
The TAZ-KO C2C12 cell line generated in the current study represents the first tafazzindeficient mammalian cell culture model system established in an immortalized skeletal
myoblast cell line. Skeletal myopathy associated with BTHS is presumed to result
primarily from impaired ATP production owing to alterations in mitochondrial oxidative
phosphorylation. In the present study, we provide evidence for an additional link
between dysfunctional CL remodeling and disturbed myocyte ontogenesis. Our findings
suggest that myocyte differentiation may be affected in BTHS and may contribute to the
skeletal myopathy observed in these patients. The current study has generated a new
BTHS model for the study of skeletal myopathy. The TAZ-KO C2C12 cells provide an
isogenic model system for exploring the muscle-specific effects of tafazzin-deficiency.
C2C12 cells are widely used for biochemical and metabolic studies of skeletal myocytes,
and are relatively easy and inexpensive to manipulate. TAZ-KO C2C12 myoblast cells
display a mitochondrial phenotype similar to that of BTHS patient tissues and other
mammalian models of BTHS. Loss of tafazzin was associated with a significant
increase in the MLCL/CL ratio, and a reduction in the number of unsaturated fatty acyl
chains incorporated into CL. Furthermore, TAZ-KO myoblast cells display decreased
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membrane potential, decreased mitochondrial respiratory capacity, and increased
mitochondrial ROS production.
Although we found that loss of CL remodeling leads to defective skeletal myocyte
differentiation, the mechanism by which myocyte differentiation is affected remains to be
elucidated. CL content is an important determinant of mitochondrial membrane structure
and cristae density (Schlame, 2013), and structural changes resulting from the loss of
remodeled CL or from the accumulation of monolyso-CL may physically interfere with
normal mitochondrial network fusion status. In BTHS patient-derived lymphoblast cells,
mitochondrial hyperproliferation and increased mitochondrial network fragmentation are
observed (Acehan et al., 2007; Xu et al., 2005). Currently, little is known regarding the
role of mitochondrial network dynamics in controlling cellular differentiation. However,
actively dividing blast cells have highly fragmented mitochondrial networks that
progressively fuse during terminal differentiation, which is associated with increased
respiratory capacity (Zhang, 2011). In general, highly fused mitochondrial networks are
associated with maximal respiratory capacity (Chen et al., 2005a; Chen et al., 2003; Yu
et al., 2006). Thus, it is tempting to speculate that loss of tafazzin may interfere with
normal differentiation owing to a reduced ability to form highly fused mitochondrial
networks. Consistent with this notion, increased mitochondrial network fragmentation
and hyperproliferation have been linked to IKK/NF-κB signaling, which partially inhibits
myocyte differentiation (34).
What is the relationship between tafazzin deficiency, cellular energy metabolism,
and myocyte differentiation? To meet the anabolic demands of proliferation, actively
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dividing blast cells limit mitochondrial oxidative metabolism to increase cellular biomass
via anabolic pathways.

Consequently, differentiation requires remodeling of

mitochondrial oxidative metabolism to support oxidation of glycolysis-derived pyruvate
to CO2.

Differentiation is associated with a spectrum of changes in mitochondrial

metabolic machinery, including upregulation of enzymes of the tricarboxylic acid (TCA)
cycle and subunits of the mitochondrial respiratory chain, and downregulation of
glycolytic enzymes (Armstrong et al., 2010; Chung et al., 2007; Prigione et al., 2010;
Tormos et al., 2011). This metabolic transition from glycolysis to mitochondrial oxidative
metabolism is necessary for cellular differentiation. Studies of pluripotent stem cell
differentiation confirm that inhibition of key glycolytic enzymes promotes differentiation,
while impairment of mitochondrial function with respiratory inhibitors improves
pluripotency and inhibits differentiation (Chung et al., 2007; Mandal et al., 2011).
Accordingly, it is plausible that defective mitochondrial oxidative metabolism contributes
to the observed differentiation defect in tafazzin deficient C2C12 myoblast cells.
Given their roles as energy and redox sensors, AMP-activated kinase (AMPK),
and the sirtuin family of NAD-dependent deacetylases have been implicated in
regulating skeletal muscle differentiation in response to metabolic status (Ryall, 2013).
Although very little is known about the role of these proteins in the development of
skeletal myopathy, increased AMPK and sirtuin activity have been proposed to inhibit
differentiation (Fulco et al., 2003; Williamson et al., 2009). It it possible that metabolic
and/or redox signaling pathways that regulate myoblast differentation are affected in
tafazzin-dificient cells. Future studies will determine what effect tafazzin-deficiency has
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on cellular metabolism and redox in order to further elucidate the molecular
mechanisms regulating myogenic determination in the TAZ-KO C2C12 cells.
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CHAPTER 7 UNFINISHED PROJECTS AND FUTURE DIRECTIONS
The studies described in this thesis elucidate functions of CLD1 and CL
remodeling in the yeast S. cerevisiae and murine myoblasts. Our data demonstrated
that an increased MLCL/CL ratio, but not decreased CL unsaturation, is likely the
primary cause of growth defects observed in yeast taz1. This suggests that the
physiological defects in BTHS patients is possibly caused by an increased MLCL/CL
ratio, and possibly amenable to treatment by attenuation of CL phospholipases.
Through nutritional and genetic manipulation of yeast CL species, we identified a novel
role for Cld1 in mitigating the effects of CL peroxidation, suggesting that elucidating the
role of CL remodeling may shed light on approaches for mitigating oxidative stress. The
findings from this study will serve as the basis on which we will improve our
understanding of CL remodeling and its mechanistic roles in mitigating oxidative stress.
The tafazzin knockout C2C12 cells provides a mammalian model with a congenic
control for future studies, and the link between CL deficiency to myotube differentiation
is identified.
Additionally, an important function of CL remodeling is to accumulate CL with
unsaturated fatty acyl chains. It is still a mystery why cells need PUFA-containing CL. In
this chapter, I summarize several interesting projects pertaining to CL remodeling that
are left unfinished. These projects can be considered for future studies that could lead
to a better understanding of CL remodeling and potential BTHS treatments.
1. Identification of human CL phospholipase that is deleterious to tafazzindeficient cells
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My previous study indicated that deletion of CLD1 rescues growth, life span, and
respiratory defects of the taz1Δ mutant, suggesting that these defects in tafazzindeficient cells are caused by increased MLCL/CL (Ye et al., 2014). This led to the
hypothesis that the deleterious effects of the loss of tafazzin can be alleviated by
inhibiting the deacylation of CL. A large number of phospholipases complicate the ability
to test this hypothesis in mammalian cells.

A 50% decrease in MLCL levels was

observed in mouse cells carrying a deletion in iPLA2Υ, suggesting that phospholipase
not yet identified deacylate CL (Kiebish et al., 2013a). Several other phospholipases
were shown to deacylate CL in vitro, including sPLA2-GIA and iPLA2-GVIA (Hsu et al.,
2013). Treatment of BTHS lymphoblasts with the iPLA2 inhibitor, BEL, partially restored
the MLCL/CL ratio (Malhotra et al., 2009). Taken together, these published studies
indicate that there are several human CL phospholipases and that inhibition of their
activities may alleviate deficiencies in BTHS cells.
I have developed a method utilizing a yeast functional bioassay to identify the
human phospholipases that deacylate CL in vivo and determine if inhibiting their
expression alleviates the respiratory defects in BTHS cells. iPLA2 was cloned into the
yeast high copy expression vector pYPGK18. Expression of iPLA2 leads to decreased
growth of taz1 cells at elevated temperature (Figure 7-1). This is a straightforward and
inexpensive bioassay that can be used as a functional screen for CL phospholipases.
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taz1
EV
CLD1
iPLA2
iPLA2
pYPGK18
Figure 7-1. Expression of iPLA2 leads to decreased growth of taz1Δ at
elevated temperature
To identify the human phospholipases that deacylate CL, the previously described PLA2
phospholipases (Hsu et al., 2013) were cloned into the yeast expression vector
pYPGK18. The yeast bioassay was utilized to identify those that exacerbate yeast taz1
growth defects, which may be deleterious to BTHS cells. This can be tested by inhibiting
their expression. To do so, BTHS lymphoblasts and TAZ-KO C2C12 cells can be
transfected with lentivirus-derived small hairpin RNA (shRNA) against specific CL
phospholipase genes. The effects of knocking down these phospholipases on
parameters that are defective in BTHS lymphoblasts, including MLCL/CL ratio, CL acyl
composition, respiration, and mitochondrial membrane potential can be assayed (Xu et
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al., 2005). The identification of new CL phospholipases will facilitate the understanding
of CL remodeling pathways in mammalian cells, possibly leading to new strategies for
BTHS treatment.
2. Does loss of PGS1 function correlate with low HDL-C level?
High-Density Lipoprotein-Cholesterol (HDL-C) alleviates plaque build up in
arteries, while low HDL-C levels correlate with heart disease (Ahmed et al., 2016;
Hashemi Nazari et al., 2015). A study from the laboratory of Dr. E Shyong Tai in the
Department of Medicine at the National University of Singapore identified 250 people
with the highest HDL levels and 250 with the lowest HDL from a population of 3000. The
PGS1 gene was sequenced, and four rare PGS1 variants were found in patients with
low HDL. These variants had amino acid substitutions A2E, I114V, A302V, and R343H.
Due to the decreased levels of HDL in these patients, these variants were predicted to
be harmful to humans. Based on the above finding, it was hypothesized that loss of
PGS1 function correlates with low HDL-C level.
To test the hypothesis, Pgs1 activity and CL levels were assayed in pgs1Δ yeast
cells expressing human PGS1 variants. To determine if the yeast model is appropriate
for testing this hypothesis, we first compared the mammalian and yeast PGS1
sequence. 33% of the human PGS1 amino acid sequence is identical to yeast Pgs1.
The conserved sequences include the 96 – 269 amino acid and 349 - 534 amino acid
catalytic domains. Overexpression of human PGS1 rescues yeast pgs1Δ growth defects,
showing that human PGS1 is functional in yeast (Figure 7-2A). Furthermore, results
from thin layer chromatography (TLC) demonstrated that yeast pgs1Δ cells do not
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Figure 7-2. Overexpression of human PGS1 rescues yeast pgs1Δ growth
defects
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Figure 7-3. Overexpression of human PGS1 variants rescues yeast pgs1Δ
growth defects
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synthesize CL; however, expression of human PGS1 leads to CL synthesis in yeast
(Figure 7-2B). The difference between wild type human PGS1 and the four variants
(A2E, I114V, A302V, and R343H) in complementing yeast pgs1Δ was determined. All 4
variants were successfully expressed in yeast pgs1Δ (qRT-PCR) (Figure 7-3A).
However, overexpression of all four variants rescued yeast pgs1Δ growth defects
(Figure 7-3B). Although the overexpression of all four hPGS1 variants rescued pgs1Δ,
the possibility of defective enzymatic activity of Pgs1 variants, expressed at
endogenous levels, cannot be excluded. In addition, suppressors frequently arising in
the pgs1Δ mutant can easily affect growth. As a result, growth phenotype is not an
effective indicator for determining the functionality of human PGS1 variants. In order to
continue with this project, the CL profile in strains expressing variant human PGS1
should be measured. An alternative strategy is to complement a diploid heterozygous
pgs1Δ mutant with a human PGS1 variant. Tetrad analysis can be performed with the
diploid cells carrying the PGS1 variant in a low copy expression vector followed by
observing colony growth. A decrease in colony growth (of haploid pgs1Δ expressing the
PGS1 variant) can identify variants that leads to defective Pgs1 activity.
Pgs1 ablation eliminates de novo synthesis of PG, the CL precursor, and
decreased CL is correlated with decreased HDL level (Chang et al., 1998a; Hauff and
Hatch, 2010). Therefore, identification of human PGS1 variants that have decreased
Pgs1 activity may provide a molecular marker for decreased HDL level. People who
carry the defective PGS1 variant can then be diagnosed using these molecular markers
and receive corresponding treatment.
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3. Does ferroptosis exist in yeast?
Ferroptosis is a unique iron-dependent form of nonapoptotic cell death that is
dependent on intracellular iron but is not affected by other metals. It is morphologically,
biochemically, and genetically distinct from apoptosis, necrosis, and autophagy (Cao
and Dixon, 2016; Dixon et al., 2012). Ferroptosis was initially identified in cancer cells.
In these cells, classic features of apoptosis, including cytochrome c release, caspase
activation, and chromatin fragmentation, were not observed. Ferroptosis is prevented by
iron chelation or genetic inhibition of cellular iron uptake (Dixon et al., 2012). The
manipulation of ferroptosis could be exploited to selectively destroy tumor cells.
Additionally, inhibition of ferroptosis could be utilized to preserve neuronal cells exposed
to specific oxidative conditions. The mechanism of ferroptosis regulation is not fully
understood. Yeast can serve as a powerful model in studying ferroptosis because most
essential cellular functions are conserved from yeast to humans. Additionally, lipid
species and intracellular iron can be readily manipulated in yeast. However, it is not
known if ferroptosis exists in yeast cells.
Previous studies identified mammalian Gpx4 as a key regulator in ferroptotic cell
death. Depletion of Gpx4 leads to peroxidation of arachidonic acid (AA) and ferroptosis
in mammalian cells (2017; Conrad and Friedmann Angeli, 2015; Imai et al., 2017;
Maiorino et al., 2017; Sakai et al., 2017; Yang et al., 2014). Yeast Gpx3 is the homolog
of mammalian Gpx4. To determine if ferroptosis exists in yeast, spotting experiments
were

AA
5 mM FeSO4
AA+5mM FeSO4

Figure 7-4. Deletion of GPX3 increases the sensitivity of cells to arachidonic acid.
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performed to test if Gpx3 deficient yeast exhibit growth retardation when supplemented
with AA. Briefly, cell cultures were grown to stationary phase. Serial dilutions of the
culture were plated on YPD plates in the presence or absence of AA or FeSO 4. Cells
were incubated at 30 ℃ or 37 ℃ for 2 days. The results showed that deletion of GPX3
increased the sensitivity of cells to AA. Sensitivity was more pronounced at the elevated
temperature. Supplementation with 5 mM FeSO4 was lethal in the presence of AA
(Figure 7-4). These data suggest that deletion of GPX3 possibly leads to ferroptosis of
yeast cells supplementated with AA.
To confirm that GPX3 deletion in yeast leads to ferroptosis in the presence of AA,
cells should be grown with an iron chelator that has been shown to inhibit ferroptosis. A
finding that growth of gpx3 in medium containing AA is restored when an iron chelator
is supplemented would support the hypothesis that ferroptosis exists in yeast, which can
then serve as a potent model to study the mechanism and regulation of this death
pathway.
4. Does Drosophila ABHD5 have CL phospholipase activity?
Alpha beta hydrolase domain-containing 5 (ABHD5), also known as comparative
gene identification 58 (CGI-58), belongs to the AB hydrolase superfamily, which is
composed of hydrolytic enzymes of widely differing phylogenetic origin and catalytic
functions (Brown and Mark Brown, 2017; Ollis et al., 1992). Mutations in ABHD5 have
been associated with Chanarin-Dorfman syndrome, a triglyceride storage disease with
impaired long-chain fatty acid oxidation (Lefevre et al., 2001) and neutral lipid storage
disease (Schweiger et al., 2009). Understanding functions and regulation of ABHD5
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Figure 7-5. Overexpression of B-isoform of the ABHD5 ortholog exhibits a
growth defect like overexpression of CLD1 and iPLA2γ in taz1
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may provide clues for deciphering physiological defects caused by ABHD5 mutations.
Dr. James G. Granneman (Center for Molecular Medicine and Genetics, Wayne State
University School of Medicine) recently identified a Drosophila AB hydrolase (CG1882)
that is likely an ortholog of human ABHD5. Interestingly, the yeast mitochondrial
phospholipase Cld1 is more closely related to ABHD5 than any other protein in the
database. ABHD5, however, is not considered a mitochondrial lipase (deacylase)
because it lacks a nucleophilic serine and is not targeted to mitochondria. Unlike
ABHD5 CG1882 has the nucleophilic serine and a splice variant that is specifically
targeted to mitochondria. Given the evolution of this gene and the targeting of a specific
splice variant to mitochondria, it might function as a CL lipase.
Our previous study showed that expression of yeast CLD1 or human iPLA2γ in
yeast taz1 leads to decreased growth (unpublished). In collaboration with Dr.
Granneman, we determined if expression of CG1882 in taz1 leads to decreased
growth There are two isoforms of CG1882, A and B, which have the same sequence
except that isoform B has a mitochondrial targeting sequence.

CLD1, iPLA2γ, and

CG1882 (isoforms A and B, with a RFP tag) were expressed on pYPGK18. Both
CG1882 isoforms were expressed in taz1 cells and the B isoform localized to
mitochondria. Cells were spotted on solid synthetic complete Leu- medium with either
glucose or glycerol/ethanol as a carbon source and incubated at 30 ℃, 37 ℃, and 39℃.
The results showed that overexpression of the B-isoform exhibits a growth defect similar
to overexpression of CLD1 and iPLA2γ in taz1Figure 7-5This suggests that
CG1882 and yeast Cld1 may have similar functions.
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Future experiments using confocal microscopy could be performed to confirm
mitochondrial targeting. In addition, CG1882 enzymatic activity could be determined by
targeted mutation of the catalytic domain. Enzymatic activity can be verified by in vitro
studies followed by assaying phospholipase activity in vivo. The CG1882B CL
phospholipase activity could be confirmed in Drosophila cell lines followed by
characterization of CG1882-null Drosophila. The outcome of this study may provide
insight for deciphering physiological defects of Chanarin-Dorfman syndrome and neutral
lipid storage disease to develop potential therapeutic treatment.
5. Using genetically-modified yeast cells to screen for iPLA2γ inhibitors
We have shown that a high level of expression of CL phospholipase (CLD1 or
iPLA2γis lethal to TAZ1 deficient cells. To identify iPLA2γ inhibitors, a yeast bioassay
strain was genetically manipulated to express the H. brasiliensis Δ12-desaturase gene.
My colleague Wenxi Yu engineered the pBEVY-L plasmid, which contains a bidirectional promoter, to constitutively express the human iPLA2γand the H. brasiliensis
Δ12-desaturase genes in the cld1∆taz1∆ double mutant. The Δ12-desaturase expressing
strain exhibited decreased growth on non-fermentable carbon sources in the presence
of tert-butyl-hydroperoxide (TBHP), a mitochondrial oxidant (Figure 7-6). It was
especially interesting to discover that dose-dependent sensitivity to TBHP was observed
only on non-fermentable growth medium, suggesting that the lipid mediators generated
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Figure 7-6. Humanized yeast bioassay strain displays sensitivity to
mitochondrial oxidative stress.
Serial dilutions of cld1∆taz1∆ double mutant yeast cells expressing the H.
brasiliensis Δ12-fatty acid desaturase gene (desa), the human iPLA2γ gene (iPLA2γ),
or both genes (desa + iPLA2γ) were spotted on synthetic complete media containing
either 2% glucose or 2% glycerol and lactate. cld1∆taz1∆ double mutant yeast cells
containing the empty pBEVY-L plasmid (EV) served as a control. Plates were treated
with either 50 µM TBHP or vehicle control and immediately spotted. Following 5 days
of incubation at 30C, plates were imaged for subsequent analysis.
by iPLA2γ impact cell metabolism only during respiratory conditions.
The laboratory of Dr. Valerian Kagan (University of Pittsburg) demonstrated that
R-BEL, an inhibitor of iPLA2γ, suppressed hydrolysis of peroxidized CL and the
production of peroxidized free fatty acids in a radiation-induced injury mouse model
(Buland et al., 2016). To test the hypothesis that inhibitors of iPLA2γ protect against cell
damage caused by CL peroxidation, we examined whether the sensitivity of the Δ12desaturase expressing strain to TBHP is affected by supplementation of R-BEL. In
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Figure 7-7. Humanized yeast bioassay strain displays sensitivity to
mitochondrial oxidative stress.
Serial dilutions of cld1∆taz1∆ double mutant yeast cells expressing the H.
brasiliensis Δ12-fatty acid desaturase gene (desa), the human iPLA2γ gene (iPLA2γ),
or both genes (desa + iPLA2γ) were spotted on synthetic complete media containing
2% glycerol and lactate. cld1∆taz1∆ double mutant yeast cells containing the empty
pBEVY-L plasmid (EV) served as a control. Plates were treated with either 50 µM
TBHP, 50 µM TBHP + R-BEL, or vehicle control and immediately spotted. Following
5 days of incubation at 30C, plates were imaged for subsequent analysis.
accordance with our hypothesis, we found that the sensitivity of the Δ12-desaturase
expressing strain to TBHP on non-fermentable medium was rescued by R-BEL
supplementation (Figure 7-7). These experiments highlight the utility of this powerful
yeast model. Future experiments will seek to screen other potential inhibitors of iPLA2 γ
using this strain.
Pathways that negatively regulate iPLA2γ activity can be identified by
transforming the bioassay strain with a mammalian cDNA library and screening for
suppressors of the iPLA2γ-mediated lethality phenotype.
It is possible to identify activators of iPLA2γ through assessing mutants that
rescue cells from iPLA2γ-mediated growth inhibition by synthetic genetic array (SGA)
analysis. Genes and associated pathways that are identified in the yeast screens can
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12

Figure 7-8. MLCL species in ∆ -desaturase-expressing cells.
(A) Heat map of MLCL. (B) Quantitative assessment of total MLCL.
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be further characterized. Subsequent studies testing the suppressive effects of human
homologs on the iPLA2γ phenotype would help identify regulatory pathways of iPLA2γ
present in human cells.
The yeast bioassay can also be utilized to identify new inhibitors of iPLA2γ that
protect against oxidative damage of CL. Furthermore, a possible outcome of this study
is the identification of new pathways that regulate iPLA2γ, which will contribute broadly
to our understanding of lipid mediators. These inhibitors and regulators could be
examined in animal models to elucidate their role in radiation-induced injury.
6. Is there a novel CL phospholipase in yeast?
Cld1 is the only known CL phospholipase that deacylates CL to form MLCL in
yeast. Although cld1 has decreased levels of MLCL, MLCL is still detectable (Figure 78). Interestingly, the expression of 12-desaturase increased levels of MLCL (Figure 7-8)
suggesting that there is an unidentified CL phospholipase that prefers to deacylate CL
with polyunsaturated fatty acyl chains. Future studies to identify this novel CL
phospholipase will understand functions and regulations of CL remodeling, possibly
leading to treatment for BTHS.
7. Novel roles of CL and CL remodeling
Although roles of CL remodeling have been shown in removal of damaged CL
acyl chains and in cell differentiation in this dissertation, the functions of CL，CLox and
CL remodeling in cellular signaling pathways are still unclear. My lab colleagues, Cunqi
Ye and Jiajia Ji, determined that Cld1 is required for activation of the PKC pathway by
SGA analysis. Additional genetic interactions of CLD1 have yet to be uncovered and
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further analysis of the SGA data can be used to identify functions of CL and CL
remodeling.
Although we are at the end of this dissertation, people in our lab will not stop
studying functions and regulation of CL and CL remodeling. I will be excited if future
researchers are interested in joining in the world of CL research because of my studies.
It will be a great pleasure if my findings stimulate creative ideas in the minds of fellow
researchers.
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Cardiolipin (CL) is a unique phospholipid that is primarily localized within the
inner mitochondrial membrane. Newly synthesized CL undergoes acyl remodeling to
produce CL species enriched with unsaturated acyl groups. The tafazzin gene (TAZ)
encodes a transacylase that remodels CL. Deficiencies in CL remodeling cause Barth
syndrome (BTHS), an X-linked genetic disorder resulting from TAZ mutations that lead
to reduced total CL content and an accumulation of monolysocardiolipin (MLCL), an
intermediate of the CL remodeling pathway. However, which of these biochemical
outcomes contributes to the physiological defects is not fully understood.
Deletion of yeast CL phospholipase rescues the taz1growth phenotype. We
concluded that an increased MLCL/CL, but not decreased CL unsaturation, is likely the
primary cause of decreased respiratory growth and chronological life span observed in
taz1. This suggests that the physiological defects of BTHS patients is possibly due to
increased MLCL/CL ratio instead of decreased unsaturated CL, and that attenuation of
CL phospholipases may potentially treat BTHS.
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Furthermore, our findings suggested a possibility that CLD1 expression is
upregulated in response to oxidative stress. CL peroxidation, resulting from oxidative
stress, has been described in mammalian cells. Based on this, one of the physiological
roles of CL remodeling is to remove peroxidized CL. Liquid chromatography−massspectrometry-based phospholipidomics was combined with genetic and nutritional
manipulations to assay CL incorporation of PUFA during the CL biosynthetic and postsynthetic remodeling processes in yeast. Our results demonstrated that yeast readily
incorporate PUFA to synthesize oxidizable CL. Although multiple CL-hydroperoxides
and CL-dihydroperoxides were readily detected in these cells, cell growth and life span
were not impacted. cld1Δ cells expressing ∆12-desaturase were utilized to determine the
effect of peroxidation on CL remodeling. Using this novel yeast model, in which cells
expressed ∆12-desaturase, the specificity of Cld1 to peroxidized CL, and its role in
deacylating peroxidized CL, was determined. In cells expressing desaturase, loss of
CLD1 led to increased peroxidized CL species, as well as decreased cell growth and life
span. The findings from this study may contribute to our understanding of CL
remodeling and its mechanistic roles in mitigating oxidative stress.
To probe defects resulting from CL deficiency in mammalian cells, I constructed
a tafazzin knockout C2C12 cell line, which exhibits an increased MLCL/CL ratio,
decreased respiration capacity, increased ROS generation and decreased membrane
potential. Although WT and TAZ-KO C2C12 cells can differentiate into myotubes,
differentiation was significantly decreased in TAZ-KO C2C12 cells under certain
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conditions. Taken together, these findings indicate that CL remodeling plays a role in
myotube differentiation.
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